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In this thesis I describe the work that I have done on the 
isolation and characterization of a plasminogen activator, Mel-PA, tha~ 1.s 
released by human melanoma cells cultured in vitro. This enzyme was 
compared to the urinary plasmi.nogen activator, urokinase. 
The human melanoma cell line, RPMI-7272, (also referred to as 
the "Bowes" melanoma cell line) released large amounts of Mel-PA into 
the surrounding medium when cultured under serum-free conditions. A 
subline of these cells (Bowes II) was developed that was capable of 
continuous growth in the absence of serum. These cells released only 
one type of plasminogen activator with a molecular weight of approximately 
70 000 daltons. 
A technique was developed in which plasminogen activators were 
separated electrophoretically and detected in polyacrylamide gel slabs 
containing the co-polymerized substrates, plasminogen and gelatin. The 
technique was compared with the zymographic procedure developed by Granelli-
Piperno and Reich (62) using fibrin-plasminogen-agarose underlays. 
Mel-PA was concentrated and partially purified by affinity 
chromatography on benzamidine-sepharose. This preparation was used to 
prepare rabbit antisera to the enzyme. These antibodies inhibited the 
activity of plasminogen activators released by all melanoma cells but 
had no effect on urokinase. Antibodies to urokinase had no effect on 
Mel-PA. A survey of human plasminogen activators and their distribution 
by immunochemical and electrophoretic techniques showed that tissue 
extracts and body fluids, with the exception of normal urine, contained 
mixtures of Mel-PA- and urokinase-type enzymes. Urine of patients with 
some types of renal disease also contained a Mel-PA type enzyme. 
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A study of the distribution of plasminogen activators in tissues 
and body fluids obtained from a number of animals showed that all mammals 
examined had two immunochemically distinct plasminogen activators that 
corresponded, in their distribution, to the urokinase-like and Mel-PA-like · 
enzymes of man. Antibodies to human Mel-PA cross-reacted with the 
corresponding enzyme in all mammals tested, whereas antibodies to human 
urokinase were species specific. 
The seeds of the South African legume, Erythrina latissima, 
contain a 20 000 dalton protein that functioned as an inhibitor of 
Mel-PA, plasmin, and trypsin, but had no effect on urokinase. During 
its reaction with the enzymes the inhibitor was cleaved by Mel-PA and 
trypsin but not by urokinase . . The susceptible bond was straddled by an 
intrachain disulphide bridge. The inhibitor bound reversibly to Mel-PA 
and could therefore be used to develop an affinity reagent for a one-
step purification procedure for Mel-PA in melanoma cell harvest fluids. 
Purified preparations of Mel-PA c0uld be shown to comprise both 
active enzyme (two chain form) and pro-enzyme (one chain form). The one 
chain form could be converted to the two chain form by treatment with 
plasmin. It could also be shown that fibrinogen and fibrin contained 
a · contaminating protease that was capable of converting pro-Mel-PA to 
Mel-PA. 
A comparative study of the kinetic behaviour of Mel-PA and 
urokinase showed numerous differences between the catalytic activities 
of these two enzymes. Mel-PA was capable of binding to fibrinogen 
insolublilized on a plastic surface whereas urokinase did not. The 
presence of fibrinogen enhanced the plasminogen activating activity 
of Mel-PA but had no effect on urokinase activity. 
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Biological mechanisms for the liquefaction of blood clots have 
been known and studied for at least a century. Possibly the earliest 
systematic studies and definitive reports were those of Sahli in 1885 (1) 
who found that urine dissolved blood clots and Loeb in 1898 (2) who showed 
that regenerating epithelial cells in vivo caused dissolution of clotted 
plasma. Dastre in 1893 (3) was the first to use the term "fibrinolysis11 
for this phenomenon. Barker in 1908 (4) identified a "proteolytic factor" 
associated with fibrinolysis and Demuth and von Riesen (1928) (5), while 
studying cells cultured in vitro, suggested that the lysis of the fibrin 
clot substrate by these cells involved the activation of a pro-enzyme 
present in the surrounding plasma-containing medium. Similar observations 
were made by Fischer in 1946 (6) who also worked with cells cultured in 
vitro. At approximately the same time, Tillet and Garner (7) discovered · 
a fibrinolytic agent in culture filtrates of beta haemolytic streptococci. 
In 1941 Milstone (8) showed that lysis of fibrin by this agent depended on 
the presence of a 11 lytic factor" in human plasma. Although these early 
observations generated a great deal of research interest for their possible 
relevance to the control and management of thrombosis, work on fibrinolysis 
was constrained by a lack of expertise in protein chemistry, a limited 
knowledge of enzyme action and relatively crude techniques. · 
It was not until the mid 1940 1 s that Kaplan (9) and Christensen 
(10) demonstrated that the "lytic factor" of Milstone was a powerful proteo-
lytic enzyme capable of digesting fibrin, fibrinogen, casein and gelatin. 
This "lytic factor" was named 11plasmin11 , and its inactive precursor 
· 
11 plasminogen11 by Christensen and MacLeod in 1945 (11). 
In 1915, Fleisher and Loeb (12) demonstrated that a wide variety 
of tissues could induce fibrinolysis, but it was only in 1947 that Astrup 
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and Permin (13) showed that this fibrolytic activity of tissues was due 
to the activation of plasminogen by a "tissue factor" which was later 
named "tissue activator of plasminogen" (14, 15) or 11plasminogen activator". 
At the same time Goldhaber et al (16) made a similar observation with 
tumour cells cultured in vitro. 
In recent years, advances in technical and conceptual knowledge 
have brought us to a stage at which a number of facts regarding fibrinolytic 
systems may be regarded as definitely established. These relate to 
plasminogen, its activation to plasmin, and inhibitors of the enzymes 
involved in fibrinolysis. These I propose to discuss briefly as introduct-
ory material to the substance of this thesis, identifying those respects in 
which I believe my results have contributed to knowledge of the subject. 
Native human plasminogen is a 92 000 dalton glycoprotein containing 
2% carbohydrate and a single polypeptide chain with glutamic acid as its 
NH2-terminal residue (17,18). During the activation of plasminogen by 
plasminogen activators a single Arg-Val bond is cleaved to form plasmin with 
a heavy chain (67 000 daltons) and a light chain (25 000 daltons) conn~cted 
by disulphide bridges (17,19). Plasmin is a serine-histidine protease with 
its active site located on the light chain (20,17). 
The primary structures of plasminogen and plasmin have been eluci-
dated by the studies of several groups (21, 22, 23, 24, 25, 26, 17). 
Plasminogen is composed of three distinct domains, namely a "heavy chain", 
a "light chain" (these two giving rise to the heavy and light chains respect-
ively of plasmin) and "preactivation peptides". The heavy chain has an 
interesting structure that results from the presence of a series of triple, 
intrachain disulphide bonds (27). These give rise to a series of loops in 
the chain referred to as "kringles" from their similarity to the Scandi-
navian pastry by that name. The "kringle" region shows extensive homology 
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with prothrombin (25,27). The light chain of plasminogen shows extensive 
homology with chymotrypsin (23) and contains the active serine site (20,23). 
During the activation of Glu-plasminogen to plasmin, the plasmino-
gen molecule is also cleaved at two sites in the amino terminal part of the 
molecule. Cleavage at these points (Arg 67-Met 68; Lys 76-Lys 77; or 
Lys 77-Val 78) results in the release of preactivation peptides with a 
combined molecular weight of 8 000 daltons (21,28,29,30) and in formation 
of an alternative form, Lys-plasminogen, with a molecular weight of 85 000 
daltons and with an amino terminal of lysine. Since the release of the 
amino terminal peptides from Glu-plasminogen causes a conformational change 
in the molecule that facilitates the activating cleavage at a susceptible 
Arg-Val (560-561) bond, into the two chain plasmin molecule, the term 
"preactivation peptide" or "PAP" was given (31,32,33,34,29). It has been 
established, however, that the release of PAP from Glu-plasminogen is not 
necessary for the generation of plasmin by the action of urokinase (35,36) 
although it has been shown that activation .occurs at a much faster rate with 
Lys-plasminogen (29,32,33,34). The cleavage of the bonds necessary for the 
release of PAP has been ascribed mainly to the action of plasmin (37,36). 
A diagrammatic presentation of the sequence of events is shown in Fig. 1. 
Purification of plasminogen from plasma usually yields both Glu-
and Lys-plasminogen (18,19,38). Since the addition of protease inhibitors 
during purification gives a better yield of Glu-plasminogen (47), it is now 
felt that Lys-plasminogen originates from partial proteolytic degradation 
of Glu-plasminogen during the isolation procedures (18,38). 
The biochemistry of plasminogen is noteworthy in several other 
functional aspects. Firstly the kringle region of the heavy chain contains 
5 "lysine binding sites" through which plasminogen binds strongly to fibrin, 
to lysine analogues such as EACA and to the inhibitor ~
2 
antiplasmin (24,39, 
40,41,42,43,44). This capacity for reversible binding to lysine is 
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exploited in the use of affinity chromatography with sepharose-lysine for 
the purification of plasminogen (45). The binding of EACA at low 
concentration is known to facilitate activation of Glu-plasminogen to plas-
min (31,46) . and binding to fibrin or a2 antiplasmin may have important 
implications for fibrin:olytic regulation in vivo that I discuss in a later 
chapter. 
Secondly, plasminogen represents approximately .25% of the 
total protein present in human plasma (48) and thus constitutes a very 
considerable pool of potential proteolytic activity. Considered 1n 
conjunction with the inducible nature of plasminogen activator release, 
the implications of this fact for biological mechanisms that involve 
regulated local proteolysis are considerable. 
Thirdly, the metabolic turnover of plasminogen 1n man 1s relatively 
rapid. A daily fractional turnover rate of 55% (48) suggests that the 
constant levels of the zymogen found in plasma represents an equilibrium 
between synthesis and loss through continuous activation and degradation. 
This in turn may be taken to imply a need for such a mechanism to handle 
continuous thrombus deposition in the human vascular tree. 
Plasminogen activators of mammalian origin comprise a group of 
divers serine proteases that have been demonstrated in many tissues, body 
fluids and secretions. They are also released by a wide variety of cells 
cultured in vitro (Table 1), 
The different human plasminogen activators first came into 
comparison when they were detected separately in urine (49,50). and in 
tissues (13). Since, at the time, techniques were not available for the 
definitive molecular identification of the enzymes from these two sources, 
they were referred to as "urokinase" (49) and "tissue plasminogen activator" 
(14,15) and it was tacitly agreed that they should be regarded as different 
until proved otherwise (14). The discovery of plasminogen activators in 
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blood vessels and in plasma added "vascular plasminogen activator" and 
"blood plasminogen activator" to the list. 
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Thus, a classification of plasminogen activators developed that 
was based upon the origins of the enzyme rather than upon more satisfactory 
biochemical criteria. This classification was to some extent justified 
by the finding that urokinase and tissue plasminogen activator were, in all 
probability, not the same since they were antigenically dissimilar (51,52, 
53,54,55,56) and had different binding affinities for fibrin (46,57,58,59). 
Vascular plasminogen activators and blood plasminogen activators occupied 
an uncertain position. In a comprehensive review of the subject presented 
as recently as 1979, Collen stated that "the plasminogen activator found in 
blood probably represents released vascular plas~nogen activator and that 
these activators are similar or identical to the tissue activator, but 
different from urokinase" (60). 
The successful application of more advanced analytical and 
preparative techniques to the study of human plasminogen activators has 
brought us to the stage wher.e it is now possible to say with certainty that 
normal urine contains plasminogen activator activity, more than 95% of which 
is attributable to a number of enzymes that are exclusive in the sense that 
they all belong to the same immunochemically-defined family (198). There 
is thus reasonable justification for retaining the term "urokinase" to 
describe the major fraction of these urinary plasminogen activators. 
Melanoma cells cultured in vitro release plasminogen activators 
that are similarly exclusive in that they all show immunochemical cross-
reactivity with each other but not with urokinase (61). Since urokinase 
enzymes and the enzymes released by melanoma cells are antigenically unrelated 
there is justification for referring to the latter group as melanoma-
plasminogen activators or Mel-PA. 
This thesis is concerned for the most part, with the study of 
Mel-PA's and in particular plasminogen activators released by a cultured 
melanoma cell line, · RPMI-7272. 
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These cells proved to be a convenient source of enzyme for the 
fact that they released no plasminogen activators of the urokinase type. 
In Chapter I of this thesis I describe the procedures used to cultivate 
these melanoma cells and to isolate a partially purified plasminogen 
activator from the conditioned medium in which these cells had been grown. 
In Chapter II I describe a technique that I developed for the 
analysis and characterisation of plasminogen activators separated by 
electrophoresis in polyacrylamide gel slabs containing co-polymerized 
subs tr ates. This technique was compared with the zymographic procedures 
developed by Granelli-Piperno and Reich (62) using plasminogen-fibrin-
agarose underlays. 
Partially purified enzyme isolated from melanoma cell cultures was 
used to prepare rabbit antisera. These antibodies inhibited all Mel-PA's 
but did not inhibit urokinase. Conversely, antibodies prepared to 
urokinase inhibited the urinary enzyme but had no effect upon Mel-PA. 
Having serological reagents that distinguished clearly between 
Mel-PA and urokinase and electrophoretic techniques for the characterisation 
of these enzymes accord_ing to their molecular weights, I was able to undertake 
a comprehensive survey of human plasminogen activators and their distribution. 
These studies showed that plasminogen activators present in tissue extracts were 
invariably mixtures of the urokinase and Mel-PA type enzymes. The same was 
true for plasminogen activators that could be identified in a variety of body 
fluids and secretions. Normal urine was found to contain virtually only 
urokinase with very little of the Mel-PA type enzyme. Urine obtained from 
patients with renal disease, however, contained considerably more of the 
Mel-PA. A study of plasminogen activators present in tissues and body 
fluids obtained -from a variety of animal species showed that, with the 
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exception of the pig, all mammals examined contained plasminogen activators 
of the two immunochemically distinct types that corresponded in their 
distribution to the Mel-PA and urokinase found in the human situation. 
The interesting fact also emerged that antibodies to human Mel-PA 
cross-reacted with the corresponding enzyme in all matmnals studied. Anti-
bodies to human urokinase, however, were species specific. The pig proved 
to be an interesting exception to the general rule in that po~cine urinary 
plasminogen activator was consistently inhibited by antibodies to human Mel-PA. 
These combined electrophoretic and immunochemical studies are described in 
Chapter III. 
In Chapter IV I present the results of work that I did to identify 
a 20 000 dalton protein present in the seeds of the South African Erythrina 
species. This compound functioned as an inhibitor of Mel-PA and plasmin, 
but had no effect on urokinase. It bound reversibly to Mel-PA and could thus 
be used to develop an affinity reagent for the one step purification of Mel-PA 
from melanoma cell harvest fluids. Studies with radioactive inhibitor showed 
that the compound was cleaved by Mel-PA at a susceptible bond straddled by 
an intrachain disulphide bridge. 
urokinase had no effect. 
Trypsin cleaved at the same bond, but 
Mel-PA purified by benzamidine- or Erythrina-inhibitor-affinity 
chromatography could be shown to comprise both active enzyme and pro-enzyme. 
The latter could be converted to active Mel-PA by treatment with plasmin or by 
incubation with fibrinogen and fibrin. These studies, together with the more 
extensive investigations that I did to define kinetic parameters of Mel-PA 
and the way these differed from those of urokinase, are presented in Chapter V. 
In this chapter and in Chapter VI I also produce evidence to show that the well 
known effect of fibrin as a "catalyst" of plasminogen activation is due, on the 
one hand, to the tendency of fibrin to bind to Mel-PA and, on the other hand, 
to the contaminating presence in most preparati~ns of fibrinogen end fibrin 
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of a serine protease that converts pro-Mel-PA to Mel-PA. 
In Chapter VI I discuss methods for the measurement of plasminogen 
activators and the reasons for the different results that are obtained when 
different methods are used. I conclude that Mel-PA is best standardized 
using a direct assay in which enzyme activity is linearly related to the 
rate of hydrolysis of fluorogenic or chromogenic synthetic substrates. 
Under standard conditions 1 pmol of active sites of Mel-PA as measured by 
labelling with radioactive DFP, would hydrolyse 9.8 pmol of substrate/min. 
Other assay procedures are related to this standard meth'od. 
Although urokinase and Mel-PA type enzymes could be identified as the 
major if not the only plasminogen activators in tissues and most body fluids, 
blood plasma could be shown by electrophoretic and immunochemical techniques 
to contain plasminogen dependent fibrinolytic and caseinolytic enzymes that 
are different from either of these two groups. The situation in blood is 
made more complex by the observation that normal plasma contains urokinase 
in a pro-active form (63); it contains Mel-PA after exercise and venous 
occlusions (64,65,66); and it contains a number of potent inhibitors of 
plasmin and possibly plasminogen activators (67). 
The fact that blood, urine and tissues are so easily shown to 
contain varying mixtures of plasminogen activators makes it inappropriate to 
retain such terms as "tissue plasminogen activator", "urokinase" or "blood 
plasminogen activator". Since techniques are now available for the 
definitive identification of each of the components of these mixtures, it 
is therefore high time that a standard and internationally accepted nomen-
clature was adopted. 
The need to bring order to the subject of plasminogen activation 
is particularly pressing in view of their potential usefulness as thrombo-
lytic agents and the increasing extent to which they are being seen as 
agents for achieying regulated, local and limited proteolysis in a wide 
range of physiologically important situations that have no obvious 
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relationship to fibrinolysis. If, for example, we see reason to agree 
that plasminogen activators are involved in such diverse processes as 
ovulation (119-122), marrnnary involution (88) trophoblast implantation (123) 
and embryogenesis (124), as well as inflarrnnatory processes (81,84,125) 
we should also be able to agree on which particular enzyme it is that is 
responsible for each of these functions. 
CHAJ.'TER. 1 
ISOLATION AND CONCENTR.ATlON Of THE PLASMlNOGEN ACTlVATOR. S'.{NTHE.SIZED BY 
MELANOMA CELLS CULTURED IN VITR.O. 
It is now well established (51,126,61,62,117,127,128,129,115) 
that human cells cultured in vitro release plasminogen activators that 
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may be divided into two distinct types on the basis of their immunochemical, 
physical and biochemical characteristics. 
The first type is in all respects similar to urokinase in that it 
comprises a mixture of plasminogen dependent proteases with major proteases 
having molecular weights of 60 000 and 32 000 daltons. 
inhibited by antibody to urokinase. 
These are all 
The second type is made up of plasminogen activators with a 
predominant molecular weight species of 70 000 daltons. These are not 
inhibited by antibody to urokinase. Most cell lines derived from human 
malignant melanomas release exclusively the activator of this non-urokinase 
type (61,117,115). 
I therefore felt that a melanoma cell culture would provide a 
useful source of material for the purification of the non-urokinase activator 
since it would avoid the problems attendant upon separation of two closely 
related and similar enzymatic functions. 
Of the several melanoma cell lines available to me, the RPMI-7272 
line was selected for this purpose sirice these cells produce relatively 
large quantities of the enzyme and are easily maintained in culture. 
For the sake of convenience I refer to the non-urokinase type of 
plasminogen activator released by melanoma cells as "melanoma plasminogen 
activator" or "Mel-PA". 
In Chapter III I present the work that I did to characterize 
Mel-PA and to demonstrate its close similarity to the "tissue activator" 
first described by Astrup and Permin in 1947 (13). My results are 
essentially in accord with those presented by Rijken and Collen (130) in a 
paper published while my studies were in progress. These workers used 
enzyme derived from the same cell line as did I. In view of the close 
agreement between our two laboratories on the nature of Mel-PA and for 
reasons which I discuss in further detail in Chapter III, I shall continue 
to refer to this enzyme as "Mel-PA" and not as "tissue activator". 
In the present chapter I report the results of experiments that 
were performed to define conditions for cell culture and isolation that 
would provide optimal yields of enzyme under the most convenient circum-
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stances. While this work was in progress, I was at the same time involved 
in studies to examine assay techniques, to characterize the activator and 
to purify the enzyme. For the sake of orderly presentation I have relegated 
thes.e results to other chapters. Since, however, they had an important 
bearing on my experimental approaches to defining optimal conditions, it is 
appropriate for me to make brief mention at this stage of two observations 
that are more completely documented in other chapters. 
In the first instance, I found that melanoma cells released 
plasminogen activator both as the active enzyme and as a pro-activator 
which could be converted, by limited proteolysis, to the active form of the 
enzyme. Evidence for this fact comes from the data presented in Chapter 
V ., in which I showed that plasminogen activator content of harvest fluids 
could be increased by treatment with .plasmin. In the present chapter, 
therefore, when I describe the effect of culture conditions on enzyme 
release, these- results take into account the fact that both enzyme and 
pro-enzyme were involved. 
Secondly, I found it possible to prepare an affinity reagent for 
the one-step purification of Mel-PA by coupling· an inhibitor from the seed 
of the South African tree, Erythrina latissima to sepharose-CL. This 
work is described in detail in Chapter IV. 
MATERIALS AND METHODS 
Cultivation of melanoma cells " 
The cell line (RPMI-7272) used for these studies was isolated 
in 1974 by Dr. G. Moore, Denver Hospital, Denver, Colorado from a primary 
culture of a malignant melanoma removed from a female patient. It is 
also known as "Bowes melanoma" and has been referred to as such in the 
literature (130). The subculture that I obtained was generously provided 
by Dr. E. Reich of the Rockefeller University, New York. 
Stock cultures of these cells were maintained in disposable 
plastic petri dishes (100 mm or 60 mm, Falcon No. 3003 and 3002) at 37°c 
in a humid atmosphere of 95% air/5% CO 2• The cells grew as adherent 
monolayers in RPMI 1640 tissue ·culture medium suppl~mented with 10% heat-
inactivated (56°C; 30 min) foetal bovine serum (FCS), and antibiotics 
(300 µg/ml penicillin; 200 µg/ml streptomycin; and 10 -µg/ml of tylocine). 
The cells were passaged at confluence (approximately 4 x 105 
2 5 
cells/cm) by trypsinisation and reseeding at 5 x 10 cells/100 nnn dish. 
After aspirating the medium the cells were incubated in 0.25% Trypsin 
(Difeo, 1:250) in TD at 37°c for 5 min. Detached cells were dispersed 
by gentle pipetting and the suspension was added to an equal volume of 
medium containing FCS to neutralize the protease. The cells were then 
washed by centrifugation at 350g for 5 min, resuspended and reseeded into 
fresh dishes. 
Dormant stocks were maintained in liquid nitrogen according to 
the following procedure: Healthy cultures were trypsinized and suspended 
at 2 x 10
6 
cells/ml in RPMI 1640 medium containing 10% FCS and 10% DMSO 
at o0 c. The suspension was distributed as 1 ml aliquots into 3 x 12,5 nnn 
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screw cap nylon storage vials (Nunc, Cat. No. 1078). These were then 
frozen in an automatic liquid nitrogen cooled freezing apparatus of our own 
manufacture. This was programmed to freeze the cell suspension according 
to the protocol of Farrant et al (131), in which suspensions were cooled 
as rapidly as possible (-4°C/min) to a temperature of -26°C; they were 
then maintained at this temperature for a period of 20 minutes after which 
they were frozen rapidly to a temperature of -6o 0 c. At this point they 
were immersed in liquid nitrogen in a storage container. 
To reestablish cultures from frozen cells a vial was removed from 
liquid nitrogen and thawed rapidly by immersion, with gentle manual agitation, 
in a 37°c waterbath. As soon as the last visible ice crystals had melted, 
the contents of the vial were added to 10 ml complete tissue culture medium 
in a ·100 mm plastic dish. This was then placed in a co2 incubator. After 
allowing 6 hours for the cells to adhere, the DMSO was removed by washing 
and the cells were fed with fresh medium. 
While this work was in progress, a subline of the Bowes melanoma 
cells was developed, which would adhere, proliferate and synthesize 
plasminogen activator in the complete absence of serum. To distinguish 
these cells, I refer to them as "Bowes II" cells. The serum-dependent 
cells from which they were derived, I refer to as "Bowes I" cells. 
Bowes II were maintained as adherent monolayer cultures in tissue 
culture flasks (Costar Cat. No. 3150). Monolayers were covered with 50 ml 
of RPMI 1640 medium supplemented with tylocine and antibiotics but without 
serum. These cells were passaged at confluence by vigorous tapping. 
dislodged in this mechanical fashion were suspended in serum-free tissue 
culture medium at a concentration of approximately 106 cells/ml and used 
to reseed fresh flasks at approximately 5 x 10 7 cells/flask. 
Cells 
A detailed description of this unique serum independent Bowes II 
line is shortly to be published in association with Dr. E.L. Wilson with 
whom credit for development of the line rests. for the purpose of this 
thesis it is appropriate to record only the essential and relevant attri-
butes summarized in the Results section. 
Collection of conditioned medium. 
Observations made by ourselves (106) have shown that it is 
preferable to collect harvest fluids in the absence of serum since in 
this way the effect of serum inhibitors on the enzyme are avoided. It 
is also known that plasminogen activators in dilute serum-free solution 
are notoriously liable to loss by adsorption to plastic surfaces, by 
denaturation, or by proteolysis. Albumin (106), gelatin (108), salt 
(132) detergents (108,130,68) or protease inhibitors or arginine (90, 
108,134) have been variously used to counteract these losses. For my 
particular purposes it was necessary to study the effects of conditions 
of storage on the enzyme. 
Protocols for the collection and storage of harvest fluids are 
therefore presented and considered in the Results section. 
Preparation of aminobenzamidine-sepharose. 
17 
Meta-aminobenzamidine was prepared from meta-nitre benzamidine by 
catalytic hydrogenation according to the method of Hixson and Nishikawa (135) 
as described in detail in the Appendix (Al.7). 
Sepharose CL-4b was activated with CNBr according to the method 
of Nishikawa et al (136) as detailed in the Appendix (A.1.7). 
Aminobenzamidine was linked to the CH-sepharose by carbodiimide 
coupling according to the method of Hixson and Nishikawa (135) in which 
meta-aminobenzamidine (8g) in 40 ml 0.2M NaCl, pH 4.75 and l-ethyl-3-
(3'-dimethyl amino-propyl) carbodiimide HCl (EDC; 5g) in H
2
0 were added 
to 100 ml of settled CH-sepharose, and the pH was maintained at 4.75 with 
2M HCl. The reaction was continued at 4°c for 24 hr, after which the 
matrix was washed sequentially with O.OlM HCl - 0.5M NaCl; O.OlM NaOH 
0.5M NaCl; and 0.2M NaCl. 
Preparation of zinc chelate-sepharose. 
Zinc-chelate-sepharose was prepared according to Rijken et al 
(130) as follows: 
Sepharose CL-4b (300 ml) was washed with distilled water on a 
sintered glass filter and mixed with 300 ml of 1,4-butanediol diglycidyl 
ether and 300 ml 0.6M NaOH containing 2 mg/ml sodium borohydride. The 
suspension was incubated at room temperature for 16 hr with stirring. 
The activated matrix was then collected under suction on a sintered glass 
funnel and thoroughly washed by the passage of 50 litres of distilled 
water. It was then mixed with 200 ml of 2M sodium carbonate, pH 11.0 
containing 40g iminodiacetic acid disodium salt. The suspension was 
rotated for 3 days at room temperature, harvested under suction and then 
washed with 30 litres of water. 
The matrix was resuspended in 2.5 litres of 7.3 mM ZnC12 and 
incubated for 1 hr at room temperature. After washing with 5 litres of 
distilled water and equilibration in 0.02M Tris HCl, pH 7.5 containing 
lM NaCl and 0.01% Triton, the matrix was ready to use. 
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The matrix could be regenerated by washing consecutively with 
0.05M EDTA pH 8.0; 0.05M ammonium hydrogen carbonate, pH 10.5; distilled 
water; 7.3 mM ZnC1 2 ; and 0.02M Tris-HCl pH 7.5 in 0.01% Triton, lM NaCl. 
Assay for plasminogen activator. 
Plasminogen activator activity was quantitated by one of two 
techniques. In the first I measured the time course of plasminogen-
dependent release of radioactive fibrin-degradation peptides from 
125I-labelled fibrin deposited as an insoluble coating on to plastic 
surfaces (106). 
In the second, I measured the increase in fluorescence that 
resulted from the direct hydrolysis of the synthetic substrate Cbz-Gly-
19 
Gly-Arg-AMC (133). This method, although less sensitive had the advantage 
of plasminogen independence. It could also be used in the presence of 
plasmin inhibitors, such as Trasylol, that did not inhibit Mel-PA. 
Both of these techniques are described in detail in the Appendix 
(A3) and are considered fully in Chapter V and VI . . 
SDS-polyacrylamide gel electrophoresis. 
Sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis 
in gel slabs was carried out according to the method of Maizel (137). 
Plasminogen activator activity in gels was detected by the zymographic 
technique of Granelli-Piperno and Reich (62) or by the method of Heussen 
and Dowdle (138)(see Appendix A2). 
3 Autoradiography of gels containing H-labelled proteins was 
performed according to the method of Bonner and Laskey (139) (Appendix 
A.2.5). 
RESULTS 
Cultivation of RPMI 7272 melanoma cells. 
The results of preliminary experiments and considerations of 
convenience, economy and available facilities, led to the adoption of a 
standard tissue culture system in which cells were grown as adherent 




tissue culture flasks. These containers 
had the advantage over others, such as petri dishes, that harvest fluids 
could readily be collected by decantation and it was thus easier to 
maintain flasks free of bacterial and fungal contamination. Under usual 
circumstances 30 such flasks yielding approximately 1.5 litres of 
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conditioned medium per day, constituted a manageable and convenient operation. 
The appearance of the cell monolayers is shown in the photographs 
presented in Figure 1.1. Bowes I cells in presence of serum had a poly-
gonal appearance (Fig. 1.1.a). At confluence they tended to pile up in 
local clusters which detached from the monolayers in viable floating groups. 
After 4 days of serum deprivation, Bowes I cells appeared less well spread 
(Fig. 1. lb). The cytoplasm became vacuolated and the cells detached 
readily as confluent sheets. These changes were reversible within 24 hr 
by serum replacement. Bowes II cells that had been passaged 13 times 
in absence of serum over a period of 5 months grew as adherent monolayers 
(Fig. 1. lc). The cells were less well spread than Bowes I cells. At 
confluence they too tended to detach from the dish as viable clusters 
which could easily be dispersed as suspensions. The addition of serum 
to these cells resulted in a pronounced morphological change (Fig. 1.ld) 
that came about in a matter of hours. Individual cells spread more 
extensively; abundant mitotic figures became apparent and the cultures 
came once more to resemble Bowes I cells from which they were originally 
derived but had a slightly flatter appearance. 
Figure 1.1 Morphological appearance of Bowes I and Bowes II 
melanoma cells cultured in vitro. 
The photographs show the appearance, under phase contrast 
microscopy, of adherent monolayers of 
(a) Bowes I cells 1n RPMI/ 10% FCS; . 
(b) Bowes I cells 1n RPMI after 5 days of serum deprivation 
(c) Bowes II cells cultured in RPMI without serum and 
(d) Bowes II cells to which medium containing 10% FCS had 
been added 3 days previously. 
Bowes I cells in serum had a polygonal morphology with dendritic 
processes typical of many melanoma cell lines. Mitotic cells were 
frequent. When confluent, cells tended to aggregate and to separate 
, from the adherent monolayer . (Figure 1.la). Serum deprivation for 5 days 
caused the cells to round up and to retract their processes (Figure 1.lb). 
Bowes II cells showed an appearance similar to Bowes I after 
serum deprivation, although mitoses were noticeably more frequent. 
Addition of serum to Bowes II cells produced a marked morphological 
change. The cells became large and flat and were quite distinct from 
the original Bowes I cells grown in serum. 
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As is evident from the graphs presented in Fig. 1.2, Bowes l 
cells under standard culture conditions grew with a doubling time of 
5 2 27.3 hours to reach maximum adherent cell density of 5 x 10 cells/cm. 
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If medium was not replenished frequently after confluence had been reached 
or if the cells were not passaged, rapid deterioration of the cultures 
resulted. Removal of serum from Bowes I cultures resulted in a rapid 
and complete cessation of growth. 
Bowes II cells in the absence of serum maintained a healthy 
appearance and grew with a doubling time of 5,7 days. Addition of serum 
to Bowes II cells resulted in a rapid increase in proliferative rate with 
a doubling time of 2.1 days. 
Collection and storage of conditioned medium. 
Conditioned medium containing plasminogen activator was collected 
in one of two ways, depending upon whether the enzymes were derived from 
Bowes I or Bowes II cells. 
2 In the case of Bowes I, cells were $eeded into 75 cm tissue 
5 . 
culture flasks (Falcon Cat. No. 3024) at a density of 2-5xl0 cells, and 
allowed to grow to near confluency in medium supplemented with 10% FCS. 
The cultures were then washed once and covered with 20 ml of serum free 
medium. 
added. 
After 24 hr the medium was collected and fresh medium was 
The process of taking sequential 24 hr, serum free harvest 
fluids could be repeated 3-4 times before the cells degenerated and tended 
to detach from the plastic substrate. Vitality and adherence was readily 
restored by treatment for 24 hours with medium containing 10% serum. 
When Bowes II . cells were used as the source of enzyme, they 
7 2 were seeded at 5 x 10 cells per 150cm flask (Costar Cat. No. 3150) and 
covered with 50 ml of medium. The cells proliferated slowly in serum free 
medium and were hence plated at near confluence. The taking of 24-hour 
Figure 1. 2 Growth curves of Bowes I and Bowes II melanoma cells in 
vitro. 
A. Bowes I melanoma cells were seeded in RPMI supplemented 
with 10% FCS on 35 mm dishes at 5 x 104 cells/dish. Medium was 
changed and cells in replicate cultures were counted at 24 hr 
intervals for the indicated period of time (.--~~~~~~ ). After 
5 days the medium in some cultures ( - - - - - - ) was replaced with 
serum-free RPMI to observe the effects of serum deprivation on 
cell number. 
B. Bowes II melanoma cells were seeded either in RPMI at 
2.5 x 106 cells/35 mm dish (- - - - -) or in RPMI supplemented with 
10% FCS at 1.9 x 105 cells/35 . mm dish ( ). Medium was changed 
every 48 hr and cells in replicate cultures were counted at the indicated 
times. 
The doubling times, calculated from the exponential part 
of the growth curves, were as follows: 
Bowes I cells in IPMI/10% FCS - 1.1 days 
Bowes II cells in RPMI - 5.7 days 
Bowes II cells in RPMI/10% FCS - 2.1 days 
Although Bowes II cells in the absence of serum, did not 
attain saturation density, it can be seen that they would have 
achieved a higher density at confluence than did Bowes I cells in the 
presence of serum. 
24 
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serum free harvest fluids started immediately when cells had become 
adherent. Daily collection of 50 ml from each flask were taken until 
confluence of the monolayers necessitated passaging. 
amounted to approximately 2 weeks. 
This usually 
Mel-PA containing harvest fluids were centrifuged at 2000 rpm 
for 5 IIll.n to remove whole cells and cellular debris. To define optimal 
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conditions for the storage of harvest fluid prepared in this way, the 
activity of Mel-PA was determined after treatment at different temperatures 
for various times. The activities were compared with those of harvest 
fluids kept at -20°c and thawed just before assay. Fig. 1.3 shows that 
all Mel-PA activity was lost after incubation for 20 hr at 4°c or for 
0 4 hr at 37 C. Methods to prevent this loss of activity were therefore 
explored. 
As is shown in Fig. 1.4 the presence of 0.4 mg/ml of protease-
and inhibitor-free bovine serum albumin (PIF-BSA) in harvest fluids greatly 
preserved enzyme activity. 
Nonionic detergents such as Tween 80 and Triton X-100 have been 
reported by others to stabilize plasminogen activator activity (108,130,68). 
The effect of Triton X-100 on Mel-PA activity was therefore tested. Results 
given in Table 1.1 show that Mel-PA activity can also be preserved in all 
cases by the addition of the nonionic detergent, Triton X-100, provided 
it was added to the container either with the enzyme or before it. Addition 
after the enzyme had been · added and shortly before assay abrogated the 
protective effect of the detergent. These. time relationships led me to 
conclude that the detergent was acting by inhibiting losses of enzyme by 
absorption to the wall of the tube. 
Since I was loath to add a foreign protein, and in particular, 
one such as albumin with a molecular weight so close to that of Mel-PA, I 
elected to stabilise the enzyme with nonionic detergents i.e. either 0.1% 
Figure 1.3 Thermostability of plasminogen activator in harvest fluids. 
Harvest fluid from melanoma cells was stored at -20°c 
in 100 ;il volumes. Samples were thawed and incubated in duplicate 
for the times and at the temperatures shown. After incubation 
. d 1 . . d . h 1251 f. b . d resi ua enzyme activity was measure int e - i rin assay an 
expressed as apercentage of that present in solutions maintained 
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Eigure 1. 4 
0 10 20 30 40 50 
Time (hr) 
Thermostability of plasminogen activator in the presence 
of bovine serum albumin. 
The effect of temperature on Mel-PA was determined using 
the same protocol as that described in . the legend to Fig. 1.3. 
In this case, however, the samples were adjusted to contain 0.4 mg/ml 
of BSA before incubation at 4°C or 37°c for the times shown. 
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TABLE 1.1 Effect of Triton X-100 on stability of plasminogen activator. 
Triton cone. Condition of incubation or storage 
%(v/v) 0 20 C, 4hr 
0 




-20 C(stored) 0 -20 C (stored) 
(a) (b) 
0 80 (c) 160 175 185 210 
.0001 255 215 335 220 150 
.001 555 365 425 440 315 
.01 610 390 480 440 200 
(c) Figures in the body of the table refer to plasminogen activator activity 
(% T/30 min/ml) in solutions incubated or stored as indicated. 
To 450 µl of conditioned medium from melanoma cells was added 
50).11 of 0.1%, 0.01% or 0.001% of Triton X-100 in H20 or 50)11 of H2
0 only. 
The mixtures were frozen and stored at ~20°c. 
For the experiment, samples were thawed and incubated at 20°c 
or 4°c for the times shown. 
Residual plasminogen activator activity was then measured in 
h 125 f. . t e I- 1br1n assay. 
0 Comparison tubes (columns a and b) were kept at -20 C and 
thawed immediately before assay without incubation. In samples under column (a) 
the Triton was added before freezing and storage; in (b) the Triton was added 
after thawing and before assay. 
Triton X-100 or 0.1% Tw:een 80. 
The stability of Mel-fA in harvest fluids in the presence of 
0.1% Triton X-100 at various pH 1 s is shown in fig. 1.5. As can be seen, 
0 the enzyme was stable at neutral pH at 4 C for 48 hr. The highest 
activity was maintained at pH 5.5 - 6.0. Harvest fluids were therefore 
acidified to this pH before storage at -20°c. 
noticed below pH 4.5 and above pH 8.0. 
A decline in activity was 
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Using the standard protocol for the collection and storage of 
harvest fluids, the results summarized in Tables 1.2 and 1.3 were obtained. 
Bowes I cells at a density of 1.3 x 105 cells/cm
2 
could be 
relied upon to release approximately 1200 UK units of plasminogen activator 
in 24 hr when cultivated under 2 ml of medium/106 cells. Of this enzyme 
90% was active. The remainder was in the form of proactivator. Bowes I -
cells in the presence of 10% serum grew with a doubling time of 27.3 hr. 
One 75 cm
2 
flask of adherent Bowe~ I cells at confluence could be sustained 
with cyclical serum deprivation for harvest fluid collection for an 
indefinite period provided infection of the cultures could be avoided or 
cell detachment and death due to serum deprivation or superconfluence was 
guarded against. Generally speaking one flask of Bowes I cells could be 
expected to provide harvest fluids for approximately 1 month. 
Bowes II cells proliferated more slowly, with a doubling time 
of approximately 136.8 hr in the absence of serum. 2 One 150 cm bottle 
carrying a confluent monolayer of 4 x 105 cells/cm2 and covered with 
0.8 ml medium/106 cells could ~e relied upon to produce approximately 
3700 UK units of plasminogen activator in 24 hr, of which 10% was in the 
form of active plasminogen activator and 90% in the form of pro-plasminogen 
activator. 
The slow gruwth rate in the face of active protein synthesis 
made these cells . very much easier to work with. They showed no tendency 
to detach from the plastic. 
2 ,., 
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Figure 1.5 Stability of plasminogen activator at different pH's 
in the presence of 0.1% Triton X-100. 
Harvest fluid samples containing 0.1% Triton X-100 were 
adjusted to different pH values by the careful addition of O.lM HCl 
or O.lM NaOH. They were incubated at 4°c for 48 hr after which the 
pH values were readjusted to pH 7.2. 
d . h 125 f. . was assaye int e I- ibrin assay. 
Plasminogen activator activity 
The results are expressed 
as the percentage activity in the samples relative to that in harvest 
fluid containing Triton X-100 and incubated for the same length of 
time but without adjustment of the pH. Note that optimal stability 






Plasminogen activator release by Bowes I and Bowes II 





































; 20 ml/flask) or Bowes II cells grown in 150 cm2 
5 2 
flasks (4 x 10 cells/cm; ~O ml/flask) were taken every 24 hr over 
4 days. Plasminogen activator activity was measured in the 
1251-fibrin 
assay. Note that PA release stayed constant over the 4 day period in 
the case of Bowes II cells. 
In the case of Bowes I cells, PA activity increased slightly 
over the first 3 days, but then decreased on the 4th day. By this time 
most of the cells had detached from the surface, and RPMI supplemented 
with 10% FCS had to be added to restore adherence. 
N S . h 1251 f'b ' b h P A d PA .. ote: ince t e - i rin assay measures ot ro P an activity 




Table 1.3 Plasminogen activator release by Bowes I and Bowes II cells 
Plasminogen activator release 
6 . 
(FU/10 cells/24 hr) 
Cell type Days in Cell density 
culture 
5 -2 (cellsxlO xcm ) Total activity (a) PA(%) Pro PA(%) (b) 
Bowes I 1 1.04 46.62 87.5 12.4 
2 1. 27 51.96 92.1 7.9 
3 1.43 64. 86 83.9 16.1 
Bowes II 1 3.88 26.06 12.7 87.3 
2 3.88 25.10 12.4 87.5 
3 4.01 24.40 10.9 88.9 
5 Bowes I cells were plated at 5 x 10 cells per replicate 35 mm 
dish rn 2 ml RPMI containing 10% FCS. After 24 hr the medium was replaced 
with serum free RPMI and 24 hr harvest fluids were collected for 3 consecutive 
days. At the end of each 24 hr period the cell number per plate was counted. 
6 Bowes II cells were plated at 3 x 10 cells per 35 mm dish 
in 2 ml RPMI. 
Plasminogen activator activity was determined using the 
fluorometric assay with Cbz-Gly-Gly-Arg-AMC as substrate. 
(a) Total PA activity was measured after incubation of 295 µl harvest 
fluid with 5 µl plasmin (0.1 mg/ml) for 60 min at room temperature. 
Plasmin was inhibited by Trasylol for the assay. 
(b) The amount of proactivator (Pro PA) was estimated by subtracting 
the activity measured without plasmin activation from the total activity. 
produce enzyme in useful daily quantities for a period of 3-6 months. 
Attempts were made to increase the yield of plasminogen 
activator from melanoma cells by the addition of inducing agents such as 
TPA, dexamethasone or retinoic acid. None of these were successful 
on any of the melanoma cells tested (Table 1.4). 
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Effects of volume of serum-free medium on Mel-PA secretion by melanoma cells. 
Considerations of economy, convenience and enzyme stability made 
it desirable to keep harvest fluid volumes as small as possible without 
compromising cellular viability or the rate of enzyme synthesis by the 
cultured cells. 
Several experiments were therefore·performed in which harvest 
fluids were prepared by covering replicate monolayer cultures with different 
volumes of serum free medium. In a typical experiment Bowes I cells were 
seeded at 5 x 105 cells/100 mm dish in 10 ml of DME containing 10% FCS. 
When near confluence, the cells were washed twice with serum-free medium. 
After 24 hr the conditioned medium was harvested for assay of plasminogen 
activator activity and the number of cells per dish were counted. 
The results summarized in Table 1.5 showed that the rate of 
enzyme release per cell was relatively independent of medium volume:cell 
number ratio. Thus 5.7 x 106 cells covered by 5 ml of medium released an 
amount of 34 UK u/10
6 
cells/24 hr, whereas 5.6 x 106 cells covered with 
20 ml of medium released 40 UK u/106 cells/24 hr. It was felt that 10 ml 
of medium per 5 x 10
6 
cells provided a satisfactory compromise between the 
conflicting interests of cell viability and enzyme concentration. All 
subsequent experiments, therefore, used this ratio for medium volume:cell 
number. 
Although similar formal experiments were not performed on Bowes II 
cells, my impression was that a lower optimal ratio for medium volume:cell 
number could be used. 
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TABLE 1,4 Effect of tetradecanoyl phorbol aceta·te, retinoic acid and 
dexamethasone on plasminogen activator release by melanoma cells. 
Cell line Plasminogen activator release (% of control) 
TPA (10 ng/ml) RA (10-6M) Dex (l0-6M) 
UCT-Mel 1 27 164 143 
UCT-Mel 2 100 29 143 
UCT-Mel 3 100 100 100 
UCT-Mel 5 0 290 100 
UCT-Mel 6 100 208 34 
UCT-Mel 7 100 143 78 
with FCS. 
Melanoma cells were seeded at semiconfluence in · medium supplemented 
The following day, the test compounds were added at the concen-
tration indicated in the table. The cultures were maintained in the presence 
of these compounds for 48 hr with one medium change after 24 hr. They were 
then washed and 24 hr harvest fluids were taken for measurement of plasminogen 
' ' h 125 f 'b ' I h bl 1 . . activator int e I- i rin assay. n t eta e p asminogen activator 
release is expressed as the percentage of control values obtained with cells 
that were not exposed to the compound. 
(I am grateful to Miss E. Roal for permission to use these results. 
They came from experiments she performed during the course of her 
work for her Ph.D thesis). 
TABLE 1.5 The effect of volume of serum-free medium on plasrninogen 
activator secretion by melanoma cells. 
Volume (ml) UK u/ml Cells/dish 6 UK u/ 10 cells 
5 39.3+2.5 5. 70xl0 6 34.5 
10 23.7+3.l 5.60xl0 
6 
42.3 
15 15.6+1.l 5. lOxlO 6 46 .1 
20 10. 4+0. 8 5.20xl0 6 40.0 
Melanoma cells were grown to near confluency, washed 
twice in serum-free DME and incubated in different volumes of 
serum-free DME. After 24 hr conditioned medium was harvested 
for assay of plasrninogen activator and the number of cells per 
dish was counted. 
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The effects of different media and substrata on the growth of melanoma 
cells and plasminogen activator release. 
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To optimise medium and culture substratum, Bowes I melanoma cells 
were seeded into tissue culture (,Falcon Cat. No. 3003) or standard plastic 
bacteriology petri dishes at a density of 5 x 105 cells/100 mm dish. In 
all cases the cells were suspended in 10 ml medium supplemented with 10% 
FCS. Different media were used ; including minimal Eagle's medium (MEM), 
MEM-Spinners medium (MEM-S), Dulbecco's modified Eagles medium (DME) or 
RPMI-1640 medium. These media were buffered with bicarbonate or Hepes 
buffer as indicated in Table 1.6. 
The cells were incubated in the presence of 10% foetal calf serum 
for a total of 72 hr, with a medium change after 24 hr. After 72 hr in 
the presence of serum, the cells were washed and covered with 10 ml of the 
corresponding serum-free medium and incubated for a further 48 hr period 
after which time the harvest fluid was taken for plasminogen activator assay. 
The results of these experiments summarised in Table 1.6 show that optimal 
cell growth was observed in bicarbonate-buffered RPMI or DME in both tissue 
culture and bacteriology dishes. 
Optimal activator production (in terms of enzyme/ml of harvest 
fluid) was similarly observed in bicarbonate-buffered RPMI or DME. 
The detrimental effects of Hepes buffer are evident from the data, 
and particularly so when Hepes-RPMI was used in combination. In bacteri-
ology dishes cell growth was arrested; in tissue culture dishes the cells 
detached and died. 
Spinner medium, which might have been used to cultivate cells in 
suspension, failed to support growth as well as did RPMI or DME. For 
subsequent work RPMI was used. 




TABLE 1.6 The effect of different media on the growth of melanoma 
cells and plasminogen activator release. 
No. of cells/ml X 105 
Medium 24 hr+FCS 72hr+FCS 48hr-FCS PA Activity (c) 
(%T/hr/ml) 
MEM o. 42 2.40 7.8 9550 
MEM-H 0.92 2.6 3.7 8350 
MEM-S 0.72 2.8 3.8 9050 
MEM-S-H 0.80 2.0 1.2 3600 
RPMI 0.98 3.1 8.6 13950 
RPMI-H 0.93 1. 7 0 1500 
DME 1. 20 2.9 8.5 13400 
DME-H 1.10 1.8 3.8 9100 
MEM 0.17 2.6 9.9 11600 
MEM-H 0.53 1.2 2.2 
MEM-S 0.66 3.0 4.2 11800 
MEM-S-H 0.43 1. 7 1.0 
RPMI 0. 78 3.0 14.0 15100 
RPMI-H 0.50 1.2 0.9 
DME 0.84 2.8 6.9 13350 
DME-H 0.13 1.6 2.7 
a) - Cells were plated in Falcon tissue culture dishes (cat. No. 3003) 
b) Cells were plated in bacteriology petri dishes 
c) - Enzyme activity is expressed as the percentage total cpm 
released from 1251-fibrin coated wells in 1 hr. 
Abbreviations: MEM - minimum essential medium (Eagle) 
MEM-S - minimum essential medium for suspension culture 
DME - Dulbecco 1 s modified Eagle medium 
H - HEPES (N-2-hydroxyethylpiperazine - N'-2 ethanesulfonic acid) 
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drawn continued to proliferate at approximately the same rate as they had 
done in the presence of serum. This "serum-independent" proliferation 
lasted· for approximately 48 hr and required that the medium be bicarbonate-
buffered RPMI 1640, MEM or DME. 
Since the doubling time of Bowes II cells in serum-free medium 
was considerably longer than 48 hr (Figure 1.2), I presume that either 
growth factors present in serum continue to exact their effects on the 
Bowes I cells for some time after their withdrawal or, alternatively, 
serum depletion was not complete. It is, in fact, not difficult to show 
that despite extensive washing with medium, it is very difficult to remove 
all traces of residual serum. 
Large volumes of harvest fluid were required as starting material 
for the purification of Mel-PA and attempts were therefore made to cultivate 
melanoma cells on a large scale. Since the melanoma cells seemed capable 
of growth and Mel-PA synthesis when maintained in bacteriological petri 
dishes that impaired attachment, cultivation of these cells in suspension 
in spinner flasks was explored. 
A 250 ml spinner flask (Bellco, Cat. No. 1960-00250) was 
inoculated with melanoma cells at a concentration of 7.0 x 104 cells/ml 
in a total volume of 250 ml of RPMI/10% FCS equilibrated with 5% CO 2 in air. 
The culture was kept at 37°C and stirred magnetically at 30 rpm. 
At 24 hr intervals 100 ml of the suspension was removed. After 
taking a 100 µl sample for a cell count, the cells were collected from ·each 
100 ml aliquot by centrifugation at 350g for 5 min, resuspended in 100 ml of 
fresh medium, and returned to the flask. 
After 6 days of cultivation in medium supplemented with serum, 
all cells were taken out of the flask, washed in serum-free medium and added 
back in 250 ml RPMI. Medium was again changed every 24 hr when the cell 
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number was determined and plasminogen activator activity was measured. 
There was a slow, steady increase in cell number over the 6-day 
period of growth in medium supplemented with 10% FCS (Fig. 1.6). After 
change to serum-free medium, there was a slight decline in cell number 
which then stabilized at 4.3 x 10
5 
cells/ml. Plasminogen activator 
secretion per cell remained constant during the 4 day period in serum-free 
meidum. On the basis of these results it was decided to attempt the 
mass cultivation of melanoma cells in 1 litre spinner flasks in RPMI medium. 
For this purpose a system was devised for changing the medium without having 
to remove the cells from the flask. This is depicted diagrammatically in 
Fig. 1.7. Medium was pumped out of the flask at a rate of 5-10 ml/hr and 
replaced at the same rate with fresh medium which had been equilibrated 
with 5% co2/air. The cells were retained by a glass tube filled with 
glass wool at the outlet. This type of filter proved superior to the 
various types of Millipore filters in that position, since the latter 
became clogged with cells very rapidly. Despite the improvised glass wool 
filter, however, cells escaped through the outlet and accumulated in the 
tubing thus necessitating frequent changes. Contamination of the effluent 
with microorganisms consequently became a major problem and led to my 
abandoning this method of collecting harvest fluid. Furthermore, the 
Mel-PA concentration in these harvest fluids was very low, varying from 
4 UK u/ml to 6 UK u/ml. 
A second method of mass cultivation of melanoma cells on Melanex 
sheets in Sterilin bulk cell culture vessels (ICRF spiral system)(l40) was 
unsuccessful. The melanoma cells did not seem to multiply on the Melanex 
substrate, nor was I successful in inducing the cells to grow on "Cytodex" 
beads (Pharmacia) (141). 
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Figure 1. 6 Plasminogen activator release and proliferation exhibited 
by Bowes I cells grown in a spinner flask. 
A 250 ml spinner flask was inoculated with melanoma cells 
at a concentration of 2 x 105 cells/ml in a total volume of 250 ml of 
RPMI/10% FCS. At 24 hr intervals 100 ml of the suspension was removed, 
the cells were collected by centrifugation and returned to the flask 
after resuspension in 100 ml of fresh medium. Cells were counted in 
100 µ l aliquots. After 6 days of cultivation the medium was replaced 
by 250 ml RPMI without serum. Medium was again changed every 24 hr 
at which time the cell number was determined and plasminogen activator 
activity was measured. PA activity is expressed as %T/hr x 103 
(see Appendix A.3). 
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Figure 1.7 Mass cultivation of melanoma cells in a spinner flask 
A 1 litre spinner flask was inoculated with melanoma cells 
at a concentration of 5 x 105 cells/ml in a total volume of 1 litre 
of RPMI/10% FCS. 0 The flask was kept at 37 C and stirred magnetically 
at 30 rpm. Medium was pumped out of the flask at a rate of 5-10 ml/hr 
and replaced at the same rate with fresh medium that had been equilibrated 
with 5% CO
2 
in air. The cells were retained in the culture vessel 
by an outlet glass tube plugged with glass wool. 
Electrophoretic analysis of proteins released by RPMI-7272 cells. 
To obtain some idea of the extent to which plasminogen activator 
synthesis occupied the protein synthetic machinery of RPMI-7272 melanoma 
cells and, in an attempt to determine whether or not these cells released 
more than one species of serine~protease, protein synthesis was measured 
by incorporation of radioactive leucine and serine proteases released by 
labelling with 3H-labelled DFP. 
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Harvest fluids containing biosynthetically labelled proteins and 
3H-DFP labelled proteases were precipitated with 10% TCA and the precipitated 
proteins were redissolved in SDS. These solutions were analysed by 
electrophoresis followed by autoradiography or counting of the slic~d 
gel. The results of these experiments are presented in Fig. 1.8 and 
Fig. 1.9. 
figures. 
Detailed technical aspects are described in the legends to the 
As can be seen from the results, only one 70 000 dalton DFP-
labelled protease could be detected. Many species of labelled protein 
however were discernible, varying in molecular weight from> 100 000 to 
10 000. Of these the 70 000 molecular weight component corresponding 
to the DFP-labelled enzyme constituted approximately 3%. 
Plasminogen-dependent fibrinolytic activity migrated electro-
phoretically with the same mobility as the DFP-labelled protein. 
Figure 1. 8 
a b 
Autoradiographs of 3H-leucine- and 3H-DFP-labelled 
proteins in harvest fluid. 
Proteins released by melanoma cells were labelled bio-
synthetically by cultivation in the presence of 
3
H-leucine. Serine 
proteases released by these cells were labelled by incubation with 
3
H-DFP. Details of the methods used are given in the legend to 
Fig. 1. 9, 
Radioactive protein samples were analysed by electrophoresis 
(see legend to Fig. 1.9) and auto-fluoro-radiography. The photograph 
above depicts the results. Track (a): Total protein released 
(3H-leucine labelled). Track (b): Serine protease labelled with 
3H-DFP. 
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Ftgure 1. 9 
Figure 1.9 Electrophoretograms of 
3H-leucine labelled proteins, 
3H-DFP labelled proteins and .plasminogen activator 
activity in harvest fluid. 
Proteins in 5 ml of harvest fluid from melanoma cells that 
had been cultured in the presence of 10 µCi 
3H-leucine (48 Ci/mmol, 
Amersham TRK 170) for 24 hr were precipitated with 10% TCA and redissolved 
in 100 µ1 o{ SDS-sample buffer (0.0625M Tris HCl pH 6.8 containing 
2.5% SDS and 10% glycerol). Two samples of 50 µ1 each were electro-
phoresed in a 6-15% linear gradient of SDS polyacrylamide (120 x 170 x 1 mm). 
After electrophoresis, the gel was sliced into 1.7 mm slices, and each 
slice was incubated in 1 ml Soluene 350 (Packard Inst. Corp., 6003038) 
0 at 50 C for 3 hr. Four ml of Dimilume (Packard 6003037) was then 
added and each slice was counted after 24 hr at . 4°c, in a S scintillation 
counter. 
3H-DFP (100 µl; 3.9 Ci/mmol, 5 mCi/ml) was added to 1 ml of 
a non-radioactive harvest fluid sample that had been concentrated 160x 
to contain 3200 UK u/ml of Mel-PA. The mixture was incubated at room 
temperature for 22 hr and then precipitated with 10% TCA. The precipitate 
was redissolved in 100 µl sample buffer and two samples of 50 µ1 each 
were electrophoresed. Radioactivity measurement was done in the same 
way as described for 3H-leucine-labelled proteins. 
Plasminogen activator activity was determined in slices of a 
gel track that had been loaded with 100. µl of the identical harvest fluid 
that had been used for 
3H-DFP-labelling. After electrophoresis the gel 
was incubated in 2.5% Triton X-100 for 30 min and then sliced. Each 
slice was added to a 
125I-fibrin coated Linbro plate well together with 
200 µ1 O.lM Tris HCl containing 10 µg/ml human plasminogen. Radioactivity 
release was deter..iined after 1 hr incubation at 37°c. 
Autoradiographs of the 
3H-leucine and 3H-DFP labelled proteins 
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Concentration of Mel-PA by chromatography on aminobenza.midine-sepharose. 
The finding that benzamidine is a reversible inhibitor of 
plasminogen activators (142) led to the development of benzamidine-agarose 
as an affinity reagent for the purification of these enzymes from human 
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(99,74,126), avian (109) or murine (108) sources. I therefore investigated 
the usefulness of this procedure for the purification of Mel-PA from 
melanoma cell harvest fluids. 
In an early experiment, 100 ml of harvest fluid was adjusted to 
pH 7.0 and passed through a 5 ml column of aminobenzamidine-sepharose that 
had been equilibrated at 4°C with O.OlM potassium phosphate butfer pH 7.4 
containing 0.1% Triton X-100. All Mel-PA in the harvest fluid was 
adsorbed but little activity could be recovered from the column by elution 
either with O.lM benzamidine, pH 7,4 or with a solution of 1 mM HCl (pH 2.8) 
containing 0.2M NaCl and 0.1% Triton. Since binding of macromolecules to 
their affinity matrices is known to increase with time and to diminish with 
increasing temperature, subsequent experiments were carried out at room 
temperature and batchwise adsorption of the activator was achieved by 
tumbling the harvest fluid with a small volume of the benzamidine-sepharose. 
The matrix was then recovered by centrifugation and packed into a suitable 
column for elution. 
The capacity of the benzamidine sepharose for adsorption of Mel-PA 
was tested by adding 50 ml of harvest fluids to 0.1, 1.0, 1.5 and 2.0 ml 
of matrix in plastic centrifuge tubes and tumbling these for 30 min at room 
temperature. Elution was carried out using O.lM sodium acetate pH 3.5, 
containing 0.01% Triton. Although approximately 90% of the Mel-PA in 
50 ml harvest fluid could be adsorbed by 1.5 and 2.0 ml of matrix, the 
recovery of activity was low (13% and 11.8% respectively). Addition of 
10% ethylene gly~ol to the acetate eluting buffer increased the recovery 
of Mel-PA activity to 26.1%, Electrophoretic analysis of the enzyme 
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containing fractions showed that affinity chromatography had failed to 
achieve any substantial measure of purification since most proteins present 
in the harvest fluids were adsorbed and eluted together with Mel-PA. 
In the hope that I would achieve purification of the activator, 
I added 0.5M arginine, a benzamidine analogue, to an eluting buffer 
containing O.lM sodium acetate pH 4.5; 0.1% Triton X-100; and 10% ethylene 
glycol. Before elution the column was washed with O.OlM potassium phosphate 
pH 7.6 containing 0.01% Triton X-100 and 10% ethylene glycol. Although 
recovery of the activator activity from the column was increased to 74.1% 
no further purification was achieved as judged by SDS-polyacrylamide 
electrophoresis (Fig. 1.10). The minimum concentration of arginine found 
to be required for elution of Mel-PA in this system was 0.5M. 
The method published by Danp et al (108) was used, with slight 
modifications, in a further attempt to reduce losses and improve purity. 
Amino-benzamidine sepharose that had been equilibrated with O.OlM sodium 
acetate, pH 5.5, containing 0.1% Triton and 1 mM ZnC1
2 
was added in 1.5 ml 
volumes to 50 ml centrifuge tubes. The tubes were then filled with harvest 
fluid which had been adjusted to pH 5.5 and to contain 0.1% Triton X-100 
After incubation for 60 min at room temperature with 
occasional inversion, the tubes were centrifuged at 250xg for 5 min and 
the supernatant was removed. 
and the procedure repeated. 
Equilibrating buffer (50 ml) was added 
The matrix was then resuspended in equili-
bra ting buffer containing O. 2M NaCl and 10% ethylene glycol and packed 
into a 2 x 3 cm column at a flow rate of 240 ml/hr. The matrix was washed 
with buffer until all visible traces of the phenol red present in the tissue 
culture medium had been washed from the gel. Bound protein was then eluted 
with 0.5M arginine in O.lM sodium acetate at pH 5.5 containing 10% ethylene 
glycol, 0.1% Triton and 1 mM ZnC12. The column was eluted at a flow rate 
of 50 ml/hr and fractions of 5 ml were collected. Those with the highest 
Figure 1 . 10 
a b C 
70K 
SDS po lyacrylamide gel electrophores i s of pro t eins before 
and after benzamidine-sepharose chromatography. 
The photograph shows the .fixed and stained polyacrylamide slab 
gel tracks containing electrophoresed proteins from:-
(a) 2 ml of harvest fluid from Bowes I cells 
(b) and (c) 1 ml of pooled enzyme-containing fractions 
eluted from benzamidine sepharose 
In (b) the harvest fluid was added to the affinity-matrix 
equilibrated with 0.05M sodium phosphate buffer, pH 7. 6 
containing 0.1% Triton X-100. The enzyme was eluted with 
a solution of the following compositions: 
Triton X-100:- 0.1%; ethylene glycol:- 10%; 
and arginine:- 0.5M. 
In (c) the harvest fluid was added to a benzamidine agarose 
affinity gel that had been equilibrated with O.lM sodium acetate 
pH 5.5 containing 0.1% Triton XlOO and 1 mM ZnC1
2
. Enzyme 
fractions were eluted with the same buffer to which 0.5M arginine 
and 10% ethylene glycol had been added. 
Samples were prepared for electrophoresis by precipitating with 
10% TCA. The precipitates were dissolved and boiled in 25 µl SDS sample 
buffer; 10 µl aliquots were then electrophoresed in 6-15%-linear gradient-
polyacrylamide gels containing 0.1% SDS (Appendix A.2). Note that neither 
method of benzamidine-agarose chromatography produced any useful degree of 
purification. 
plasminogen activator activity were pooled. 
was obtained from 500 ml of harvest fluid. 
Usually 30 ml of eluate 
The recovery of activity from such columns ranged from 60% to 
70% without substantially better purification (Fig. 1.10). Since the 
recovery was lower than that obtained with the phosphate system used 
previously, this method was abandoned. 
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Although none of the above methods using amino-benzamidine 
sepharose resulted in any purification of Mel-PA, the following procedure 
was finally adopted as a useful means of concentrating the proteins present 
in the large volumes of harvest fluid. 
Aminobenzamidine sepharose (5 ml; pre-equilibrated with 0.05M 
potassium phosphate buffer pH 7.0 containing 0.1% Triton X-100) was added 
to 45 ml of harvest fluid adjusted to contain 0.1% Triton X-100 to a pH 
of 7.0. Adsorption was carried out for 30 min at 4°c with tumbling of 
the tubes, after which they were centrifuged at 360xg for 5 min and the 
supernatant discarued. A fresh batch of harvest fluid was added and 
the procedure repeated five times. In this way, Mel-PA from 225 ml of 
harvest fluid could be quantitatively adsorbed on to 5 ml of affinity gel. 
After the last adsorption, the matrix from 8 tubes was packed into 
2.5 x 12 cm perspex column and eluted at a flow rate of 75 ml/hr. 
Adsorbed protein was eluted with 0.5M arginine in O.OlM sodium 
acetate pH 4.5 containing 0.1% Triton X-100 and 10% ethylene glycol. Five 
ml fractions were collected. Plasminogen activator activity in each 
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fraction was measured with the I-fibrin assay. Active fractions were 
pooled and stored in the presence of 0.5M arginine, O.OlM Na acetate at 
-20°C. 
Other methods of concentrating harvest fluids were tried including 
dialysis against Sephadex G200, dialysis against annnonium acetate and 
lyophilization, and concentration in an Amicon concentrator using various 
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membranes. The results are summarised in Table 1.7 and show that none 
of these procedures yielded as much active enzyme as did chromatography on 
benzamidine sepharose. 
Concentration and partial purification of Mel-PA using zinc-chelate 
sepharose and Concanavalin A sepharose. 
These very useful procedures were taken, with minor modifications 
from those described by Rijken and Collen (130). They exploit the tendency 
of Mel-PA to bind to its reversible inhibitor, Zn++, and the fact that 
Mel-PA is a glycoprotein which binds to Concanavalin A. 
Zinc-chelate-sepharose was prepared as described in detail in 
the Methods section and used to pack a column measuring 5 x 15 cm. The 
adsorbent was equilibrated with 0.02M Tris HCl pH 7.5 containing lM NaCl 
and 0.01% Triton X-100. 
Serum-free conditioned medium was made lM with respect to NaCl, 
0.1% with respect to Triton X-100, and the pH was adjsuted to 7.5. A 
volume of 10 litres of serum-free harvest fluid was applied to the zinc-
chelate-sepharose at a constant rate of 200 ml/hr. 
The column was then washed with equilibration buffer (1.5 litre) 
and the adsorbed protein was eluted with 900 ml of a linear gradient of 
0 to 0.06M imidazole in equilibration buffer at a rate of 100 ml/hr. Ten 
ml fractions were collected. Enzyme containing fractions were pooled as 
indicated in Fig. 1.11 to give 400 to 450 ml of solution containing 
950-1200 UK u/ml of Mel-PA activ'ity. This represented a recovery of 
approximately 80-90% of enzyme activity. SDS-polyacrylamide gel electro-
phoresis at this stage showed the presence of numerous contaminating proteins 
(Fig. 1. 11). 
Commercial Con A-sepharose (Pharmacia) was packed into a 1.2 x 10cm 
column and equilibrated with O.OlM sodium phosphate buffer pH 7.5 containing 
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Table 1. 7 Methods of concentrating proteins present in harvest fluids. 
Method PA activity Volµme after % recovery 
recovered concentration 
(% T/60) (ml) 
Dialysis against 
O.lM ammonium 53 250 1.0 16.0 
acetate pH 6.5 
and lyophilization 
Dialysis against 
dry Sephadex 122 500 4.5 36. 80 
G200 
Ultrafiltration 
26.70a) on Amicon XM 50 88 875 5.1 
membrane 
Amicon YM 10 162 509 7.8 48.82 
Amicon YM 30 49 798 3.4 14.96a) 
Harvest fluid (50 ml) containing 0.1% Triton was concentrated 
by the methods listed in the table. 
Plasminogen activator activity was measured before and after 
concentration. The total activity contained in the harvest fluid was 
332 875% T/60 min as measured in the 1251-fibrin assay. 
a) Plasminogen activator activity was detected in the ultrafiltrates. 
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Figure L 11 
Figure 1.11 Chromatography of Mel-PA on zinc-chelate sepharose 
and concanavalin A sepharose. 
a) Serum free harvest fluid was applied to the zinc-chelate 
sepharose and bound Mel-PA was eluted as described in the text. 
Fraction 36 to 76 were pooled to give 425 ml of solution containing 
1050 UK u/ml of Mel-PA activity. The insert diagram shows the 
protein pattern of the pool after SDS-polyacrylamide gel electrophoresis. 
b) Pooled enzyme containing fractions from the zinc-chelate 
chromatography step (400 ml) were applied to a Con A-sepharose 
column and bound material was eluted as described in the text. 
Fraction 47 to 65 were pooled to give 120 ml of solution containing 
1550 UK u/ml of Mel-PA activity. The preparation was contaminated 
with Con A as shown by SDS-polyacrylamide gel electrophoresis 
(diagram). 
55 
" 100 l ' 1.2 ' ~ \ l ' 70K \ 
E 




I ~.""" " 
CD 
I 4 lSl 
I I \ Cl) 
(\J . 8 I I \ 60 ' l I Ii,-.µ I I l--I ~ 
0 .6 ~ \,..,/ I 
Q) I 40 I ). 





20 > ...0 I •ri 
L .2 I 
/,. .µ 0 0 
"' I < _() 0 I 0 < 
0 20 40 60 80 100 
T .5 100 I };° •• ~ 
70K .~ " E • 4 80 lSl 
C "1. ~ Cl) 
IS} " ... ' CD : ~ f-('\J .3 ' 60 ~ ~ """' .µ 
0 I ). I 
.2 I 40 
.µ 
(D I •ri 
0 I > 
C .i. · ri 
0 .µ 
...Cl • 1 20 0 
L < 
0 
"' _-A--lir~A ..0 0 ..,JJr- - 0 --/Jr < 
0 10 20 30 40 50 60 70 
Fraction Number 
1M NaCl and 0.1% Triton. Pooled enzyme containing fractions from the 
zinc-chelate chromatography step (total volume approximately 400 ml) were 
then applied at a flow rate of 10 ml/hr. The column was washed with 
equilibrating buffer and the adsorbed protein was eluted using 200 ml of 
a linear gradient of Oto 0.4M a methyl-D-mannoside and Oto 2M KSCN in 
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O.OlM phosphate buffer pH 7.5 containing lM NaCl and 0.1% Triton. Fractions 
of 5 ml were collected and the active fractions were pooled to give~ 
120 - 150 ml of solution containing approximately 1500 - 1600 UK u/ml of 
Mel-PA. This represented an overall recovery of 40% and a recovery of 
50 - 60% for the Con A sepharose step. 
SDS-polyacrylamide gel electrophore~is at this stage gave results 
shown in Fig. 1.11. After Con A sepharose chromatography the plasminogen 
activator preparation appeared to be relatively pure save for the presence 
of contaminating Con A that had leached from the column. 
DISCUSSION 
The work described in this chapter was undertaken to define 
optimal conditions for obtaining starting material for the purification of 
Mel-PA. Although other cell types available to me could be shown to 
release a similar plasminogen activator (Table 1.8), the consistency with 
which melanoma cell lines behaved in this regard made these most attractive 
as a source of enzyme. Furthermore, melanoma cells are well known for 
the ease with which they can be cultivated in vitro. 
As is evident from the data in Table 1.8, the melanoma cell line 
RPMI-7272 (Bowes) produced more enzyme activity, in terms of units/106 cells/ 
24 hr, than did any of the other melanomas. 
efforts on these cells. 
I therefore concentrated my 
Very fortunately for me a unique subline of RPMI-7272 cells was 
established in the laboratory while this work was in progress. These cells 
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Table 1.8 Plasminogen activators secreted by cultured human cells 
Cell line Plasminogen activator species (a) Plasminogen 
activator Mel-PA UK (UK u/10 6cells/24 
100 00 70 000 60 000 60 000 
UCT-Mel 1 + +++ (b) ++ 
UCT-Mel 2 + +++ + 
UCT-Mel 3 + +++ ++ 
UCT-Mel 4a + ++ + 
UCT-Mel 4b + +++ ++ 
UCT-Mel 5 ++ +++ ++ 
Melanoma +++ ++ 
(M-127) 
Melanoma 
(M-170) + +++ 
Bowes + +++ + 
Ca. breast +++ + 
Malignant + +++ 
teratoma 
Sarcoma of + +++ 
uterus 
Glioblastoma + +++ 
The data were obtained from Wilson et al (61), Wilson and 
Dowdle (106), and Roal (151). 
a) The immunochemical type of PA 1s expressed as UK-type (UK) or 
Mel-PA-type (Mel-PA). 
approximate. 
The molecular weights given are 
b) The relative abundance of the various molecular weight species 
is based upon the area of fibrinolytic zones and the time taken 
for development of lysis in the zymographic method of Granelli-















adhere and remain healthy indefinitely in the absence of serum while 
continuing to synthesize plasminogen activator at a steady and useful 
rate. Apart from obvious considerations of economy in foetal calf serum 
and absence of contaminating serum proteins or inhibitors, use of these 
cells had an additional advantage in their low proliferative rate in the 
absence of serum. This meant that cultures require passaging only 
infrequently and one flask could be "milked" for several months. 
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Unfortunately neither TPA nor any of the other compounds known 
to enhance PA release by cells in vitro (143-150) had any useful effect on 
plasminogen activator released by melanoma cells. Christman et al 
(147) made a similar observation and noted that synthesis of melanoma 
type activator was not_ as readily modulatable as was that of urokinase. 
In devising a strategy for Obtaining adequate amounts of Mel-PA 
for isolation and purification, it was necessary to take into account the 
very small amounts of enzyme released into the medium and the very low 
concentrations of active protein I could expect. It has been estimated, 
for example, that serum-free culture fluids from MSV~transformed 3T3 cells 
contain approximately 15 nmol/1 of plasminogen activator (108). By 
labelling harvest fluid with 3H-DFP of known specific activity (Chapter V) 
I was able to estimate, as a very rough approximation, that conditioned 
serum-fre medium collected routinely in large volumes from Bowes melanoma 
cells contained approximately 10-20 nmol/1. This meant that it would be 
necessary to collect and concentrate large volumes of harvest fluid in 
order to obtain sufficient pure protein for adequate biochemical 
characterization. 
In attempting to develop the culture of Bowes . melanoma cells on 
the production scale necessary to meet this requirement, I hoped that 
"Melanex" spirals or "Cytodex" beads would offer the convenience of a 
large surface area for cell adherence without the inconvenience of a 
proportionate increase in volume of the culture vessel. Unfortunately, 
however, neither of these substrata proved propitious for satisfactory 
cell viability or function under the conditions of serum deprivation and 
medium composition that I wished to use. 
A serious problem that confronted me at an early stage in the 
work was the apparent instability of Mel-PA in harvest fluids. Others 
have encountered similar difficulties and have found that the addition of 
nonionic detergents (108,130,68), high salt concentrations (132) or 
reversible protease inhibitors such as ZnC1
2
, benzamidine, arginine and 
trasylol (93,108,134,90) have proved useful. I was able to reduce 
losses very effectively by the addition of Triton X-100 and by acidifying 
the ·sample. 
Chromatography on benzamidine-sepharose provided an efficient 
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and rapid means of concentrating the proteins present in the harvest fluids 
and it proved useful as a preliminary means of preparing the activator for 
storage. The slightly acid conditions and the high concentration of 
arginine (0.5M) may have contributed an additional stabilizing influence. 
The improvement in recovery of the enzyme that resulted from 
the addition of ethylene glycol to the eluting buffer could probably be 
attributed to non specific hydrophobic interactions between the enzyme and 
the affinity matrix. 
The tenacity with which the activator bound to the benzamidine-
sepharose colunm militated against effective purification with this reagent 
since the drastic measures (low pH, ethylene glycol, arginine and high 
salt concentration) that were reeded to release the enzyme also released 
contaminating proteins. Goldfarb et al (109) working with chicken 
plasminogen activator and Dan~ et al (108) who purified the murine enzyme, 
achieved very satisfactory purifications with benzamidine-sepharose and 
·others have found that urokinase-type activators could be eluted from 
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benzamidine columns with low pH buffers without the need for arginine or 
benzamidine in the eluant (99,74). Although I have not studied the 
matter systematically or thoroughly, my own experience would confirm the~e 
observations since I have been able to elute 81% of urokinase added to an 
affinity column with O.lM acetate buffer pH 3.5. 
Despite the fact that affinity chromatography may be more effective 
for urokinase type activator purification, Holmberg et al (99) have pointed 
out that benzamidine-sepharose chromatography does not provide the "one-step" 
purification of urokinase from tissue culture medium or urine that one would 
hope for. This was certainly true for Mel-PA, and Zn-chelate affinity 
chromatography was not much better 1n this regard. 
The recovery of activity from the Zn-chelate column ranged from 
80-90% (i.e. only slightly better than the recoveries of 75-85% obtained 
after affinity chromatography on benzamidine sepharose using the phosphate 
system) and the co_ncentration of 950-1200 UK u/ml after the Zn chelate 
column was similar to that (850-1600 UK u/ml) achieved by chromatography 
on benzamidine sepharose. SDS-PAGE showed that both preparations were 
still heavily contaminated with other proteins (Fig. 1.10 and Fig. 1.11). 
The advantage of the Zn-chelate chromatography step for the 
concentration of proteins in harvest fluids was that a large volume (10 
litres) of harvest fluid could be processed at one time with very little 
attention and in less time (3! days) than was required for the benzamidine 
sepharose chromatography step (5 days). Eluted pooled proteins from 
both columns had to be dialysed or processed further before they could be 
used in assays for the characterization of Mel-PA. Enzyme containing 
fractions from the benzamidine sepharose contained high concentrations 
of arginine, and those from the Zn chelate column contained imidazole. 
Both of these compounds interfere in protein assays and in enzyme assays. 
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Chromatography of proteins obtained from the Zn-chelate column 
on Con A sepharose yielded 120-150 ml of a 1600 UK u/ml solution of Mel-PA. 
The recoveries were 50-60%. Very good purification was achieved as shown 
by the protein pattern on SOS-PAGE. Unfortunately, however, the activator 
preparation was heavily contaminated with Con A and therefore could not 
be used unless it was further processed either by SOS-PAGE (Chapter III) 
or by gel filtration chromatography. 
CHAPTER II 
ELECTROPHORETIC ANALYSIS OF PLASMINOGEN ACTIVATORS IN SDS-POLYACRYLAMIDE 
GELS CONTAINING COPOLYMERIZED SUBSTRATES. 
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The study of the various forms of plasminogen activators occurring 
in tissue, in body fluids, and those released by cells cultured in vitro, 
has been greatly aided by electrophoresis in polyacrylamide gels containing 
SDS. Using this technique, the number as well as an approximate molecular 
size of plasminogen activators in minute amounts of sample could be deter-
mined. Two general techniques have been employed for the detection of 
enzyme bands in such gels after electrophoresis. 
In the first, exemplified by the approach of Danp, and Reich (152) 
polyacrylamide slab gel tracks containing electrophoresed enzymes were 
frozen and cut into 1.1 mm slices. Each ordered slice was then assayed for 
plasminogen-dependent lysis of 
125
I-labelled fibrin and the results were 
used to construct a profile of enzymatic activity in the track. The small 
amount of SDS in each slice was diluted in the reaction mixture to concen-
trations that did not interfere significantly with -the assay. 
The second procedure by Granelli-Piperno and Reich (62), exploited 
the fact that the catalytic activity of plasminogen activators was reversibly 
inhibited by SDS in the electrophoresis gel and could be restored by removal 
of the SDS from the polyacrylamide slab by incubating in aqueous Triton ~100. 
Bands of plasminogen activator activity could then be localized by a zymo-
graphic procedure in which the polyacrylamide slab was overlaid on an agar 
gel layer containing the two sequential substrates, plasminogen and fibrin. 
Plasminogen activator bands were visible under dark background illumination, 
as localized dark zones of fibrinolysis against an opaque white background 
of undegraded fibrin. 
I have _developed a modification of the Granelli-Piperno and Reich 
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technique that offers certain advantages for the electrophoretic analysis 
of plasminogen activators in SDS-polyacrylamide gels. It is based upon 
the observation (a) that gelatin is a sensitive and satisfactory substrate 
for plasmin and (b) that if gelatin and plasminogen are copolymerized into 
the matrix of the SDS-polyacrylamide gel at the time of casting they are 
retained during subsequent electrophoresis of enzyme samples so providing 
in situ substrates for separated bands of concentrated plasminogen activator 
activity. The necessity for separate fibrin-plasminogen-agar indicator 
gels is dispensed with. This approach was suggested by the paper of 
Hochstrasser and Schorn (153) who used azocasein-polyacrylamide gels for 
the electrophoretic analysis of plasminogen-independent proteases. 
METHODS 
Source of enzymes. 
To illustrate the usefulness of this method I have analysed 
urokinase and plasminogen activators released into serum free tissue culture 
medium by a variety of normal and neoplastic human cells cultured in vitro. 
Cultures were established and maintained as described in Chapter I for the 
melanoma cells and as described by Wilson and Dowdle (106). 
Human urokinase was obtained commercially from Leo Laboratories 
Limited, Hayes, Middlesex. 
Human plasminogen was prepared from human plasma by lysine-
sepharose affinity chromatography (45) and stored as a 1.2 mg/ml solution 
in PBS at -20°C, as described in the Appendix (Al.3). 
Electrophoretic procedure. 
Preliminary experiments led to the adoption of the following 
standard procedure for the electrophoretic analysis of most mammalian 
plasminogen activators. 
Polyacrylamide resolving gel slabs measuring 60 x 70 x 1 mm 
were cast from a mixture prepared from stock solutions as follows: 







in distilled water 
1.5M Tris-HCl, pH 8~8, containing 0.4 g% SDS 
Purified human plasminogen: 1.2 mg/ml in 
phosphate-buffered saline (PBS) 
Gelatin: 1 g% distilled water 
Ammonium persulfate (100 mg/ml in water) 











The resolving gels were carefully overlaid with 0.05% gelatin 
in 0.3M Tris-HCl, pH 8.8 and allowed to polymerize at room temperature. 
When polymerization was complete, a stacking gel with castellated sample 
wells was cast on top of the resolving gel from the following mixture of 
stock solutions: 
(i) Acrylamide (30 g%) and bisacrylamide (lg%) 





0.5M Tris-HCl, pH 6.8 containing 0.4% SDS 
Ammonium persulfate (100 mg/ml in water) 







1. 55 ml 
2.03 ml 
Reservoir buffer (0.025M Tris, 0.192M glycine-NaOH, pH 8.5, 
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0.1% SDS) was added to the upper and lower reservoirs and samples were added 
to the sample wells in a final volume of 5 - 50 µl of solution containing 
2.5 g% SDS, 10 g% sucrose, and 4 µg/ml phenol red to serve as a tracking dye. 
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0 Electrophoresis was performed at 4 Cat a constant current of 
8 mA. When the ·tracking dye front had reached the bottom of the resolving 
gel (after approximately 3.5 hr) the gel was removed and shaken gently at 
room temperature for 1 hr in 2.5% Triton XlOO in water to remove SDS. The 
gel slabs were then transferred to a bath containing O.lM glycine-NaOH, 
pH 8.3, and incubated at 37°c for 3-5 hr. 
The gels were then fixed and stained by inunersion for 1 hr in a 
0.1% solution of amido black in methanol:acetic acid:water (30:10:60). The 
gels were destained in methanol:acetic acid:water (30:10:60). 
Note that the resolving gel routinely contained a final total 
concentration of acrylamide (%T) of 11% and that the stacking gel did not 
contain gelatin or plasminogen. Plasminogen was omitted from the resolving 
gel to detect plasminogen-independent proteases. 
Since microbial contamination of electrophoretic buffers and 
other solutions occasionally contributed bacterial proteases, all solutions 
were autoclaved or sterilized by filtration and stored under conditions that 
minimized contamination. 
RESULTS 
When the standard procedure described under Methods was used for 
the electrophoretic analysis of solutions containing plasminogen activators, 
well-resolved bands of enzyme activity were seen as clear zones of proteo-
lysis against a blue background of undegraded stained gelatin. When 
plasminogen was omitted from the resolving gel mixture no proteolytic bands 
were observed in electrophoretic tracks containing urokinase or cell harvest 
fluid samples whereas trypsin and elastase showed clearly defined bands of 
plasminogen-independent proteolysis (Fig. 2.1). 
Results of preliminary experiments that were performed for the 
development of the method can be sununarized as follows: 
66 
1 2 3 4 5 6 7 8 9 10 
A B 
Figure 2.1 Identification of plasminogen activators and proteases in 11% 
polyacrylamide gel slabs containing gelatin. 
Gel slabs containing 11% polyacrylamide, 0.1% SDS and 0.1% co-
polymerized gelatin were cast with (gel A) and without (gel B) 13 µg/ml 
co-polymerized plasminogen. Samples were electrophoresed as follows: 
track 1, lactoperoxidase (78 000); tracks 2 and 6, reference protein 
mixture comprising phosphorylase B (94 000), bovine serum albumin (67 000), 
ovalbumin (43 000) and carbonic anhydrase (3b 000); track 3, 5µ1 of 
serum-free melanoma cell harvest fluid; track 4 and 9, 5 µl of serum-free 
-3 foreskin epithelium harvest fluid; track 5 and 10, 1 x 10 Ploug units 
of commercial urokinase; track 7, 6.2 x 10-3 ~ commercial elastase; 
track 8, 2.5 x 10-3 µ trypsin. 
After electrophoresis the gels were washed in Triton XlOO, 
incubated in glycine-NaOH buffer at 37°C for 3 hr and fixed, stained and 
destained as described under Methods. Note that gelatinolysis by 
urokinase and epithelial cell proteases were plasminogen dependent. 
(cf. tracks 4 and 5 and 9 and 10). 
The gelatin substrate tended to migrate out of the resolving gel 
if the total polyacrylamide concentration was less than 5% or if the ratio 
of bisacrylamide to acrylamide was less than 1:30. 
Electrophoresis at room temperature instead of at 4°c frequently 
resulted 1.n "trails" of gelatinolysis in electrophoretic tracks containing 
plasminogen activators. This phenomenon may have been due to incomplete 
inhibition of the enzymes by the SDS in the gel with the result that 
proteolysis proceeded during electrophoresis at higher temperatures. 
Alternatively, ionic discontinuities due to salts in the samples may have 
resulted in local heating during electrophoresis with "melting" of the 
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gelatin in sample tracks . Whatever the cause of this phenomenon, it could 
be obviated by electrophoresis in the cold. 
The removal of SDS by Triton X~OO before incubation in buffer was 
an absolute necessity - no bands of activity could be detected without this 
step. Incubation of gels in different buffers after the Triton wash showed 
that O.lM glycine HCl pH 8.3 was the most suitable as shown in Fig. 2.2a . 
Incubation of gel strips containing identical samples in buffers 
ranging from pH 2.5 - 10.4 showed that activity was completely inhibited 
below pH 7.5 and above pH 8.9 (Fig. 2.2b). Using a glycine buffer ranging 
in pH from pH 8.2 to pH 9.6, optimum gelatinolysis was observed between 
pH 8.2 to 8.4. 
Incorporation of 0.25% powdered skim milk as a source - of casein 
instead of gelatin yielded the same pattern of proteolytic bands as seen in 
gelatin gels. 
Molecular weight marker proteins were concentrated by electro-
phoresis into narrow zones that appeared as easily visible, intensely 
staining bands against the li~hter blue colour of the stained gelatin back-
ground. Thus plasminogen activators and molecular weight marker proteins 
were visible in the same gel. 
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Figure 2.2 
Figure 2.2 The effect ·of buffer composition and pH on the development 
of plasminogen dependent proteolytic bands in gelatin-gels. 
a) 
b) 
Electrophoretic tracks containing harvest fluid of a cell line 
derived from a carcinoma of the bladder were incubated at 37°c 
in 10 ml of the following buffers: track no. 1. O.lM Borate 
buffer pH 8.4; 2. O.lM Tris-HCl pH 8.1; 3. PBS; . 4. O; lM 
Glycine-HCl pH 8.5; 5. O.lM Carbonate buffer pH 8.7; 
6. Distilled water. 
Electrophoretic tracks containing harvest fluid of a cell line 
derived from a human melanoma (UCT-Mel 3) were incubated at 37°c 
in 10 ml of the following buffers: 
Track No. 1. O.lM Glcyine-HCl, pH 2.5; 2. O.lM Glycine-HCl 
pH 3.5; 3. 4. and 5. O.lM Sodium acetate-acetic acid pH's 
· 3.5, 4.5 and 5.5; 6. O.lM Tris HCl pH 7.5; 7. distilled 
water; 8. O.lM Tris HCl pH 8.5; 9, 10. and 11. O.lM Glycine-





As can be seen from Fig. 2.1 plasminogen activators released by 
Bowes melanoma cells appeared as a prominent, closely spaced doublet which 
migrated, in 11% polyacrylamide gels, to a position cathodal to albumin and 
a fainter third band with an electrophoretic mobility slightly greater than 
that of albumin. These corresponded to enzymes with appa~ent molecular 
weights of approximately 71 000, 69 000 and 62 000 respectively. 
Urokinase and the enzymes released by cultured foreskin epithelial 
cells showed three major bands of plasminogen-dependent proteolysis. The 
two most prominent species w_ere evident as a doublet that migrated to a 
position irmnediately anodal to albumin with approximate apparent molecular 
weights of 62 000 and 56 000. The third band had an electrophoretic 
mobility intermediate between that of ovalbumin and carbonic anhydrase 
corresponding to an enzyme with an approximate apparent molecular weight 
of 34 000. The epithelial enzyme track in Fig. 2.1 was somewhat overloaded 
for optimal resolution and higher mole~ular weight enzymes were visible. 
Since the techni~ue relied upon preservation of enzyme activity the samples 
could not be heated with SDS before electrophoresis; it is probable, there-
fore, that the high molecular weight species observed in this sample repre-
sented aggregates of the lower molecular weight forms. 
A summary of a survey of plasminogen activators released by a 
variety of cells cultured in vitro is presented in Table 2.1. The results 
agree well with those reported by Wilson et al (61), where plasminogen 
activators of human cells cultured in vitro were analysed by the Granelli-
Piperno and Reich technique. Plasminogen activators with molecular weights 
in the 70 000 dalton range, could be detected in both melanoma cell lines, 
and in cell lines derived from a carcinoma of the renal pelvis, a carcinoma 
of the breast and a glioblastoma. 
In the first analysis, copolymerization of gelatin and plasminogen 
into the resolving gel did not appear to interfere with the electrophoretic 
TABLE 2.1 
PLASMINOGEN ACTIVATORS SECRETED BY 
HUMAN CELLS CULTURED in vitro 
SOURCE OF ENZYMES MOLECULAR WEIGHT SPECIESa) 
>95 000 70 000 60 000 
Connnercial urokinase +++ 
Normal bladder epithelium ++b) +++ 
Normal kidney +++ 
Normal thyroid +++ 
8-wk embryo fibroblasts ++ +++ 
Melanoma (Bowes I) +++ + 
Melanoma 1 (UCT Mel 3) +++ + 
Hypernephroma +++ 
Hypernephroma ++ +++ 
Sarcoma of uterus +. + +++ 
Carcinoma of bladder + +++ 
Carcinoma of renal pelvis + ++ +++ 
Carcinoma of breast +++ ++ 
Lipoma +++ 
Glioblastoma + ++ +++ 
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of "70 000" has been assigned to enzymes showing a doublet with 
apparent molecular weights of 69 000 and 71 000, and "60 000 11 has 
been assigned to the doublet corresponding to apparent molecular 
weights of 62 000 and 56 000. ">95 000" signified bands that 
migrated cathodally to phosphorylase b. 
b) The relative abundance of each molecular species within a sample 
is based on a scale of+ to+++. 
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behaviour of the marker proteins. In gels containing total polyacrylamide 
concentrations of 8, 10, 11 and 12%, marker proteins migrated distances 
that were inversely and linearly related to the logarithms of their 
molecular weights (Fig. 2.3). 
The electrophoretic behaviour of the plasminogen activators was, 
however, anomalous in that their mobilities relative to the reference 
proteins were critically dependent upon the total polyacrylamide concentration 
in the resolving gel. As is evident from Fig. 2.3, the apparent molecular 
weights that could be assigned to the enzymes by interpolation from the 
standard curves diminished with decreasing %T. 
Since, in the technique I describe, protein substrates were co-
polymerized into the resolving gel ~ixture, the concentration of SDS in the 
resolving gel and reservoir buffers may have been marginal for the abolition 
of specific noncovalent interactions between electrophoresed activators and 
their innnobilized substrate, plasminogen. In this case, one might have 
expected specific affinity reactions to have retarded the electrophoretic 
mobility of the enzymes. To examine this possibility, two series of 
experiments were performed. In the first enzymes were electrophoresed in 
11% gels containing amounts of co-polymerized plasminogen that varied from 
10 to 30 µg/ml. In the second series, the concentration of plasminogen in 
the resolving gel was maintained constant at 10 µg/ml and the SDS concen-
tration was varied from 0.1 to 1%. There appeared to be no effect of 
either plasminogen or SDS concentration on the mobility of the plasminogen 
activators relative to the marker proteins. 
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Figure 2.3 
Figure 2.3 Effect of varying %Ton electrophoretic mobility of plasminogen 
activators. 
Reference p,roteins and plasminogen activators were electrophoresed 
' 
on SDS-polyacrylamide gel slabs containing 8 , 10 or 12% T and copolymeri~ed 
gelatin and plasminogen as described under methods and in the legend to 
Fig. 2.1. After electrophoresis and processing, the distances migrated 
relative to the phenol red tracking dye were measured (Rf) and plotted 
against the logarithms of the ~olecular' weights of the reference proteins 
( .. ). Straight lines were fitted for each %T series by the method of 
least squares. The numbered open squares represent points interpolated 
from Rfs of enzyme bands as follows: 1, 2 and 3, upper,middle and lower 
bands, respectively, of the melanoma cell activators: 3, 4 and 5, upper 
middle and lower bands, respectively, of urokinase. Note that the apparent 
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In this chapter I describe a technique in which samples containing 
plasminogen activators were electrophoresed in SDS-polyacrylamide gels 
containing co-polymerized plasminogen and gelatin as sequential substrates 
for detecting proteolytic bands. After electrophoresis the gels were 
incubated at room temperature in Triton X~OO to remove the SDS and so restore 
enzymatic activity. Subsequently,incubation at 37°C in glycine-NaOH, 
pH 8.3, buffer for 3 - 5 hr followed by fixation and staining revealed 
sharp clear zones of proteolysis against a blue background of undegraded 
substrate when as little as 1 mU of enzyme was electrophoresed. Plasminogen-
independent proteases could be detected and analysed by omitting plasminogen 
from the polyacrylamide-gelatin matrix. 
My procedure is a direct modification of the fibrin-agar underlay 
technique of Granelli-Piperno and Reich (62) with which it compares favourably 
in some respects and unfavourably in others. The advantages offered by the 
method I present are as follows: First, by incorporating substrate(s) 
directly into the resolving polyacrylamide gel the necessity for a second, 
indicator gel is obviated. Second, the relatively compact structure and 
smaller pore size of the polyacrylamide m~trix limits lateral diffusion of 
proteases from concentrated zones, with the result that prolonged incubation 
at 37°c at the developing stage has a less deleterious effect upon the 
sharpness, and hence resolution of bands of enzymatic activity. This is 
particularly desirable when bands containing different amounts of enzyme 
are present in the same electrophoretic track and lengthy incubation periods 
are required to demonstrate minor components. The 1% agar matrix in the 
fibrin-agar underlay procedure imposes less of a constraint upon lateral 
diffusion so that zones of fibrinolysis spread with time, resolution is lost, 
and substrate cl~aring due to a major component may engulf that due to 
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adjacent minor bands. Third, gelatin is susceptible to hydrolysis by a 
wide variety of proteases, whereas fibrin is a relatively restricted 
substrate. Fourth, since polyacrylamide gels shrink with fixation and 
staining, absolute register between the molecular weight marker tracks in 
the resolving gels and fibrinolytic zones in the fibrin-agar indicator gels 
is lost. In the polyacrylamide-gelatin gels, marker proteins and protea-
lytic bands are visible in the same fixed and stained slab. Finally, 
gelatin is inexpensive and is readily available commercially in a form that 
is suitable for use without further purification. 
these two attributes. 
Fibrinogen does not have 
On the other hand, the Granelli-Piperno and Reich technique, 
being a two-stage procedure, offers a degree of .technical versatility that 
the polyacrylamide-gelatin gel technique does not have. When, for example, 
sequential reactions are being analyzed, the effects of inhibitors or 
experimental conditions on the two stages of the reaction can be studied 
separately. Furthermore, one is able to incorporate particulate substrates, 
such as erythrocytes, into the agar-underlay for the study of complement 
or other haemolytic macromolecules; this is not possible in the case of 
the polyacrylamide-substrate gels. In addition the polyacrylamide-gelatin 
gels are unsatisfactory for the analysis of crude samples when they contain 
proteases and proteins with very similar electrophoretic mobilities; the 
darkly staining protein bands then obscure or distort the clear proteolytic 
zones. Finally, with the fibrin-agar · technique, the time course of the 
fibrinolytic reaction may be followed and recorded photographically under 
dark-ground illumination during the development stage. This confers the 
advantage that enzymatic activity of any band may be judged from the rate 
of its appearance. In our procedure proteolytic bands are only visible 
after the reaction has been terminated by fixation and staining. The 
Granelli-Piperno and Reich procedure and the one that I describe should 
therefore be regarded as complementary to each other. 
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In a recent extensive survey (61) of human cells cultured in vitro, 
the Granelli-Piperno and Reich technique was used to show that melanoma 
cells characteristically release plasminogen activators that differ from 
the urokinase-type enzymes secreted by most normal cells and the majority 
of other tumours. The melanoma-type enzymes have, as the predominant 
electrophoretic components, a closely spaced doublet in the 70 000 M 
r 
range whereas the major components of urokinase-type enzymes appear as 
a doublet in the 60 000 M region of the gel. r As can be seen from Fig. 2.1, 
the procedure I describe readily distinguishes the melanoma- and urokinase-
type enzymes. 
Although the procedure has proved useful for discriminating between 
plasminogen activators of different types, it has been of less value for 
assigning precise molecular weights to the enzymes owing to the anomalous 
electrophoretic behaviour in gels of different total polyacrylamide concen-
trations. For reasons that are not entirely clear, I have been unable 
to resolve this difficulty by analysing the results obtained in gels of 
different %T by graphic procedures recommended oy Chrambach and Rodbard 
(154) and Maizel (137) in which Ferguson plots (%T vs log electrophoretic 
mobility) are constructed for each of the reference proteins and enzyme 
bands. The slopes of these linear plots are measured to give retardation 
coefficients (KR) for each protein species. It should, in theory, be 
possible to obtain a linear relationship between molecular weight and the 
square root of the retardation coefficient from which molecular weights of 
the enzymes could be assigned by interpolation. In the polyacrylamide-
plasminogen-gelatin system, however,the Ferguson plots, although linear, 
did not extrapolate to the same ordinate intercept at zero %T for migration 
in free solution and the relationship between(~)! and molecular weight 
for the reference proteins was not linear. Since the migration of enzyme 
bands was not affected by varying the concentration of plasminogen or SDS 
in the resolving gel I am unable to attribute the anomalous electro-
phoretic behaviour of the plasminogen activators to affinity interactions 
with the partially denatured specific substrate, plasminogen. 
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In summary, therefore, the technique is of value for distinguishing 
different plasminogen activators on the basis of their relative sizes, but 
it cannot, without further improvements, be used to assign precise molecular 
weights. 
CHAPTER III 
THE IMMUNOCHEMICAL LOCALISATION OF HUMAN AND ANIMAL PLASMINOGEN ACTIVATORS 
It is now well established that plasminogen activators that are 
released by human cells cultured in vitro or that are detected in human 
tissues can be divided into at least two groups (61,51,52,107,111,115, 
117,198). 
The first group of enzymes are those that are inhibitable by 
antibodies to urokinase. These exist in several molecular weight forms. 
When, in any given specimen, multiple forms are present, those with 
molecular weights of 60 000 and 32 000 daltons usually predominate with 
lesser relative amounts of 46 000 and approximately 100 000 MW components 
(61). 
The second group of plasminogen-dependent proteases are those 
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that are not inhibitable by antibodies to urokinase. As with the previous 
group these, too, comprise enzymes with different molecular weights, but 
here a 70 000 dalton species predominates with lesser amounts of 100 000, 
60 000 and 38 000 dalton enzymes (61). It is now known that melanoma 
cells characteristically release plasminogen activators representative 
of the second group (61, 115,117,130) and it has also been noted (198,56,55) 
that "tissue activator" is not inhibited by anti-urokinase antibodies 
but that it is inhibited by antibodies to melanoma activator (130). 
At the time at which this work was started, an obvious deficiency 
of the classification of human plasminogen activators into "urokinase-like" 
and "non-urokinase-like" categories was the lack of a positive basis for 
establishing membership of the latter group or for establishing relation-
ships between members of the "non-urokinase-like" enzymes. Could one, 
for example, consider "tissue activator" and "melanoma activator" as 
closely related or identical enzymes (as their molecular weights would 
suggest) or were they entirely different molecules related neither to 
urokinase nor to each other? 
Since I felt that an antibody dire~ted towards any one of 
these non-urokinase-like activators would clearly be a useful reagent 
for establishing such relationships or class membership on the basis of 
innnunochemical cross-reactivity, I prepared and characterised a rabbit 
antibody directed towards Mel-PA. This antibody has been used to confirm 
the distinction between urokinase and melanoma activator; it has been 
used to demonstrate cross-reactions between Mel-PA and plasminogen 
activators found in most tissues and body fluids; and it has been used 
to identify phylogenetic relationships between melanoma-type plasminogen 
activators that do not appear to exist for urokinase. 
MATERIALS AND METHODS 
Mel-PA released by Bowes I or Bowes II melanoma cells cultured 
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in vitro was partially purified using affinity chromatography on benzamidine-
agarose or zinc chelate-agarose and Con A-agarose as described in Chapter I. 
Human urokinase was obtained connnercially (Leo Pharmaceutical Products, 
Ballerup, Denmark). 
Serum-free harvest fluids containing plasminogen activators 
were obtained from a number of melanoma cell lines established in this 
laboratory. The tissue culture techniques used for establishment of 
these cell lines have been described in detail by Wilson and Dowdle (106) 
and Roal (151). 
Harvest fluids were prepared by washing the adherent monolayer 
cultures three times with DME or RPMI medium and incubating them for 24 hr 
under serum-free medium. The medium was then removed, centrifuged at 
0 750g for 10 min and stored at -80 C. Protease- and inhibitor-free 
bovine serum albumin (Appendix 1) was added to a final concentration of 
0.4 mg/ml to stabilize the enzyme. 
Urine samples were centrifuged at 750g for 10 min and the 
supernatants were stored at -20°c until use. 
Human semen was obtained from normal, infertile and vasectomised 
males attending the Fertility Clinic at Groote Schuur Hospital. Samples 
were kept at room temperature for 30 min for liquefaction to take place. 
They were then centrifuged at 20 OOOg for 60 min. 
plasma was then stored at -20°c. 
The clear seminal 
Saliva and tear samples were centrifuged at 20 OOOg for 15 min 
and used immediately. 
Human breast milk was centrifuged at 20 OOOg for 60 min. The 
0 upper fatty layer was discarded and the supernatant was stored at -20 C 
before use. 
Fresh samples of human tissue were obtained at surgery or from 
cadaver transplant donors. Animal tissues were procured freshly after 
slaughter. Tissue samples (usually approximately 200 mg) were rinsed 
in saline, fragmented with scissors and then homogenized in 1 ml of 0.5% 
Triton X-100 using a glass homogenizer. The homogenized tissue samples 
were extracted with 4 ml of 0.5% Triton X-100 in water for 2-4 hr at 4°C. 
The suspensions were then centrifuged at 1700g for 30 min to remove 
cellular debris and the clear supernatants were s~ored at -20°c until 
use. 
Human plasminogen was purified from fresh frozen plasma by 
affinity chromatography on lysine-sepharose according to a modification 
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of the method of Deutsch and Mertz (45) (Appendix 1.3). Human fibrinogen 
(A.B. Kabi) or bovine fibrinogen (Sigma) was further purified by salt 
precipitation according to the method of Laki (182) and freed of plasminogen 
according to the method of Mosessan (162) as described in detail in the 
Appendix (Al.l). 
Rabbit antibodies to Mel-PA and urokinase. 
Harvest fluids containing Mel-PA were partially purified by 
benzamidine-agarose chromatography or chromatography on Zn-chelate-
agarose and Con A-agarose to give 10-30 ml of solution containing 10 000 
to 15 000 urokinase units of enzyme. 
Proteins in this sample were precipitated by adding TCA to a 
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final concentration of 10%. The precipitate was collected by centrifugation 
(1700g; 30 min) and washed in acetone. It was then dissolved in 0.25 ml 
of 0.06M Tris HCl pH 6.8 containing 2.5% SDS, 10% glycerol and 0.004% 
phenol red. After boiling for 1 min, two samples of 0.125 ml volume 
each were electrophoresed in 11% polyacrylamide gel slabs (125 x 175 x 2 mm) 
containing 0.1% SDS (Appendix A2). After electrophoresis, the slabs were 
washed in 2.5% Triton X-100 for 1 hr at room temperature and in water 
for 30 min. Marker tracks (see below) were removed and the remainder 
0 
of the gel was frozen at -20 C. 
Molecular weight markers (Pharmacia) and a 100 µl sample of 
Mel-PA containing approximately 30 FU (80 UK units) of active enzyme 
were co-electrophoresed in adjacent tracks on the same gel. After 
electrophoresis the gel was washed in Triton X-100 and the track containing 
the separated molecular weight markers and that containing the electro-
phoresed enzyme were separated from the remainder of the gel. The active 
enzyme track was then cut horizontally into 1.7 rmn slices and each slice 
was added to a well in a plate coated with 1251-fibrin and containing 
2 µg of plasminogen and 80 µg BSA in 200 µl of O.lM Tris-HCl. 
After incubation at 37°c for 30-60 min aliquots of 50 µl were 
taken from the wells and assayed for release of radioactive fibrin 
degradation products. By this method the exact position of Mel-PA in the 
slab gels could be determined. A typical profile of Mel-PA activity along 
the gel and the protein bands observed in tracks containing TCA precipitates 
is presented in Fig. 3.1. 
· Sections of the frozen preparative gel containing separated 
TCA precipitated Mel-PA protein were excised and pulverised in a 
dismembranator (B. Braun, Melsungen AG, F.R.G., type 853062). The 
frozen powder was then suspended in 1 ml of PBS and homogenized with 
an equal volume of complete Freund's adjuvant. Each of two rabbits 
was then immunized by subcutaneous injection of 1 ml of this emulsion. 
After 2 to 3 weeks the rabbits were boosted with subcutaneous injections 
of 1 ml of emulsion prepared identically but with Incomplete Freund's 
adjuvant. The rabbits were bled at 2 to 4 weekly intervals thereafter. 
Further booster injections were given at approximately 2 monthly 
intervals. 
Antibodies to crude commercial urokinase were prepared as 
described by Wilson et al (61). 
Immune IgG was isolated from the rabbit sera by precipitation 
with 33% ammonium sulphate, dialysis into 0.015M sodium phosphate buffer 
pH 8.0 and ion exchange chromatography on DEAE-cellulose equilibrated 
in 0.015M sodium phosphate buffer pH 8.0 (199). 
Active proteases were eliminated from the IgG preparation 
with 10 mM DFP at 45°c for 1 hr and subsequent dialysis into PBS (61). 
The IgG was then stored frozen at -20°c until required. 
Detection of anti-Mel-PA and anti-UK antibody activity. 
Two procedures were used for the detection and quantitation 
of antibodies to plasminogen activators. Both methods depended upon 
the specific inhibition of plasminogen-dependent fibrinolytic activity. 
In the first procedure known amounts of the enzymes were 
incubated with serial dilu~ions of antibody and samples of the mixtures 
d f . . d 1 . . . . h 125 f. b . were assaye or resi ua enzymatic activity int e I- i rin assay. 
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Electrophoresis of Mel-PA in polyacrylamide gel slab 
containing SDS. 
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Approximately 2 litres of serum-free harvest fluid was collected 
from cultures of Bowes I cells and subjected to benzamidine-agarose 
chromatography as described in Chapter I. Enzyme-containing fractions 
were pooled to give 30 ml of solution of which 15 ml was made 10% with 
respect to trichloracetic acid to precipitate enzyme and other proteins 
present. The precipitate was recovered by centrifugation (1700g; 30 min) 
and dissolved in 0.25 ml of 0.06M Tris-HCl pH 6.8 containing 2.5% SDS, 
10% glycerol and 0.004% phenol red. 
The photograph in the figure shows a fixed and stained 11% 
polyacrylamide gel slab track in which 15 µ1 of the TCA-precipitated 
Mel-PA sample had been electrophoresed. 
A 100 µ1 sample of Mel-PA containing approximately 30 FU 
of active enzyme was co-electrophoresed in an adjacent track. This 
track was washed in 2.5% Triton X-100 after electrophoresis, frozen, 
and cut horizontally into 1.7 mm slices. The fibrinolytic activity 
in each slice was measured in the 125r-fibrin assay. 
The figure shows the profile of Mel-PA activity along the 
gel. The segment of the gel containing the TCA precipitated protein 
that was used for immunization of the rabbits is also indicated (-.f It-). 
In brief, Mel-PA or urokinase preparations were diluted with T-T(0.1) 
so that 10 µ1 of solution, when assayed in the standard 
125
I-fibrin 
assay, would release approximately 30% of the total trypsinisable 
radioactivity in one hour. Fifty microlitre volumes of these solutions 
were added to tubes each of which contained an equal volume of purified 
IgG dissolved and diluted in PBS. The most concentrated antibody 
tube usually contained 1 mg/ml of IgG. 
The tubes containing antibody and plasminogen activator were 
incubated at 4°c for 1 hr after which 20 µl samples were removed for 
0 d 1 1 . . . . . h 125I f 0 b . assay of resi ua p asminogen activator activity int e - i rin assay 
(Appendix A3.1). A typical antibody titration is shown in Fig. 3.3. 
In the second procedure I used a combined immunochemical and 
electrophoretic approach that permitted identification of the molecular 
species of the inhibited plasminogen activator. This method was based 
on the electrophoretic and zymographic technique of Granelli-Piperno and 
Reich (62) as modified by Wilson et al (61). 
Plasminogen activators were separated on a molecular size basis 
in 11% polyacrylamide gel slabs (60 x 70 x 1 mm) containing 0.1% SDS, 
The slabs were washed in 2.5% Triton X-100 for 1 hr at room temperature, 
rinsed briefly in water and then layered on indicator agar slabs 
containing 1.25% agar, 5 µg/ml human plasminogen, 0.06 unit~/ml thrombin 
and 2.5 mg/ml fibrinogen. The assemblies were then incubated at 37°c 
in a humid environment and examined periodically under darkground 
illumination for the presence of clear zones of fibrinolysis against 
an opaque background of undegraded fibrin. 
To examine the susceptibility of electrophoresed plasminogen 
activator bands to inhibition by antibody, a narrow trough was cut into 
the fibrin-plasminogen-agar indicator slabs and filled with 100 µ1 of 
antibody solution containing 5 to 8 mg/ml IgG. The antibody was then 
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allowed to diffuse laterally into the gel by incubation at 4°C for 
approximately 5 hr. The polyacrylamide slab gels containing separated 
plasminogen activators were then carefully layered on the indicator 
gels in such a manner that one of a pair of adjacent electrophoretic 
tracks lay next to the trough and the other containing a duplicate 
sample lay one track width removed from the trough. The enzyme in 
the track close to the trough was thus exposed to the antibody while 
the duplicate was not. Typical examples of results obtained with 
this technique are shown - in Fig. 3.5 and 3.8. 
RESULTS 
Immune response of rabbits to Mel-PA. 
Rabbits were immunized with Mel-PA by repeated injections of 
enzyme and serum samples were obtained at 2-4 weekly intervals after the 
initial injection. The IgG fraction was isolated from each antiserum 
and assayed for its ability to inhibit Mel-PA using the 125I-fibrin ~ssay. 
The results obtained with 4 of the rabbits are shown in Fig. 3.2 where 
antibody activity is plotted as a function of time after the start of the 
immunization schedule. Antibody is expressed as the reciprocal of the 
concentration of antibody (in mg/ml) that was required to inhibit 50% of 
the activity of a standard Mel-PA preparation. Technical details are 
given in the Methods section and in the legend to Fig. 3.2. 
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As can be seen from the figure, antibody only became detectable 
after approximately 10 weeks and four injections of antigen had been given. 
Thereafter antibody titres increased. In two of the rabbits a plateau 
in serum antibody titre was reached after 4-5 months. At this stage 
7 µg/ml of IgG in the incubation tube was capable of inhibiting 50% of the 
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Figure 3.2 Innnune resEonse of rabbits to Mel-PA 
Four rabbits were innnunized by subcutaneous injection of 
1 ml of an emulsion consisting of pulverized polyacrylamide gel 
segments containing 2000 - 3000 FU (approximately 0.1-0.2 mg; 
5000-7500 UK u) of Mel-PA. The priming injection contained complete 
Freund's adjuvant; subsequent injections contained incomplete Freund's 
adjuvant. 
The times at which the rabbits were injected are indicated 
in the Figure by arrows. 
The rabbits were bled at various intervals after immuni-
zation and the IgG fractions were prepared from the antisera. Antibody 
activity of these fractions was determined by measuring the inhibition 
of Mel-PA in the 1251-fibrin assay as described in the Methods section 
and in the legend to Fig. 3.3. Antibody activity in the IgG fraction 
is expressed as l/I:50 or the reciprocal of the antibody concentration 
(in mg/ml) that inhibited the fibrinolytic activity of 0.1 FU of Mel-PA 
by 50% in the 1251-fibrin assay. 
Antibody titres started to increase after 2 months and after 
3 injections of antigen had been given. Titres reached a maximum level 
after 4-5 months. 
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slowly and the maximum titre achieved was 8 µg/ml~ 
On the basis of these results a satisfactory immunization schedule 
was adopted in which rabbits were immunized and boosted 3 weeks later and 
at 2 monthly intervals thereafter. Seru~ samples were taken for antibody 
measurement 3-4 months after the initial injection. Only those antibody 
preparations that, at a concentration of 10 µg/ml or less, showed 50% 
inhibition of the enzyme activity were retained as satisfactory reagents. 
A typical antibody titration curve given by a useful antibody preparation 
is shown in Fig. 3.3. 
Some idea of the affinity of such antibody for the enzyme is 
given by the fact that 7 µg/ml (i.e.~ 5 x l0-8M) IgG solution inhibited 
50% of the Mel-PA activity when the enzyme was present at a concentration 
of 1 x 10-gM (as calculated from active site titrations with 3H-DFP; 
Chapter V). 
It was important to eliminate all proteolytic activity from 
the IgG preparations and this was usually accomplished by treatment with 
DFP. On occasion this was not effective and such preparations were 
discarded. 
Antibody specificity 
Antibodies raised to Mel-PA or to urokinase were inhibitory 
only for the homologous enzyme and no cross reactions were observed either 
b f 'd 1 ' ' ' h 125 f' b . . h ' ( ' 3 4) y assay or resi ua activity using t e I- i rin tee nique Fig .. 
or by the immunoelectrophoretic procedure (Fig. 3.5). Although urokinase 
and Mel-PA showed no apparent immunochemical relationship in inhibition .. 
assays, cross-reacting determinants that did not involve the active sites 
may still have existed on these two enzymes. To examine this possibility 
a binding assay was developed using solid-phase antibody. 
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yigure 3.3 Inhibition-titration of Mel-PA with rabbit antibody to Mel-PA 
Volumes of 50 µl of Mel-PA in T~ (O.l) were added to tubes 
each of which contained an equal volume of purified anti-Mel-PA IgG 
diluted in PBS. The starting concentration of IgG was 1 mg/ml. 
The tubes were incubated at 4°c for 1 hr and 20 µ1 samples were 
then removed for assay of residual plasminogen activator activity 
. h 125 f"b . int e I- i rin assay. 
Mel-PA incubated in presence of an equal volume of PBS 
that did not contain antibody released 45% of the total radioactivity 
in one hour. 
The antibody inhibited Mel-PA by 50% at a final concentration 
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Fi~re _3. 4 Specificity of anti-Mel-PA IgG or anti-urokinase IgG. 
Mel-PA or urokinase in 25 µ1 O.lMrris-HCl pH 8.1 containing 
1.6 mg/ml BSA were incubated with 25 µl of serial 2-fold dilutions 
of antibody for 1 hr at 4°c. Residual plasminogen activator activity 
h d . h 125 f.b . wast en measure int e I- 1 rin assay. 
Undiluted antibody solution contained 5 mg/ml of IgG. 
Control samples of Mel-PA released 30% of the total radioactivity 
in 1 hr and urokinase released 37% in 1 hr. 
Antibody to Mel-PA(~) inhibited the activity of Mel-PA 
but not of urokinase and antibody to urokinase (~) inhibited the 














Combined immunoelectrophoretic and zymographic analysis 
of Mel-PA and urokinase. 
Samples of urokinase (wells 1, 2, 7 and 8) or Mel-PA 
(wells 3, 4, 5 and 6) were electrophoresed in 11% polyacrylamide 
gel slabs containing 0.1% SDS. The slabs were washed in 2.5% 
Triton X-100 for 1 hr at room temperature, rinsed briefly in water, 
and layered on indicator-agar slabs containing fibrin and plasminogen. 
Narrow troughs (Ab+) had been cut into the indicator slabs and 
either anti-urokinase (Gel A) or anti-Mel-PA (Gel B) had been added 
and allowed to diffuse into the indicator slabs. The gel assemblies 
were incubated at 37°c in a humid environment. When distinct areas 
of fibrinolysis could be observed, the assemblies were photographed 
under dark-background illumination. 
It can be seen that both bands of urokinase were inhibited 
by antibody to urokinase (Gel A) but not by antibody to Mel-PA (Gel B). 
Similarly, Mel-PA was inhibited by anti-Mel-PA (Gel B) but not by 
anti-urokinase (Gel A). 
by linking 18 mg of anti Mel-PA antibody to 5 ml of cyanogen bromide-
activated sepharose . 4b (Appendix A.1). 
The matrix was washed sequentially with O.lM NaHC03 pH 8.3 
containing 0.5M NaCl; 1 M ethanolamine pH 9.0; O.lM Na acetate pH 4.0 
containing 0.5M NaCl; and was then equilibrated in O.lM Tris HCl pH 8.0 
containing 0.1% Triton X-100 and 0.4M NaCl. Two 2 ml columns of the 
matrix were prepared and either 1 ml of urokinase c~ 1.5 pmol) or 1 ml 
of Mel-PA c~ 8 pmol) in RPMI containing 0.1% Triton X-100 were added. 
The columns were washed with the Tris buffer and adsorbed enzyme was 
eluted with O.lM glycine-HCl pH 3.5 containing 0.15M NaCl and 0.1% Triton 
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~100. Fractions of 1 ml were collected and plasminogen activator activity 
. hf . . h 1251 f.b . was ~asured in eac raction int e · - i rin assay. The elution 
profiles shown in Fig. 3.6 demonstrate that all of the Mel-PA was adsorbed 
by the matrix whereas negligible amounts of urokinase bound. Approximately 
75% of the total Mel-PA added could be recovered by elution at pH 3.5. 
Inhibition of plasminogen activator by antibody in the fluorometric assay. 
The anti-Mel-PA antibody readily interfered with the ability 
of Mel-PA to function as a plasminogen activator. It was therefore of 
interest to see whether or not it would also inhibit the direct amidolytic 
action of Mel-PA in a fluorometric assay. An experiment was accordingly 
performed in which 100 µl volumes of 5 serial two-fold dilutions of anti-
Mel-PA antibody in PBS (undiluted concentration:- 5 mg/ml) were added 
to test tubes. An equal volume of Mel-PA (26 FU/ml) in T-T(0.02) was 
then added to each tube and these were incubated at room temperature for 
1 hr. Samples of 50 µl of each mixture were then assayed for residual 
amidolytic activity in the fluorometric assay using the substrate Cbz-Gly-
Gly-Arg-AMC (Appendix 3.2). 
The amidolytic activity of Mel-PA was not inhibited by any of 
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Figure 3.6 Immunoadsorption of Mel-PA or urokinase .to solid-
phase antibody. 
Anti-Mel-PA IgG (18 mg) was coupled to 5 ml of sepharose 
4b and the matrix was equilibrated with O.lM Tris HCl pH 8.0 
containing 0.1% Triton X-100 and 0.4M NaCl. Two 2 ml columns 
of the matrix were prepared and either 1 ml urokinase or 1 ml 
Mel-PA in RPMI containing 0.1% Triton X-100 were added. The 
columns were washed with Tris buffer and bound enzyme was eluted 
with O.lM glycine-HCl pH 3.5 containing 0.15M NaCl and 0.1% Triton 
x-100. Fractions of 1 ml were collected 
activity was measured in each fraction in 
The elution profiles demonstrate 
and plasminogen activator 
h 125I f"b . t e - i rin assay. 
that all of the Mel-PA 
(~~) was adsorbed by the matrix whereas negligible amounts of 
urokinase (-----) bound. Approximately 75% of the total Mel-PA 
added could be recovered by elution at pH 3.5. 
20 
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activity from 11.27 FU/ml to 13.19 FU/ml was seen. 
Immunochemical relationships between Mel-PA and plasminogen activator 
released by other melanoma cell lines. 
Mel-PA's released by Bowes I or Bowes .II cells comprised 
predominantly a 70 000 MW doublet with insignificant amounts of 60 000 
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and 40 000 MW species and no evidence of higher molecular weight components. 
One would have expected therefore that antibodies to Mel-PA would have 
been directed largely against the 70 000 MW component particularly since 
polyacrylamide gel fragments containing this species were used to immunize 
the rabbits. 
While other melanoma cell lines produce 70 000 MW plasminogen 
activators that do not cross-react with urokinase (61,115,117) the immuno-
chemical identity of these enzymes to Mel-PA has not been formally estab-
lished. Furthermore other melanoma lines frequently release plasminogen 
activators with molecular. weights of approximately 110 000 daltons, 60 000 
daltons and 40 000 daltons and the relationship of these plasminogen 
activators to each other and to the 70 000 MW species have not been clarified. 
It was therefore of interest to test harvest fluids from other melanoma 
cell lines for the presence of enzymes that would cross-react with Mel-PA. 
The results of these experiments are presented in Fig. 3.7 and Table 3.1. 
All plasminogen activators secreted by all melanoma lines were inhibited by 
anti-Mel-PA antibody. None were inhibited by urokinase. 
Occurrence of Mel-PA and urokinase in tissues and physiological fluids 
of human origin. 
Radioenzymatic and irmnunoelectrophoretic procedures were used 
to define molecular species of plasminogen activators present in various 
Figure 3.7 
1 2 3 
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Electrophoretic and immunochemical analysis of 
plasminogen activators released by melanoma cells. 
Samples of serum-free harvest fluids containing plasminogen 
activators released by UCT-Mel 5 (tracks 1 and 2) or UCT-Mel 1 
(tracks 3 and 4) were analysed by the combined zymographic and 
immunochemical method. The trough contained antibody to Mel-PA. 
All molecular species of plasminogen activators released 














Plasminogen activators released by melanoma cells 
cultured in vitro. 
Plasminogen activator species 
(Molecular weight) 
>lOOK 73K 60K 
++++ ++ 
++++ ++ 
++ ++++ +++ 
++ ++++ ++ 
++ ++++ +++ 
++ ++++ +++ 
+++ ++++ +++ 








Plasminogen activators released by various melanoma cell lines 
were analysed by the radioenzymatic and immunoelectrophoretic procedures 
described in the Methods section. The entries in the table indicate 
the relative abundance of the different molecular weight species within 
a given sample and are scored on an arbitrary scale of - to++++, 
where - indicates no enzyme. 
All plasminogen activator species released by all melanoma 
cell cultures were inhibited by anti-Mel PA antibody. 
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normal body fluids and tissues of human origin. The samples were collected 
and analysed as described in the Methods section to give the results 
summarized in Table 3.2. Typical results are shewn in Fig. 3.8 for the 
case of uterine tissue. 
All tissues examined with the exception of liver, contained 
plasminogen dependent fibrinolysins. None contained measurable plasminogen 
independent fibrinolytic activity. 
Most tissue homogenates and body fluids contained both Mel-PA 
and urokinase. Normal urine invariably contained only urokinase. 
Plasminogen activators present 1n plasma and serum presented 
an extremely complex picture. The amounts present, their molecular 
weights and the readiness with which they could be detected were 
influenced by the anticoagulant used, by the conditions of storage of 
the samples and by clotting. 
the tables. 
I have therefore, omitted these data from 
In all cases plasminogen activators present in tissues or 
body fluids that cross-reacted with Mel-PA had similar molecular weights 
to the enzyme released by melanoma cells in culture. As shown in Table 
3.2 plasminogen activators of the Mel-PA type with the molecular weight 
of 70 000 daltons predominated with minor amounts of plasminogen activator 
with a molecular weight greater than 100 000 daltons. Urokinase type 
activators had a major component with a molecular weight of approximately 
60 000 daltons with minor species of 32 000 daltons. In no single ~ase 
have I observed a urokinase-like enzyme with a molecular weight of 70 000 
daltons. 
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Table 3.2 Plasminogen activators released in human tissues and 
body fluids 
Source Species of plasminogen activator 
(Molecular weight; P ,A. Type) 
Mel-PA Urokinase 
lOOK 70K lOOK 60K 32K 
Urine ++++ ++ 
Seminal plasma + +++ +++ + 
Breast milk ++ +++ +++ 
C.S.F. + + 
Tears + + +++ 
Saliva + +++ + 
Uterus ++++ ++ 
Kidney ++ +++ 
Liver 
Lung +++ +++ 
Brain (grey) + ++ +++ 
Brain (white) ++ 
Thyroid +++ ++++ 
Heart + ++ 
Aorta ++ + 
Vein ++ ++ 
Oesophagus ++ + 
Prostate ++ ++++ ++ 
Adrenal + + 
Plasminogen activators present in tissue extracts and body fluids of 
human origin were subjected to electrophoretic and immunochemical analysis to 
define their molecular weight and their relationship to Mel-PA or urokinase. 
The relative abundance of the different molecular species within a given 
sample was scored on an arbitrary scale of - to++++ where"-" indicates 
no enzyme. 
Human tissues and body fluids contained both immunochemical types 
of plasminogen activator, with the exception of urine, which only contained 
urokinase and liver, which contained no detectable enzyme. 
Figure 3.8 
Ab 




Electrophoretic and immunochemical analysis of 
plasminogen activators in uterine tissue extracts. 
Samples of human uterine tissue extracts (wells 1, 2, 5 and 6), 
of urokinase (wells 3 and 4) or of Mel-PA (wells 7 and 8) were electro-
phoresed and analysed immunochemically as described in the Methods 
section and in the legend to Fig. 3.5. 
The human uterine tissue extract contained two species of 
plasminogen activator. The species with a molecular weight of 
approximately 70 000 daltons was inhibited by antibody to Mel-PA 
(gel B) and the species with a molecular weight of approximately 
60 000 was inhibited by antibody to urokinase (Gel A). 
Relationship of plasminogen activators found in other species to human 
Mel-PA and urokinase. 
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In order to determine whether or not phylogenetic relationships 
exist between human plasminogen activators and those found in other species, 
a survey was undertaken in which enzymes from a number of animal sources 
were examined for their susceptibility to inhibition by antibody to Mel-PA 
or urokinase. The results of this survey are presented in Tables 3.3 
to 3.6 and Fig. 3.9. 
The different species of plasminogen activators present in 
tissue extracts and body fluids were first analysed by the electrophoretic 
and zymographic procedure to determine their molecular weight and the 
approximate values for these are given in the tables. 
The immunochemical types of plasminogen activator present in 
a few representative samples of the tissue extracts or urines of the 
various animal species were then determined first by the radioenzyme 
assay and then by the combined electrophoretic and immunochemical procedures 
described in the Methods section. 
The entries in tables 3.3 to 3.6 give the relative abundance 
of the different molecular weight species within a given sample scored 
on an arbitrary scale of - (no plasminogen activator activity) to ++++,. 
The results are not quantitative and do not provide a comparison between 
total amounts of plasminogen activators in the different tissues. 
Most of the monkey tissue extracts tested contained plasminogen 
activators with a molecular weight of 60 000 daltons. Sometimes minor 
amounts of a 70 000 dalton and a 100 000 dalton species were encountered. 
This species could be inhibited by antibodies to Mel-PA but not by anti-
urokinase antibodies. The 60 000 dalton species on the other hand could 
be inhibited by anti-urokinase antibody. 
Monkey ·urine contained exclusively plasminogen activators of the 
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'rable 3. 3 Plasminogen activators 1n tissues and body fluids from 
















See legend to Table 3. 2 
a) Enzymes in these 
b) Enzymes in these 
c) Spleen contained 



























all inhibited by antibody to Mel-PA. 
inhibited by antibody to urokinase. 
plasminogen-independent fibrinolytic activity. 









































a) Enzymes in these columns were inhibited by antibodies to Mel-PA 
b) Enzymes in these columns were not inhibited by antibodies to 
Mel-PA or urokinase. 
c) This sample contained plasminogen-independent fibrinolytic 
activity. 
Note: Pig urine contained a plasminogen activator ·irmnunochemically 
identical to Mel-PA. 
Table 3.5 Plasminogen activators in rabbit and mouse tissues 
























See legend to Table 3.2 


















a) Enzymes in this column were inhibited by antibody to Mel-PA. 
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b) Enzymes in this column were not inhibited by antibody to Mel-PA 
or urokinase. 
c) This sample contained plasminogen-independent fibrinolytic activity. 






Plasminogen activators in various animal tissues and 
body fluids 
Source Species of plasminogen activator 
(Molecular weight) 
70Ka) 47Kb) 43Kb) 25Kb) 
Uterus + +++ 
Urine +++ 
Uterus + +++ 
Urine ++++ +++ 
Uterus + +++ 
Urine ++++ 
Urine + + + + 
Heart 
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See legend to Table 3.2 
a) Enzymes in this column were inhibited by antibody to Mel-PA. 
b) Enzymes in these columns were not inhibited by antibody to 
Mel-PA or urokinase. 
Figure 3.9 
A B 
Electrophoretic and immunochemical analysis of plasminogen 
activators present in pig tissues. 
Samples of extracts of pig prostate (wells 1 and 2) and pig 
kidney (wells 5 and 6) were compared to samples of Mel-PA (wells 3 and 4) 
or urokinase (wells 7 and 8) by the electrophoretic technique described 
in the Methods section and in the legend to Fig. 3.5. The troughs 
contained either anti-Mel-PA antibody (Gel A) or anti- urokinase 
antibody (Gel B). 
Plasminogen activators with a molecular weight of 70 000 daltons 
and one with a molecular weight of> 100 000 daltons could be inhibited 
by antibodies to Mel-PA (Gel A) but not by antibodies to urokinase 
(Gel B). On the other hand, plasminogen activators with molecular 
weights of approximately 47 000 daltons and 25 000 daltons and one of 
> 100 000 daltons could not be inhibited by anti-urokinase or anti-
Mel-PA. 
urokinase-type. From these results it could be concluded that the 
distribution of plasminogen activators in monkey tissues and urine is 
similar to that found in the human. In addition both major species 
of plasminogen activator of monkey origin were immunochemically related 
to the equivalent human enzymes. 
The analysis of the distribution of plasminogen activators 
present in tissues and body fluids of other animals such as pigs, rabbits, 
mice, dogs, hamsters and guinea pigs showed that they too contained two 
major species of enzyme. These had molecular weights of approximately 
70 000 daltons and 47 000 daltons. Minor species with molecular weights 
of 100 000 daltons and 25 000 daltons were sometimes encountered. In 
the cases where immunochemical analyses were performed on the enzyme, 
the 70 000 dalton species in all of the animals tested could be inhibited 
by antibodies to human Mel-PA and not by antibodies to human urokinase. 
The 47 000 dalton enzyme, on the other hand, was not inhibitable 
by antibodies directed to human urokinase or Mel-PA. 
The distribution of the different species of plasminogen 
activators in the animals was frequently similar to that seen in man 
and the monkey in that tissues usually contained a mixture of Mel-PA-like 
enzyme and a lower molecular weight enzyme (usually 47 000 daltons) that 
was not Mel-PA. Urine from most animals contained exclusively tne lower 
molecular weight species of plasminogen activator. The pig was quite 
unique in this respect in that it excreted exclusively a 70 000 dalton 
Mel-PA related plasminogen activator in the urine. 
The goat was also found to be an exception to the general rule 
in that its urine contained 4 equally abundant enzymes with molecular 
weights of 70 000, 47 000, 43 000 and 25 000 daltons. Unfortunately no 
W6 
immunochemical : analyses have been performed on urine samples from this 




The experiments I report in this chapter have shown that human 
Mel-PA was inununogenic in rabbits and that the techniques used for raising 
antibodies to this enzyme proved successful. It was particularly useful 
to note that TCA precipitation of the enzyme did not compromise its 
inununogenicity and that the rabbits could be inununized with segments of 
polyacrylamide gel containing electrophoresed protein. Dan6 was able 
to raise satisfactory antibodies to murine plasminogen activator using 
a similar approach (200). The efficacy of this procedure enables one 
to exploit a very powerful method for achieving a considerable purification 
of the inununogen before injecting it, so avoiding the complications that 
result from heterodisperse antibody responses or from antigenic competition. 
It was also convenient that the urine an·d melanoma harvest fluid were 
sources of functionally pure plasminogen activators. Since the object 
was to achieve antibody to each enzyme that inhibited in a specific way, 
it did not matter if other proteins were present provided enzymatic purity 
could be relied upon. 
In essence, the antibodies to Mel-PA and urokinase were required 
for purposes of classification of human plasminogen activators. The 
ability of inununoglobulins to discriminate between closely related antigenic 
determinants has made them extremely valuable reagents in other contexts 
and this particular case is no exception. I have been able to show with 
antibodies to Mel-PA and urokinase that two unequivocally distinct groups 
of plasminogen activator exist. Each of these groups comprises several 
molecular weight species and both of these are widely distributed in tissues 
and body fluids. 
The antibody to Mel-PA clearly reacted with an antigenic 
determinant that was somehow involved in the catalytic function of the 
enzyme, although it did not combine directly with the active site. The 
evidence for this is to be found in the fact that the antibody interfered 
with plasminogen activation but did not inhibit amidolytic activity in 
the fluorometric assay. I suspect that combination of antibody with the 
enzyme blocked binding of the plasminogen to Mel-PA at some point removed 
from the active site. Similar conclusions may be drawn from the results 
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of Dan~ et al (200) who found that antibody to murine plasminogen activator 
did not inhibit binding of radioactive DFP to the active site; and from 
the results of fucinski et al who found that the esterolytic action of 
urokinase was not blocked by antibody to this enzyme (56). It would have 
been of interest to have performed the synnnetrical experiment to determine 
if binding of antibody to plasminogen activator could be blocked by 
plasminogen, but unfortunately I did not have sufficient enzyme to enable 
me to do this experiment in a conclusive way. 
Lack of sufficent pure enzyme that could be appropriately labelled 
has also precluded attempts to develop a radioimmunoassay for Mel-PA. In 
any event this would have been difficult since the best antibodies I 
could raise only inhibited 50% of enzyme activity at a Mel-PA concentration 
-9 
of 1 x 10 ~. They thus lacked the affinity for the enzyme that would 
have made them useful antibodies for clinical or physiological measurement 
where I suspect enzyme concentrations are lower by an order of magnitude. 
Th~ fact that antibodies to Mel-PA inhibit all plasminogen 
activators released by all melanoma cell lines merits connnent in two 
respects. In the -first place this observation confirms the general 
impression that melanoma cells cultured in vitro generally release 
plasminogen activators that are not the same as urokinase (61,115,117,202) 
and adds the positive observation that such enzymes are immunochemically 
identical. This would suggest that melanoma cells by virtue of their 
neuro-ectodermal origin are constrained by differentiation to produce only 
one family of plasminogen activators. Alternatively it· may mean that 
in vitro culture procedures select from a mixed melanoma cell population 
those clones that have the capacity to survive in vitro and that, fortuit-
ously, make enzyme of the Mel-PA type. The observations by Markus et al 
(201) have a bearing on this question since they found that fragments of 
melanoma tissue removed from patients at the time of surgery invariably 
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contained a mixture of urokinase and Mel-PA type enzymes. It is distinctly 
possible therefore that cellular synthesis and release of Mel-PA in 
melanoma cell populations correlated with in vitro proliferative potential. 
Secondly, the fact that, irrespective of their molecular weights, 
all plasminogen activators that are released by melanoma cells are inhibited 
by anti Mel-PA provides good reasons to believe that these different species 
represent post-translational modification of a single gene product. A 
similar diversity of molecular size within the urokinase group of enzymes 
has been well documented (61,117,74,102). In view of studies I have 
performed on urinary plasminogen activators in health and disease and that 
I refer to in an appendix to this chapter, it should be noted that although 
it was not uncommon to find melanoma-type enzymes with a molecular weight 
of approximately 60 000 (corresponding to the predominant component of 
urokinase) I have not observed plasminogen activators inhibitable by 
urokinase antibody that have a molecular weight of 70 000. The fact that 
representativesof both Mel-PA and urokinase classes of enzyme may have 
similar molecular weights testified to the superiority of immunochemical 
criteria for classification over those based on molecular mass alone. 
The analyses that I have performed have shown that most human 
tissues contain a mixture of urokinase and Mel-PA. They do not contain 
as the observations and conclusions of others would imply (198,75,76,85, 
55) a single plasminogen activator that is distinct from urokinase and 
that justified the term "tissue plasminogen activator" to describe it. 
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Markus and co-workers (53,69,72), in comparing plasminogen activators 
extracted from neoplastic and normal tissues, obtained results essentially 
similar to mine in that they found that both contained mixtures of urokinase 
and Mel-PA. My results are at variance, however, with those of Rijken 
et al (198) who in their survey of extracts of human tissues, concluded 
that they lacked measurable urokinase and contained only plasminogen 
activators inhibitable by antibody to purified uterine tissue activator. 
Technical differences may explain the discrepancies between the results 
of these wo~kers and those obtained by Markus et al (52) and myself. 
Firstly, they used a 1 M NaCl solution to extract their samples whereas 
I used 0.5% aqueous Triton X-100. Secondly, the fibrin-plate assay that 
they used may have been relative1y more sensitive for the measurement of 
the Mel-PA type enzyme than it was for urokinase. Camiolo et al (53), 
for example, found that the apparent relative amounts of Mel-PA and urokinase 
present in the same sample differed according to whether a fibrinolytic 
or a caseinolytic assay was used. The electrophoretic and zymogr~phic 
procedures that I employed not only separated urokinase and Mel-PA so 
that smaller amounts of the former might still be detectable in the presence 
of relatively large amounts of the latter, they also (as I show in Chapter 
VI) detected urokinase with greater sensitivity . than they detected the 
Mel-PA type enzyme. 
Whatever the reasons for these differences, analytical procedures 
have now advanced to th·e stage where it is clear that most tissues contain 
a mixture of Mel-PA and urokinase. The term "tissue plasminogen activator" 
is therefore a misnomer and should be abandoned. 
The observations I have made on the innnunochemical relationships 
between plasminogen activators present in the tissues and body fluids of 
different species confirm and extend those made by Kucinsky et al (56) who 
found that antibodies to human urokinase inhibited the enzyme present in 
the urine of the baboon and the rhesus monkey but not those present in 
urine samples from dogs, pigs, rabbits or guinea pigs. Similarly, 
Dan~ et al (200) found that antibodies to the 48 000 dalton plasminogen 
activator isolated from MSV-infected mouse cells inhibited the enzyme 
present in urine from the mouse and the rat but had no effect on human 
urokinase or on the avian enzymes. Christman (107) prepared antibodies 
to the 50 000 dalton plasminogen activator released by SV-40 infected 
hamster ·cells and showed that this inhibited some hamster enzymes but not 
others; it did not inhibit plasminogen activator released by human cells 
in culture nor those released by murine melanoma cells or mammary car-
cinoma cells. Finally, Kok (55,66) has shown that pig tissue activator 
cross-reacts immunochemically with the enzyme isolated from human tissues. 
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The data that I have accumulated on the phylogeny of plasminogen 
activators justify the proposal that there is strong immunochemical homology 
between plasminogen activators of the Mel-PA type in all manunals. This 
would suggest that the Mel-PA type enzymes have an evolutionary significance 
that has preserved their identity throughout evolution and has safeguarded 
them against substantial mutation. 
One may speculate that the basis for this selection 1s to be 
found in the need, shared by all warm blooded animals, for an enzymatic 
mechanism to preserve patency of the vascular tree. Observations are 
accumulating (195,209) to indicate that the Mel-PA type enzyme is particularly 
suited for this function since it combines readily with fibrin and hence 
focuses fibrinolytic activity on the blood clot without producing relatively 
unselective plasminogen activation. 
The data also suggest that enzymes of the urokinase type, 
although present in all species, are immunochemically unique to certain 
orders. If, as seems probable, all serine proteases were derived from 
some single ancestral precursor, it is possible that the Mel-PA type 
enzyme represents a more ancient form from which urokinase was derived by 
mutation at the time of evolutionary speciation. The fact that the 
pig has melanoma-type plasminogen activator in the urine whereas all 
other species have an enzyme corresponding to urokinase in the urine 
would be consistent with this notion. These speculations provide 
the motivation for a more thorough and systematic survey of molecular 
similarities between plasminogen activators in the hope that these will 
provide additional phylogenetic probes for the study of animal evolution. 
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ANALYSIS OF PLASMINOGEN ACTIVATORS PRESENT IN URINE SAMPLES COLLECTED 
FROM NORMAL INDIVIDUALS AND FROM SUBJECTS WITH RENAL DISEASE. 
The survey that I have reported in this chapter of plasminogen 
activators present in normal tissues and body fluids has shown that 
urine collected from healthy subjects contained only the urokinase type 
enzyme whereas extracts of normal kidney tissue contained a mixture of 
urokinase and Mel-PA. These observations indicated that physiological 
or anatomical barriers exist that effectively confine Mel-PA to renal 
tissue and exclude it from the urine. If this were the case, damage 
to the kidneys might breach these barriers and so lead to the appearance 
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of measurable amounts of Mel-PA in the urine of patients with renal .disease. 
Since these suggestions have important diagnostic implications I have 
examined urine samples from 15 normal subjects -and from 39 patients 
with one or other form of renal disease. In the paragraphs that follow 
I report the results of this study. 
MATERIALS AND METHODS 
Urine samples 
Random urine samples were collected from 15 normal subjects 
and 39 patients with the renal diseases listed in Table 3.7. Freshly 
voided midstream or catheter urine specimens were transported to the 
laboratory on chipped ice. Samples for plasminogen activator analysis 
were taken from each specimen, centrifuged and made 0.1% with respect 
to Triton X-100. These were examined immediately or stored at -20°c 
for a maximum of one month without loss of activity. A second sample 
of each specimen was examined for bacterial contamination, for protein 
content and for the presence of cellular or other formed elements. 
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Electrophoretic detection of urinary Mel-PA. 
The method used to detect Mel~PA in human urine depended upon 
the fact that this is the only plasminogen-dependent caseinolytic protease 
that migrates with a mobility that is immediately cathodal to albumin 
and corresponds to a molecular weight of approximately 70 000 daltons 
when it is electrophoresed in 11% polyacrylamide gel slabs containing 
0.1% SDS. 
Urine samples prepared as above were diluted with an equal 
volume of a buffer consisting of O.lM Tris HCl pH 6.8, 2% SDS, 20% glycerol, 
0.004% phenol red and 100 µg/ml of BSA that had been labelled with . 
fluorescein isothiocyanate (Appendix 1). Samples ( 5 µl) of this mixture 
were then electrophoresed in 11% polyacrylamide gel slabs (70 x 115 x 0.5mm) 
containing 0.1% SDS. When the phenol red tracking dye had reached the 
bottom of the gel, electrophoresis was discontinued and the polyacrylamide 
gel slabs were washed in 2.5% Triton X-100 to remove the SDS. 
The gels were then examined under ultraviolet light when the 
position of albumin could be identified without difficulty as a sharp 
green fluorescent band. The gel was divided with a sharp blade at this 
band so separating Me1-PA (cathodal to the band) from urokinase (immediately 
anodal to the albumin band). Both portions of the polyacrylamide gel 
slab were then layered on an indicator gel slab containing 2% powdered skim 
milk (Carnation), 1.25% agar and 5 µg/ml purified human plasminogen in 
O.lM Tris HCl pH 8.1. Plasminogen was omitted from control indicator gel 
slabs to exanune for plasminogen-independent caseinolysis. The assembly 
was then incubated at 37°c in a humid environment for detection of plasminogen 
activator activity as clear bands of caseinolysis against an opaque 
background. A typical result is shown in Figure 3.10. 
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Figure 3.10 Electrophoretic analysis of urinary plasminogen activators. 
Urine samples were diluted with an equal volume of O.lM Tris 
HCl pH 6.8 containing 2% SDS, 20% glycerol, 0.004% phenol red and 
100 µg/ ml FITC-BSA. Samples (5 µ1) of these were electrophoresed in 
an 11% polyacrylamide gel slab containing 0.1% SDS. After electro-
phoresis, the polyacrylamide gel slab was washed in 2.5% Triton X-100 
and then examined under ultraviolet light for the position of the 
fluorescent albumin band. The gel was cut along this band and both 
portions were then layered on an indicator agar gel slab containing 
2% powdered skim milk, 1.25% agar, 5 µg/ml human plasminogen in O.lM 
Tris HCl pH 8.1. The assembly was then incubated at 37°c in a humid 
environment. 
The photograph shows a typcial gel assembly after incubation 
for 24 hr. The tracks contained the following samples: 
1) Mel-PA; 2) normal urine; 3) to 7) urine obtained after renal 
transplantation; 8) urine from patient with mesangio capillary GN; 
9) - with IgA nephropathy; 10) - with membraneous proliferative GN; 
11) - with chronic GN. 
Reference samples consisting of normal urine and partially 
purified Mel-PA (approximately 1.5 UK u/track) ·were co-electrophoresed 
with each set of test samples. After 24 hr of incubation, the zones 
of caseinolysis corresponding to Mel-PA and urokinase were graded on a 
scale ranging from O (no plasminogen activator) to++++ by visual 
comparison with the Mel-PA and urine reference standards which were 
assigned a value of++++ in all cases. 
Reagents 
Plasminogen and protease- and inhibitor-free BSA were prepared 
as described in the Appendix (Al). 
RESULTS 
All electrophoresed urine samples tested contained plasminogen 
dependent ca·seinolytic activity that could confidently be identified as 
Mel-PA or urokinase in type by reference to the fluorescent albumin 
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band and the co-electrophoresed enzyme markers. In no case was plasminogen 
independent caseinolysis observed with this protocol. In Table 3. 7 
I present the results of a survey in which these m~thods were applied 
to urine samples obtained from normal subjects and patients with different 
renal diseases. The urine samples from 15 normal individuals contained 
urokinase as the only caseinolytic agent whereas 13 of the 39 patients 
with renal disease had detectable Mel-PA in their urine in addition to 
urokinase. 
Urine samples that contained Mel-PA levels came from patients 
with IgA nephropathy (4 out of 5), post infective glomerulonephritis (2/2), 
membrano-proliferative glomerulonephritis (2/3), renal tuberculosis (1/2), 
polycystic kidneys (2/3). 
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Table 3. 7 
Table 3.7 
Samples of urine from patients with renal disease were 
analysed by the electrophoretic method described in the Methods section. 
The presence or absence of Mel-PA (70K) or urokinase (60K) 
was graded on a scale ranging from O (=no plasminogen activator) 
to++++ by visual comparison with the Mel-PA and urokinase reference 
standards which were assigned a value of++++ in all cases. 
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Table 3. 7 Electrophoretic analys.is of plasminogen activators in urine. 
Diagnosis 
Mesangio capillary GN 
Postinfective GN 















Systemic lupus erythematosus 
Haematuria .. , 


















































































I have also examined urine samples obtained on successive 
immediate post-transplant days in six renal allograft recipients. In 
all cases Mel-PA appeared transiently in the urine during the early 
post-operative period and disappeared as renal function improved. This 
temporal relationship was particularly well seen in the data depicted 
graphically in Fig. 3.11. 
No correlation was observed between the presence of Mel-PA 
in the urine and the degree of proteinuria seen. 
DISCUSSION 
The results that I report in this brief survey provide reason 
to believe that the demonstration of Mel-PA in human urine by this 
technique is an abnormal finding that signifies the presence of renal 
disease. In making this suggestion I recognize that the absolute 
differences between normal and pathological urine specimens that I 
have documented may be quantitative rather than qualitative if my 
protocol were relatively insensitive to the detection of Mel-PA. It 
is significant to note in this regard that Rijken et al (198) using 
antibodies to urokinase or uterine "tissue activator" in conjunction 
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with a fibrin plate assay, could detect small amounts of "tissue activator" 
in normal human urine. It is probable therefo_re that the fibrin plate 
assay is selectively more sensitive for the detection of Mel-PA. 
It should be noted that only approximately one third of patients 
whom I examined showedthe presence of Mel-PA using this particular protocol. 
The numbers involved are small and hence permit only tentative conclusions 
to be drawn. It is, nevertheless, worthy of connnent that the five urine 
samples obtained from patients with mesangiocapillary glomerulonephritis 
and the three samples obtained from patients with acute tubular necrosis 
contained no Mel~PA whereas this enzyme was found in most other forms 
of diffuse parenchymal renal disease. It is possible, therefore, that 
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Figure 3.11 Analysis of plasminogen activators in urine of a renal 
allograft recipient. 
Urine samples taken from a patient on successive days after 
renal transplantation was analysed for the presence of Mel-PA by the 
electrophoretic method described in the Methods section. 
the day of transplantation. 
Day O was 
The relative amount of Mel-PA in the urines was plotted 
as a function of time after transplantation, and compared to the 
levels of creatinine in the serum of the patient. 
Mel-PA was present in the urine during the early post-
operative period when serum creatinine levels were also high. After 
16 
13 days both Mel-PA and creatinine levels had decreased to normal levels. 
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the urinary excretion of Mel-PA is found only with certain renal lesions 
and not with others. 
In this survey I have not included patients with disease of the 
ureters or urinary bladder. Mel-PA may appear in the urine of patients 
with lesions in these areas, in which case its presence in the urine 
would not be a specific indicator of disease of the kidneys. 
To the best of my knowledge these data provide the first record 
of an attempt to correlate the presence or absence of renal disease with 
the immunochemical characterization of plasminogen activators present in 
the urine. Several studies have been reported in which absolute levels 
of urinary plasminogen activator have been measured in patients with renal 
disease and generally speaking a diminution in urinary enzyme content has 
been observed (203-206). Since most reported studies were undertaken 
before techniques and reagents were available for the distinction between 
Mel-PA and urokinase, these results are not strictly comparable to those 
that I have obtained. 
Although one may postulate that Mel-PA appears in the urine of 
patients with renal disease as a result of leakage across damaged cell 
membranes or other barriers that would normally contain the enzyme at some 
intracellular location within the kidney, there is as yet no entirely 
satisfactory justification for this assumption. It may be, for example, 
that Mel-PA is a constituent of the normal glomerular filtrate and is 
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removed during traverse of the healthy collecting system. These removal · · 
mechanisms may be defective in patients with certain forms of renal disease. 
It is also possible that Mel-PA in diseased urine is derived from tDe plasma 
as a result of a selective filtration defect at the level of the 
glome!ular basement membrane. Some support for this suggestion comes 
from the observations of Ekberg and Pandolfi(207) and McConnel et al (208) 
who have noted that plasminogen activators in normal human kidney are 
localized to the collecting tubules and major blood vessels whereas in 
disease the enzyme is found in the glomeruli (207). These authors 
made no attempt to discriminate between urokinase or Mel-PA however 
and the appropriate studies using immunohistochemical procedures will 
be required to clarify this issue. 
It was hoped that urinary Mel-PA concentrations could be used 
to monitor rejection after renal transplantation but this hope was not 
entirely realized. The enzyme was present as a transient phenomenon 
1n all recipients of renal allografts and appeared to resolve with return 
of normal renal function in a manner that was not specifically related to 
other manifestations of immunological rejection or to immunosuppressive 
therapy; It would seem more likely that the transient release of Mel-PA 
into the urine of these patients is an indicator of the minimal degree of 




CHARACTERIZATION OF AN INHIBITOR OF MEL-PA ISOLATED FROM THE SEEDS OF THE 
SOUTH AFRICAN LEGUME ERYTHRINA LATISSIMA. 
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Although plasminogen activator·s have been implicated in a number 
of physiological processes that appear to have a connnon requirement for 
regulated local proteolysis (60,81,211) the relative biological roles of 
urokinase and Mel-PA in these situations are uncertain. 
As a general rule, studies of complex biological systems are 
facilitated by the availability of inhibitors of participating enzymatic 
components. I therefore felt that it would be useful to attempt to 
identify inhibitors of plasminogen activators that would distinguish 
between urokinase and Mel-PA. Such reagents might be of use for assigning 
specific functions to urokinase or Mel-PA and for the purification of these 
enzymes. 
Dr. F. Joubert and his co-workers at the National Chemical Research 
Laboratories in Pretoria have a special interest in protease inhibitors derived 
from natural products. The close association that I enjoy with this 
laboratory enabled me to obtain samples from Dr. Joubert and to study these 
for their ability to function as specific and useful inhibitors of human 
plasminogen activators. A survey of compounds derived from seed extracts 
or snake venoms revealed that the seed of the legume Erythrina latissima 
contained a trypsin and plasmin inhibitor, DE-3, that strongly inhibited 
the action of Mel-PA but had no effect on urokinase. In this chapter 
I report the results of the experiments I performed to establish these facts. 
It could also be shown that the inhibitor formed reversible 
complexes with Mel-PA but not with urokinase. This fact was exploited 
by coupling DE-3 to sepharose to provide an affinity reagent for the 
one-step purific_ation of Mel-PA and pro-Mel-PA. 
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MATERIALS AND METHODS 
DE-3 Inhibitor 
Erythrina latissima seeds were collected and processed as described 
by Joubert et al (212) . . Briefly, the seeds were ground, defatted, and 
extracted at 10°c overnight with 0.5M sodium chloride solution. The 
extract was centrifuged and DE-3 inhibitor was recovered from the super-
natant by annnonium sulphate precipitation followed by chromatography on 
Sephadex G50, DEAE-cellulose and DEAE-sepharose. .The finally purified 
material migrated as a single band with an apparent molecular weight of 
-22 000 daltons when electrophoresed on a 15% polyacrylamide gel containing 
0.1% SDS. 
The purified DE-3 protein was labelled with 
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I by using the 
chloramine T method of Greenwood et al (213) as described in the Appendix 
(Al. 9) . Electrophoresis and autoradiography of the labelled material 
showed one radioactive band with an apparent molecular weight of 22 000 
daltons. 
Enzymes 
Mel-PA was obtained as serum-free harvest fluid collected from 
Bowes I or Bowes II melanoma cells as described in Chapter I. As each 
harvest fluid was removed it was centrifuged to remove cellular debris, 
acidified to pH 5.5 with glacial acetic acid and made 0.1% with respect 
to Triton X-100. Harvest fluids treated in this way could be kept frozen 
at -2o 0 c without apparent loss of enzyme activity for at least siA months. 
For certain experiments concentrated enzyme solutions were 
required. These were obtained by batch-adsorption of 2 litres of pooled 
serum-free harvest fluid with 40 ml of benzamidine-sepharose as described 
in Chapter I. 
Active eluate fractions from the benzamidine-sepharose were 
pooled to give approximately 70 ml of solution containing 500 (Range 350 
to 670) FU of active enzyme/ml. This was concentrated 5-10 fold by 
negative pressure ultrafiltration and dialysis in a 1.0 cm diameter 
Visking cellophane membrane immersed in O.lM Tris HCl pH 8.1 containing 
0.1% Triton X-100. Enzyme recovery to this point ranged from 60-80%. 
This solution was stored in portions at -20°c. 
Urokinase was purchased as a lyophilized powder from Leo 
Pharmaceutical Products, Ballerup, Denmark. This material contained at 
least 7 different proteins as judged by SDS-gel electrophoresis and 
Coomassie-blue staining. It was free of plasminogen-independent fibrin-
olytic activity and contained no Mel-PA as judged by electrophoretic and 
immunochemical criteria (Chapter III). 
Plasmin was generated from human plasminogen by incubation with 
insolubilized urokinase (Appendix Al.3). Protease- and inhibitor-free 
bovine serum albumin was added to give a final concentration of 1 mg/ml 
0 and the solution was kept at -20 C. 
125 
Trypsin was purchased from Worthington as thrice-crystallized 
bovine pancreatic trypsin and dissolved in 1 mM HCl to give a stock solution. 
The molarity of trypsin active sites in this solution was determined by 
titr~tion with 4-methylumbelliferyl-p-guanidinobenzoate (MUGB) according 
to the method of Jameson et al (164) as described in Chapter V. 
Plasminogen activator assay 
The fluorometric assay of Zimmerman et al (133) was used in which 
the direct amidolytic action of urokinase and Mel-PA was measured fluoro-
metrically by following the rate of increase in fluorescence at 455 nm 
that resulted from the amidolytic release of amino methyl coumarin (AMC) 
from the fluorogenic substrate Cbz-Gly-Gly-Arg-AMC. The reaction took 
place at 25°c in a glass cuvette in the sample compartment of a fluores-
cence spectrophotometer (Perkin-Elmer; Model MP~-43A), and was initiated 
by the addition of 50 µl of enzyme solution so that the final reaction 
mixture consisted of 500 µl of O.lM Tris-HCl pH 8.1 containing 4% DMSO 
and 5 x l0-4M substrate. The excitation wavelength was 383 nm and the 
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instrument was so set that a 4 x 10-?M solution of AMC in the assay mixture 
gave a full scale recorder pen deflection. One fluorometric unit of 
enzyme was arbitrarily defined as that amount catalyzing the release of 
10 pmol AMC/min. The activities of trypsin, plasmin and thrombin could 
also be measured with this assay. 
The assay for the inactive precursor of Mel-PA, "pro-Mel-PA", 
depended upon the facts that (a) pro-Mel-PA is converted to Mel-PA by 
plasmin and (b) that plasmin is inhibited by bovine pancreatic trypsin 
inhibitor whereas Mel-PA is not. In a typical assay for pro-Mel-PA, 
5 µl (2.5 µg) of plasmin solution was added to 295 µl of sample solution. 
After incubating for 60 min at 20°c, 50 µl of this solution was added to 
10 µl of pancreatic trypsin inhibitor (10 KIU) to inhibit all plasmin 
activity and 50 µl of this mixture was assayed fluorometrically for its 
ability to hydrolyse Cbz-Gly-Gly-Arg-AMC. This result measured the sum 
of pro-Mel-PA and Mel-PA. Mel-PA content was measured on the sample 
treated identically but incubated with 5 µl of buffer instead of plasmin 
solution. Experimental results that justify these assumptions and 
procedures are given in Chapter V, 
Radiometric standardization of Mel-PA 
For the analysis of Mel-PA: DE-3 interactions in terms of 
molarities of the reactants it was necessary to define a relationship 
between fluorometric units of amidolytic activity and molarity of active 
sites of the enzyme. This was achieved by active site labelling of a 
measured amount of Mel-PA with 
3
R-DfP of known specific radioactivity as 
described in detail in Chapter V, Radioactivity in precipitated protein 
was measured and used to calculate a specific activity for Mel-PA of 
0.99 FU/pmol of enzyme. In this approach I have assumed (a) that DFP 
forms a covalent bond with the active-site serine residue in Mel-PA, 
(b) that, under the conditions of the labelling procedure (i.e. a DFP 
enzyme molar ratio of at least 1000 : 1) the enzyme was quantitatively 
labelled in a 1 : 1 stoichiometric ratio, and (c) that no protein other 
than Mel-PA was labelled. This latter assumption was verified by SDS 
gel electrophoresis of precipitated protein followed by autofluorography, 




Inhibitory effect of DE-3 
Functionally pure solutions of trypsin, plasmin, urokinase, 
thrombin and Mel-PA were diluted to contain approximately 30 FU/ml in 
O.lM Tris HCl pH 8.1 containing 0.1% Triton X-100. To a sample of each 
solution (90 µl) I added 10 µl of a solution containing 20 mg/ml of 
purified DE-3 in O.lM Tris HCl pH 8.1 to give a final concentration of 
inhibitor of approximately l0- 4M. After incubation for 30 min at room 
temperature the mixture was assayed for residual 'enzyme activity to give 
the results depicted 1n Figure 4.1. Trypsin, plasmin, and Mel-PA were 
completely inhibited whereas urokinase and thrombin were unaffected. 
Kinetics of inhibition by DE-3 
It is desirable, when describing the action of a proteinase 
inhibitor, to define the stoichiometry of the interaction between enzyme 
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and inhibitor and the dissociation constant (Ki) governing that reaction. 
Estimates of stoichiometry are usually obtained by measuring the fractional 
activity (a) that remains when enzyme, at an initial concentration E , 1s 
0 
exposed to different total concentrations (I) of inhibitor. 
0 
In such an experiment a plot of a as a function of I /E gives 
0 0 
a graph with an initial negatively sloping portion. If favourable circum-
stances obtain and if I and E are in a suitable relationship to each 
0 0 
other, this initial portion of the graph is linear and can be confidently 
extrapolated to intercept the abscissa at the molar ratio for the enzyme-
inhibitor interaction in the limiting case of complete inhibition (i.e. 
a= O). 
As Bieth (214) has shown, in a very useful treatment of the 
subject, stoichiometric titrations of this sort require an E : Ki ratio 
0 
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Figure 4.1 The effect of DE-3 on trypsin, plasmin, thrombin, Mel-PA 
and urokinase. 
Solutions of trypsin, plasmin, thrombin, Mel-PA and urokinase 
were diluted to contain approximately 30 FU/ml in O.lM Tris HCl pH 8.1 
containing 0.1% Triton X-100. 
To 90 µl of each solution was added 10 µl of a solution 
containing 1 x l0-3M purified DE-3 in O.lM Tris HCl pH 8.1 to give 
a final concentration of 1 x 10-4M inhibitor. After incubation for 
30 min at room temperature the mixtures (open bars) and control samples 
that had received 10 µl of solvent without inhibitor (shaded bars) 
were assayed for enzyme activity in the fluorometric assay. 
Trypsin, plasmin and Mel-PA were completely inhibited by 
1 x l0-4M DE-3, whereas urokinase and thrombin were not affected. 
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of 1000 : 1 or greater. If enzyme supplies are ample or if the affinity 
of the inhibitor for the enzyme is sufficiently high such conditions are 
fairly easy to meet. Thus Joubert et al (212) were able to titrate trypsin 
with DE-3 and to demonstrate a 1 1 molar interaction between the protein-
ase and the inhibitor. 
In the case of Mel-PA, supplies of enzyme were limited and the 
Ki proved to be relatively high. It was thus not feasible to perform a 
titration experiment which was amenable to "stoichiometric" interpretation. 
It was nevertheless possible to obtain data which could be used to estimate 
the Ki. These are presented graphically in Fig. 4.2 and come from an 
-8 experiment in which 2.94 x 10 M of Mel-PA were titrated with DE-3 
inhibitor in a final reaction volume of 0.1 ml. A simple interative 
computer programme was then used to define the value for Ki that would 
give the least sum of squared deviations of observed values for a from 
the calculated values derived from the theoretical relationship: 
a 1 - (E + I 
0 0 




. ) 2 4 + Ki - .E • I 
0 0 
The value for Ki obtained in this way (214) was then used to 
construct the curve shown in Fig. 4.2. 
The inhibitor-enzyme complex was not dissociated by substrate 
since addition of substrate to an equilibrium mixture of enzyme and 
inhibitor did not cause an exponential release of product nor could 























10-10 10-9 10-s 10-7 10-5 10-5 
Inhibitor Concentration CM) 
Figure 4.2 Inhibition of Mel-PA and triEsin bl DE-3 
Mel-PA (2.94 x 
-8 
10 M; .t:r----6.) or trypsin (2.05 x 10 - lOM; D--0) 
were incubated with DE-3 at the concentrations shown in 100 µl of O. lM 
Tris HCl pH 8.1 containing 0.02% Triton X-100 for 1 hr at room temperature. 
Fifty microlitre aliquots of each mixture were then withdrawn for measure-
ment of amidolytic activity in the fluorometric assay. 
Each point represents the mean of duplicate values for .the 
fractional residual enzyme activity plotted as a function of inhibitor 
concentration. 
An interative computer programme was used to determine values 
for the inhibitor constants (Ki) for the two enzyme~ that gave the best 
least mean squares fit to the relationship 
a 
1 - (Eo + Io + Ki) _J.--(E_o_+_I_o_+_K_i_)_2---4-.-E-o-.-I-o 
2 Eo 
where a= fractional residual enzyme activity; 
-8 concentration (2.94 x 10 M for Mel-PA; 
Eo = original enzyme 
-10 2.05 x 10 M for trypsin) 
and Io= the concentration of inhibitor. 
These .Ki values (1.12 x 10-?M for Mel-PA and 6.97 x 10-lOM 
for trypsin) were then substituted in the above equation to construct 
the curves. 
Chromatographic analysis of DE-3-protease interactions 
In order to determine whether or not DE-3 formed complexes 
with various proteases, mixtures of 1251-labelled inhibitor with trypsin, 
Mel-PA or urokinase were analysed by molecular sieve chromatography on a 
calibrated 1.6 x 90 cm column of Sephadex G-75 fine equilibrated and 
eluted with O.lM glycine NaOH pH 8.0 containing 0.15M NaCl and 0.1% 
Triton X-100. 
The elution profiles of the various mixtures are shown in Fig.4.3. 
The DE-3 inhibitor on its own or together with urokinase showed one large 
peak and two smaller ones. The elution volume of the main peak corres-
ponded to a molecular weight of approximately 19 000 daltons. 
The mixture of Mel-PA arid DE-3 showed 2 broad peaks. One 
of the peaks eluted with the void volume and presumably represented enzyme 
inhibitor complexes. The second peak corresponded to a molecular weight 
of approximately 19 000 daltons and represented free inhibitor. 
The mixture of DE-3 and trypsin eluted at a single peak with 
an approximate molecular weight of 32 000 daltons. 
Electrophoretic analysis of DE-3-protease interactions 
The results obtained from molecular sieve chromatography indicated 
that Mel-PA and trypsin formed complexes with DE-3 whereas urokinase did not. 
To investigate the nature of the products of DE-3-protease interactions in 
more detail, enzyme-inhibitor mixtures were analysed by electrophoresis in 
polyacrylamide gel slabs under denaturing and non-denaturing and under 
reducing and non-reducing conditions. 
E 1 h . f . f 125 3 . . . ectrop oresis o mixtures o I-DE- with trypsin, plasmin, 
urokinase, thrombin and Mel-PA in a 5-16% polyacrylamide gradient gel 
containing 0.1% SDS showed no evidence of complex formation with any of 
the proteases when the gel was fixed and studied by autoradiography (Fig.4.4). 
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Figure 4, 3 
Figure 4.3 Molecular sieve chromatography of inhibitor-protease mixtures 
125 6 I-DE-3 (18.3 pmol; 1.5 x 10 cpm) was incubated for 10 min 
at 37°c with trypsin (27.0 pmol), Mel-PA(~ 300 pmol) or urokinase (~ 250 
pmol), each in a total volume of 500 µl of O.lM glycine NaOH pH 8.0 
containing 0.15M NaCl and 0.1% Triton X-100. 
The samples were then chromatographed on a Sephadex G75 fine 
column (1.6 x 90 cm) equilibrated and developed with O.lM glycine NaOH 
pH 8.0 containing 0.15M NaCl and 0.1% Triton X-100. The flow rate was 
5.4 ml/hr and 2.4 ml fractions were collected. The radioactivity 
in each fraction was determined by counting in a Beckman Autogamma Counter 
4000. 
The column was calibrated using ferritin (450 000 daltons) 
bovine serum albumin (67 000 daltons), ovalbumin (43 000 daltons), 
chymotrypsinogen (25 000 daltons) and cytochrome C (12 500 daltons). 
(Boehringer, Mannheim). 
The elution profiles show that complex formation occurred 
between DE-3 and trypsin and between DE-3 and Mel-PA; whereas 
DE-3 treated with urokinase showed the same elution profile as the 
untreated inhibitor. 
Untreated DE-3 eluted with an elution volume (Ve) corresponding 
to a molecular weight of 18 700 !_ 1000; the DE-3-trypsin complex had 
a Ve corresponding to a molecular weight of 31 900. The DE-3-Mel-PA 
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Figure 4.4 SDS-polyacrylamide gel electrophoresis of inhibitor-
enzyme mixtures. 
1251-DE-3 (1.2 x 106 cpm) or DE-3 (1.35 nmol) were incubated 
with various proteases at room temperature for 30 min in O.lM Tris HCl 
pH 8. 0 containing 0.02% Triton X-100 in a total volume of 100 µl. 
SDS (10 µl of 25%) and glycerol (5 µl) were added and the samples boiled 
for 1 min. Aliquots of 5 µl were then electrophoresed in a 5-16% 
l inear gradient of SDS polyacrylamide. Active trypsin concentration 
was 2 nmol/100 µl giving an I o/Eo ratio of 0.7 . The other proteases 
were not pure and no estimates of molarity were made. The activities 
can be expressed in fluorometric units as follows: 
Plasmin 80 FU/ml, 0.37 mg / ml; thrombin 2 x 104 FU/ml, 1 mg/ml; 
urokinase 2 x 105 FU/ml; Mel-PA 1.6 x 10 3 FU/ml; trypsin 
1.4 x 108 FU/ml. After electrophoresis, the gel was fixed, stained 
and dried and autoradiographs were prepared. 
The tracks contain from left to right : 1) DE-3; 
2) and 3) Trypsin and DE-3; 4) and 5) Plasmin and DE-3; 
6) and 7) Thrombin and DE- 3; 8) and 9) Mel-PA and DE-3; 
10) and 11) urokinase and DE-3. 
No SDS-stable complex formation of the inhibitor with any 
of the enzymes was observed. 
The inhibitor-protease complexes seen in the previous experiment were 
therefore not stable in the presence of SDS, 
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Complex formation between inhibitor and trypsin, however, could 
be clearly demonstrated by electrophoresis 1n the absence of SDS. This 
is illustrated in Fig. 4.5 which depicts an autoradiograph of an alkaline, 
non-denaturing gel containing electrophoresed mixtures of radioactive 
inhibitor with trypsin, urokinase or Mel-PA. 
As is shown in the photograph, the radioactive inhibitor 
migrated as a single band with an Rf of approximately 0.6. When the 
inhibitor was pre-incubated with trypsin at a pH of 3.5 or 8.0 and then 
electrophoresed the free inhibitor band was no longer seen and most of 
the radioactivity was visible in a band with an approximate Rf of 0.1, 
indicating that the DE-3 had formed complexes with trypsin at both low and 
alkaline pH. An additional faint band with an Rf of app.roximately O. 7, 
just anodal to that of the free inhibitor band, could also be seen. 
In the case of the Mel-PA-DE-3 mixture, the Rf 0.7" band was 
more prominent than in the DE-3-trypsin mixtures. Furthermore, a faint 
radioactive band at the stacking gel-resolving gel interface was just 
detectable. Presumably DE-3-Mel-PA complexes were too basic to enter 
the gel. 
Urokinase and DE-3 did not form visible complexes 1n this experi-
ment nor was the Rf 0.7 band visible when the inhibitor was incubated with 
this protease. 
The Rf 0.7 band detected in the previous experiment where DE-3 
was mixed with trypsin or Mel-PA suggested that these two proteases modified 
the inhibitor in a way that urokinase did not. To examine the nature of 
th . d.f . t· · t f d 1·n wh1·ch 125r-DE-3 1s mo 1 1ca 10n an exper1men was per orme was 
incubated with trypsin, Mel-PA or urokinase. The mixtures were then 
Figure 4.5 
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Alkaline pol yacrylamide gel electrophoresis of inhibitor-
enzyme mixtures. 
125 6 Samples of I-DE-3 (12.5 pmol; 1.2 x 10 cpm) were incubated 
under different conditions of time, temperature and pH with either 
Trypsin (10 pmol), urokinase (28 pmol), Mel-PA (30 pmol) or buffer in 
a total volume of 40 µl. After incubation 30 µl water, 10 µl of 
glycerol and 1 µl of 0.04%' phenol red were added to each sample and 
5 µl aliquots of each were electrophoresed in a 7% discontinuous 
polyacrylamide gel of pH 8.9. 
After electrophoresis the gel was fixed and dried and an 
autoradiograph was prepared to give the results depicted above. 
The electrophoretic tracks in the photograph have been labelled to 
indicate (above) the nature of the enzyme and (below) the conditions 
under which enzyme and inhibitor were incubated before electrophoresis. 
Keys are as follows: 
Enzyme: T = Trypsin; U = urokinase; M = Mel-PA; "-" = buffer 
alone. 
Buffer: pH 8 :- O.lM glycine - NaOH + 0.02% Triton X-100 
pH 3.5:- O.lM glycine - HCl + 0.02% Triton X-100. 
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reduced and alkylated and electrophoresed in 10-20% polyacrylamide gradient 
gels containing 0.1% SDS. The autoradiograph of the fixed and dried gel 
is shown in Fig. 4.6 from which it can be seen that the unreduced inhibitor 
migrated with a mobility corresponding to a molecular weight of 
approximately 22 000 daltons. Reduction and alkylation altered the 
electrophoretic mobility of the inhibitor so that it now migrated with an 
apparent molecular mass of approximately 23 000 daltons. As seen 
125 previously (Fig. 4.4) treatment of the I-DE-3 with trypsin, Mel-PA or 
urokinase had no effect upon the mobility of the unreduced inhibitor in 
gels containing SDS. On the other hand, electrophoresis of enzyme-treated 
inhibitor ?fter reduction and alkylation showed, in the case of Mel-PA 
an additional band with an apparent molecular mass of 15 000 daltons and, 
in the case of trypsin, two radioactive products - one with an apparent 
molecular mass of 15 000 daltons and a second with a molecular weight of 
7000 dal tons. 
Figure 4.7 depicts the results of an experiment in which 
1251 3 d ' h . M 1 PA -DE- was treate wit trypsin or e - . The mixtures were then 
electrophoresed in the first dimension in an alkaline gel under non-reducing 
and non-dissociating conditions and, in the second dimension, in a reducing 
gel containing 0.1% SDS. As can be seen, the Rf 0.7 band detected in 
the experiment depicted in Fig. 4.5 and the 15 000 dalton band shown in 
Fig. 4.6 could both be attributed to the same inhibitor fragm~nt. 
Effect of DE-3 on active site-labelling of Mel-PA and urokinase with 3H-DFP. 
In order to determine whether or not DE-3 interacted with 
Mel-PA at the active site of the enzyme, an experiment was performed in 
which Mel-PA and urokinase were incubated in the presence of DE-3 for 30 min 
at room temperature. Radioactive DFP was then added and the mixtures 
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Figure 4.6 
Figure 4.6 SDS-polyacrylamide gel electrophoresis of inhibitor-enzyme 
mixtures under reducing and non-reducing conditions. 
125r-DE-3 (34.6 pmol, 4.5 x 106 c;m) was incubated with 
trypsin (100 pmol), Mel-PA (90 pmol), urokinase (60 pmol) or buffer 
in a total volume of 65 µl of PBS containing 0.02% Triton X-100 for 
16 hr at room temperature. 
After incubation the solutions were made 2% with respect 
to SDS; 0.5M with respect to Tris HCl pH 8.4; 0.002M with respect 
to EDTA and 8 M with respect to urea in a final volume of 100 µl. 
Proteins were reduced by addition of 1 M dithiothreitol to a final 
concentration of O.OlM and incubation at 37°c for 60 min under 
nitrogen. 
Carboxymethylation was then achieved by the addition of 
lM iodoacetamide to a final concentration of 0.022M. After incubation 
on ice for 30 min, lM dithiothreitol was added to give a final 
concentration of 0.044 Mand the solutions were then diluted ten-fold 
with SDS-sample buffer (0.06 M Tris HCl pH 6.8 containing 1% SDS and 
10% glycerol). The total volume of each sample was approximately 
1 ml at this stage. 
Nonreduced samples were treated in a similar fashion with 
the exception that water was added instead of dithiothreitol and 
iodoacetamide. 
Samples of 20 µl were electrophoresed on a 10-20% linear 
gradient of polyacrylamide, and autorad_iographs were prepared. 
The tracks of the gel shown in the figure contained radio-
active inhibitor with buffer, Mel-PA, urokinase or trypsin. Tracks 
marked with an (a) contained nonreduced samples whereas tracks marked 
with a (b) contained reduced samples. -
Mel-PA and trypsin had modified the inhibitor and a 15 000 
da.lton fragment was obtained. In the case of trypsin a faint band with 
a molecular weight of approximately 7000 dalton could be seen. 





Figure 4.7 Two-dimensional polyacrylamide gel electrophoresis of 
inhibitor-enzyme mixtures. 
DE-3 (5.6 pmol, 5 x 10
5 cpm) was mixed with Mel-PA (approximately 
70 pmol), or trypsin (50 pmol) in a total volume of 80 µ1 of 0.1 M Tris 
HCl pH 8.1 containing 0.02% Triton X-100. The samples were incubated 
for 16 hr at room temperature and 10 µ1 glycerol and 1 µ1 0.04% phenol 
red were then added. Two samples of twenty µ1 of each mixture were 
then electrophoresed in a 3-15% linear gradient of polyacrylamide gel 
slab (120 x 120 x 0.75 mm) at pH 8.9. 
After the phenol red tracking dye had migrated to a distance 
of 2 cm from the bottom of the gel, electrophoresis was stopped, and 
two tracks containing either DE-3-trypsin or DE-3-Mel-PA were separated 
from the remainder of the gel. The remainder was fixed, stained and 
dried and autoradiographs were prepared. 
The two tracks containing DE-3-Mel-PA or DE-3-trypsin were 
incubated ~n 0.06 M Tris ·Hcl, _pH 6.8 containing 2.5% SDS, 5% S-mercapto-
ethanol and 10% glycerol at room temperature.for 30 min. 
After equilibration each track was layered across the top 
of a slab gel containing a linear gradient of 10-20% polyacrylamide 
and 0.1% SDS. Close contact between the tracks and the second 
dimension slab gels was ensured by embedding the tracks in 1% agarose 
in equilibration buffer. Molecular weight marker proteins were 
applied to one side of the gel in a well made in the agarose. 
Electrophoresis was carried out at 20 mA per gel at 4°c 
until the red tracking dye of the marker proteins had reached the 
bottom of the gels. The gels were fixed, dried and autoradiographs 
were prepared. 
The figure shows autoradiographs of the two SDS-slab gels 
with the corresponding tracks on top of each. 
It .can be seen that the two DE-3 bands obtained by electro-
phoresis under alkaline conditions could be resolved into two bands of 
molecular weights of 22 000 and 15 000 dalton in the SDS-polyacrylamide gel. 
Treatment of DE-3 with urokinase (70 pmol) or buffer alone 
resulted in no change in the DE-3 molecule (Results not shown). 
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were incubated for a further 30 min at 37°c. Proteins were then pre-
cipitated by addition of TCA to a final concentration of 6%, The 
precipitates were collected by centrifugation, washed and -redissolved 
in a buffer containing SDS. Each enzyme-inhibitor solution was then 
divided into two portions. One of these was reduced by the addition of 
8-mercaptoethanol and the other was not. The samples were then electro-
phoresed in a 5-16% polyacrylamide gradient gel containing 0.1% SDS. 
143 
After electrophoresis the gel was fixed and dried and autofluoro-
graphs were prepared. The results are shown in Fig. 4.8. 
In the absence of DE-3, 3H-DFP-labelled Mel-PA migrated as a 
single band with a molecular weight of approximately 73 000 daltons. This 
was converted to a 35 000 dalton band by reduction. Both the 73 000 and 
the 35 000 molecular weight bands were reduced in intensity by pre-incubation 
of Mel-PA with ·nE-3. 
Unreduced urokinase showed two radioactive bands with approximate 
molecu:ar weights of 56 000 and 32 000 daltons. After reduction one band 
was seen with an apparent molecular weight of 32 000 daltons. The 
intensity of these bands was unaffected by DE-3. 
These results show that the active site of Mel-PA was blocked 
by DE-3 and hence not available for covalent binding to DFP. 
Purification of Mel-PA using affinity chromatography on DE-3-sepharose 
The fact that DE-3 formed non-covalent complexes with Mel-PA 
but not with urokinase suggested that the inhibitor might be coupled to a 
solid phase support to provide an affinity reagent for the chromatographic 
separation of these two enzymes and for the purification of Mel-PA. 
Purified DE-3 inhibitor was accordingly coupled to cyanogen 
bromide-activated sepharose 4b as described in the legend to Fig. 4.9. 
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Figure 4.8 
Figure 4.8 Competition of DFP labelling of active sites with the 
inhibitor DE-3. 
Samples of Mel-PA (180 pmol) or urokinase (420 pmol) were 
dissolved in 500 µl of 0.02% Triton X-100 in O.lM Tris HCl pH 8.1 
with (tracks labelled "b") or without (tracks labelled "a") 1 nmole 
of DE-3. 
After incubation for 30 min at 20°c, 
3H -DFP (150 µCi; 
23 nmol) was added and the mixtures were incubated for a further 
30 min at 37°c. 
Protein was then precipitated by the addition of SDS and 
TCA to final concentratiom of 0.1% and 6% respectively. The precipitates 
were collected by centrifugation (1700g; 30 min) and each was 
dissolved in 40 µl of 0.06 M Tris HCl pH 6.8 containing 1% SDS and 
10% glycerol. One sample (20 µl) of each enzyme-inhibitor mixture 
was reduced by addition of 2-mercaptoethanol to a final concentration 
of 57.. After boiling for 1 min, 10 µl samples were electrophoresed 
in an 5-16% linear gradient SDS polyacrylamide gel. 
After electrophoresis, the gel was fixed and stained with 
Coomassie brilliant blue and autofluorographs were made as described 
in the Appendix. 
When treated in this way, Mel-PA showed one radioactive band 
with a molecular weight of approximately 73. 000 under nonreducing 
conditions (NR) and one with a molecular weight of 35 000 under reducing 
conditions (R). In the presence of DE-3 the intensity of these 
radioactive bands was diminished. 
Nonreduced urokinase (NR) showed two bands with molecular 
weights of 56 000 and 32 000 daltons and one band of 32 000 daltons 
after reduction (R). The intensity of these radioactive bands was 
not reduced by the presence of DE-3. 
73K 
35K 





Figure 4.9 Chromatography on DE-3 sepharose 4b 
Purif ie·d DE-3 (26 mg) was coup lecl to 5 ml of commercially 
available CNBr-activated sepharose 4b (Pharmacia) according to the 
manufacturers instructions. 
The matrix was equilibrated with PBS pH 7.4 containing 
0.4M NaCl, 0.1% Triton X-100 and 0.02% sodium azide. 
then packed into a column. 
The matrix was 
Two litres of harvest fluid obtained from Bowes II cells 
was made 0.4 M with respect to NaCl and 0.1% with respect to Triton 
X-100 and filtered through a 0.45 µm membrane (Millipore). 
The harvest fluid was then applied to the column at a flow 
rate of 45 ml/hr at room temperature and the effluent was collected 
l.'nto a beaker at 4°c. Th ffl · t d f h e e uent was moni ore or t e presence 
of plasminogen-dependent fibrinolytic act~vity in the 
125I-fibrin assay. 
After the total volume of harvest fluid had passed through, 
the column was washed with 6 column volumes of PBS containing 0.4M 
NaCl and 6.1% Triton X-100. 
at this stage. 
Five mi:llilitre fractions were collected 
Adsorbed proteins were then eluted using PBS containing 
1.6M KSCN, 0.4M NaCl and 0.1% Triton X-100 and 2 ml fractions were 
collected at 4°c. 
The fibrinolytic activity in all fraction~ was determined 
in the 
125I-fibrin assay. Fractions containing the highest activity 
were pooled to give 6 to 8 ml of solution which was stored a~ -2o
0 c. 
This usually represented 70-80% of the tota~ activity · appli~d to the column. 
Fractions containing lower activity were pooled separately. The 
total recovery of activity in both pools usually amounted to 90-100%. 
The high on280 
values observed while the harvest fluid 
sample was being added to the column are attributable to the phenol 
red in the tissue culture medium. 
The photographs above the elution profile depict SDS-
polyacrylamide gel electrophoretograms of proteins precipitated with 
TCA from the corresponding subjacent fractions. Note that the 
KSCN eluate contained a single band of protein with a molecular 



























































The matrix was equilibrated in PBS pH 7.4 containing 0.4M 
sodium chloride, 0.1% Triton X-100 and 0.02% sodium azide. The matrix 
(5 ml settled volume) was packed into a column fashioned from a disposable 
syringe. Adsorption and elution of enzyme was done at room temperature 
0 and fractions were collected at 4 C. The data summarized graphically in 
Fig. 4.9 show that all of the Mel-PA present in 2 litres of Bowes II 
melanoma cell harvest fluid that had been adjusted to contain 0.1% Triton 
X-100 and 0.4M sodium chloride could be adsorbed to the column. Washing 
~ith 5 column volumes of equilibration buffer failed to displace Mel-PA. 
Elution of the enzyme could be satisfactorily achieved with 1.6M KSCN 
dissolved in a buffer consisting of 0.4M NaCl, 0.1% Triton X-100, 0.02% 
·sodium azide and O.OlM sodium phosphate, pH 7.4. 
In the early stages of its use the column behaved erratically 
inasmuch as incomplete recoveries of Mel-PA were obtained and fragments 
of bound inhibitor were eluted from the matrix with the KSCN solution. 
After 4 litres of Mel-PA harvest fluirl had been processed on the column, 
. however, reproducible results were obtained with 100% recovery of added 
enzyme. It could be shown by measurement of amidolytic activity before 
and after plasmin treatment that the affinity column adsorbed both Mel-PA 
and pro-Mel-PA. 
loss. 
The inactive enzyme precursor was also recovered without 
Electrophoretic analysis of the active fractions eluted from the 
affinity column with potassium thiocyanate revealed a single band of protein 
with an apparent molecular weight of approximately 70 000 daltons corres-
ponding to pure enzyme. No detectable contaminants were seen when the gel 
was stained with Coomassie brilliant blue or with a more sensitive silver 
stain described by Merril et al (215). 
Urokinase did not adsorb to the affinity matrix and was completely 
removed with the washing buffer. 
These data are summarized in tabular form in Table 4.1. 
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Table 4.1 Performance of a DE-3-a·ffini t}: column for the Eurification 
of Mel-PA. 
Run i) Sample Vol (ml) Total % Recovery Presence %Pro-Mel.,-PA 
No. Activity of DE-3 
(FU) 
1 harvest fluid 300 2974 42.4% 
wash 
KSCN eluate 24 2022 68% + 48.8% 
2 harvest fluid 740 6845 N.D. 
wash 
KSCN eluate 47 6639 96.9% + N.D. 
3 harvest fluid 1260 12839 45% 
wash 
KSCN eluate 40 11298 87.9% 39% 
4 harvest fluid 2000 23740 52% 
wash 
KSCN eluate 51 24356 >100% 47% 
i) Run numbers refer to sequential batches of Bowes II harvest fluids 
processed on 5 ml of DE-3-agarose. 
Note a) that enzyme recovery improved with successive use of 
the column, 
b) that DE-3 leached from the column at the beginning 
but not with later runs, 
c) that Pro-Mel-PA as well as Mel-PA could be purified. 
Primary structure of DE-3: comparison with soybean trypsin inhibitor 
In Fig. 4.10 I present the partial amino acid sequences of 
DE-3 and soybean trypsin inhibitor that had been aligned to show maximum 
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homology. The results for DE-3 were obtained by Dr. F. Joubert in Pretoria 
and he has generously permitted me to report them in this thesis. The 
results for soybean trypsin inhibitor were obtained from the literature 
(219). The reactive site for both inhibitors is one Arg-X bond marked 
with an asterisk. It is evident that little homology exists for a number 
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The seeds of the legume Erythrina latissima contain a trypsin 
inhibitor of the Kunitz type (212) that has previously been designated DE-3. 
This protein has three unusual attributes. In the first instance, whereas 
soybean trypsin inhibitor and other known plant-derived Kunitz inhibitors 
have no effect on plasminogen activators (142,133). DE-3 is able to inhibit 
Mel-PA. This is of particular interest and may be related to the fact 
that sequence homology between the two inhibitors is poor close to the 
reactive site of the protein, despite excellent agreement in other regions. 
(Fig. 4.10). 
Secondly, in-its selective ability to inhibit Mel-PA without 
affecting the action of urokinase, DE-3 is able to distinguish between two 
important serine proteases, both of which have, as their major putative 
physiological function, the activation of plasminogen. 
Thirdly, as is shown by the data presented in Fig. 4,5 to Fig. 4.7, 
DE-3 was cleaved by both trypsin and Mel-PA to give disulphide-linked frag-
ments, one of which had a molecular mass of approximately 15 000 daltons. 
No such cleavage was seen when the inhibitor was treated with urokinase. 
One may conclude, therefore, that, as has been found with other Kunitz type 
inhibitors (216), the inhibitory action of DE-3 is related to its ability 
to serve as a substrate for the enzyme and to form relatively stable 
complexes with both inactive pro-Mel-PA as well as the active form of the 
enzyme. An association between trypsinogen and Kunitz inhibitors has 
previously been documented (220). 
Considered collectively, these properties and the other data 
that I have accumulated support the proposal that the DE-3 molecule 
possesses at least two regions for interaction with serine proteases. 
The first is that -site which is cleaved by the protease. It would appear 
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to be straddled by a disulphide bridge and to be situated 63 residues 
from the N-terminal end of the inhibitor molecule. The second is that 
region which binds to the specific binding site on trypsin, plasmin or 
Mel-PA but not to the analogous site on urokinase or thrombin. Attachment 
of the inhibitor to the active site of Mel-PA would not only block access 
of the fluorogenic substrate in the amidolytic assay, but would also block 
active site labelling with radioactive DFP (Fig. 4.8). 
Immobilized DE-3 proved to be an affinity reagent that could be 
reused many times and yet remain effective despite the passage of an 
amount of enzyme that would have been expected to have converted all of 
the inhibitor into the cleaved form. It has been noted with other systems, 
that the same stable complex is formed between enzymes and either native 
or cleaved inhibitor (221,222). 
Mel-PA interaction. 
Presumably the same is true for the DE-3 
The usefulness of DE-3 inhibitor for the purification of Mel-PA 
is apparent. It is to be hoped that further knowledge of its primary and 
tertiary structure in relation to other Kunitz type inhibitors and other 
serine proteases will provide useful insights into the mechanism of action 
of these enzymes and, in particular, into finer points of difference between 
the action of Mel-PA and urokinase which may shed light upon their different 
functional roles in vivo. 
CHAPTER V 
A COMPARISON BETWEEN CERTAIN PLASMINOGEN-INDEPENDENT ENZYMATIC FUNCTIONS 
OF UROKINASE AND THE MELANOMA PLASMINOGEN ACTIVATOR. 
Distinctions between Mel-PA and urokinase have rested mainly 
upon electrophoretic and immunochemical criteria and upon differences 
in their provenance in the body. Relatively few reports have appeared 
in the literature to indicate that these enzymes also differ in such 
functional characteristics as the rates at which they hydrolyse synthetic 
substrates (155,156,157,158), the extent to which they bind to fibrin 
(57,58,130,169) and the extent to which their catalytic activity is 
enhanced by the presence of other macromolecules (53,57,159,160). 
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Since the functional differences that distinguish urokinase from 
Mel-PA have important implications for their possible physiological roles 
in vivo, and for their assay and for the study of their cellular synthesis 
in vitro, I felt it important to undertake a study of the catalytic 
activities of these two enzymes. 
The availability of chemically defined substrates for urokinase 
and Mel-PA has made it possible to measure their amidolytic activities 
directly without considering the manner in which they function in more 
complex systems involving plasminogen, plasmin, plasmin substrates or 
other macromolecules. The separate study of the amidolytic and plasminogen-
converting functions of Mel-PA and urokinase has enabled me to distinguish 
the effects of macromolecules and other substances that operate at both 
functional levels. 
In this chapter I report the results of experiments in which I 
have confined myself to the study of the plasminogen-independent, amidolytic 
activities of urokinase and Mel-PA and the extent to which these functions 
are influenced by various inhibitors. In the next chapter I consider 
urokinase and Mel-PA for their ability to activate plasminogen, for their 
role as fibrinolysins, and for the ways in which they differ 1n these 
respects. 
MATERIALS AND METHODS 
The melanoma plasminogen activator was obtained and isolated 
from Bowes melanoma cells cultured in vitro as described in Chapter I 
and Chapter IV. Human urokinase was obtained commercially (Leo 
Pharmaceutical Products, Ballerup, Denmark). Samples of Mel-PA and 
urokinase were functionally pure as judged by electrophoretic and immuno-
chemical criteria and by the use of appropriate control assays under 
plasminogen-free conditions. Bovine fibrinogen (Sigma Chemical Company, 
St. Louis, Mo., U.S.A.; Fraction I, F 4000) and human fibrinogen 
(A.B. Kabi, Stockholm, Sweden) were freed of plasminogen by the method 
of Mosesson (162)(Appendix Al.l). Plasmin was generated from purified 
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human plasminogen (Appendix Al.3) by incubation with insolubilized urokinase. 
Partially-purified thrombin was obtained from Parke-Davis Laboratories (Pty) 
Ltd., Isando, Tvl. South Africa, and was used for formation of fibrin clots 
from fibrihogen. Purified thrombin was obtained from Sigma Chemical 
Company, St. Louis, Mo., U.S.A. Bovine trypsin was obtained from 
Worthington Biochemical Corporation, Freehold, N.J., U.S.A. Other 
reagents and their connnercial sources are listed in the Appendix (AS). 
Amidolytic assays 
The amidolytic activities of Mel-PA and urokinase were measured 
according to the method of Zimmerman et al (133) using two fluorescent 
substrates, Cbz-glycyl-glycyl-arginyl-7-amino-4 methyl coumarin 
(Cbz-Gly-Gly-Arg-AMC) and Eoc-valyl-glycyl-arginyl-7-amino-4 methyl 
coumarin (Boc-Val-Gly-Arg-AMC). Assays were carried out in glass 
cuvettes at 25°c. The reaction was initiated by addition of 50 µ1 
of enzyme solution. The final reaction mixture consisted of O.lM Tris 
HCl pH 8.1 containing 5 x l0-4M substrate, 4% (v/v) DMSO, and enzyme 
in a total volume of 0.5 ml. 
The initial rate of AMC release was monitored fluorometrically 
using a Perkin Elmer fluorescence spectrophotometer model MFP-43A 
equipped with a recorder. The excitation and emission wavelengths were 
set at 383 nm and 455 nm respectively. The instrument was standardized 
so that a 4 x l0-7M solution of AMC in the assay buffer gave a full scale 
recorder pen deflection. 
Activities of enzymes were expressed in fluorometric units/ml 
(FU/ml), where 1 F~ represented that amount of enzyme which hydrolysed 
10 pmol of substrate in one minute. 
Labelling of active sites with radioactive DFP 
Urokinase, Mel-PA and trypsin were labelled at the active-site 
serine by incubation with 3H-DFP. After incubation the labelled enzymes 
were recovered and freed from unreacted radioactive ?FP by precipitation 
and washing with TCA. The methods used were those recommended by Cohen 
et al (163) for serine proteases. 
3 For experiments in which H-DFP was used as a quantitative 
reagent for measurement of the concentration of plasminogen activator 
active sites in solution, it was necessary to know the specific activity 
of the radioactive inhibitor. This was calculated from the protein-
bound radioactivity recovered after treatment of an accurately known 
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amount of trypsin with a 1000-fold molar excess of the radioactive DFP, 
In brief the procedures were as follows: 
Purified trypsin was dissolved to an approximate concentration of 1 mM 
in 1 mM HCl. The concentration of active enzyme was then determined 
accurately by active site titration using methylumbelliferyl guanidino-
benzoate (MUGB) according to the method of Jameson et al (164). This 
procedure was reproducible and reliable and gave data (Fig. 5.1) from 
which the molarity of the trypsin active sites could be confidently 
determined. 
An ethylene glycol solution of radioactive DFP (6 Ci/mmol; 
5 mCi/ml; Amersham International; Cat. No. TRK 207) was diluted with 
non-radioactive DFP (10 mM; Sigma Chemical Company) in isopropan?l to 
give an approximate specific radioactivity of 0.3 Ci/mmol such that 
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the final mixture of convenient volumes would provide statistically 
satisfactory amounts of protein-bound radioactivity in the treated enzymes 
and, at the same time, a molar excess of inhibitor over enzyme of at 
least 1000:1. Known amounts of trypsin and radioactive DFP were then 
mixed and incubated for 16 hours at 20°c in O.lM Tris HCl pH 8.1 
containing 0.1% Triton X-100. At the end of the incubation, radioactive 
protein was precipitated by the addition of TCA to give a final concentration 
of 6%. Protease- and inhibitor-free bovine serum albumin (PIF-BSA; 
Appendix Al.6) was added to a final concentration of 0.7 mg/ml to provide 
precipitate bulk and 0.2% SDS was added to maintain Triton X-100 in 
solution (165). The precipitate was washed sequentially with 6% aqueous 
TCA and acetone by suspension and centrifugation (1700g; 30 min) and 
dissolved in 1.0 ml O.lM NaOH for radioassay. The solution was transferred 
to a scintillation vial containing 10 ml of Instagel (Packard Instrument 
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Figure 5.1 Determination of trypsin concentration by active site titration. 
A stock solution of approximately 1 mM trypsin in 1 mM HCl was 
diluted 100-fold with O.lM Na phosphate buffer, pH 6.5. Incremental volumes 
of 10 µl of this solution were added to a quartz cuvette containing 1.03 ml 
of O.lM Na phosphate pH 6.5 and approximately 0.3 nmol of methyl umbelliferol 
guanidinobenzoate (MUGB). 
Fluorescence was measured within 2 min of each addition of trypsin 
in a Perkin-Elmer fluorometer with excitation and emission wavelengths set 
at 323 nm and 446 nm respectively. 
The plot of fluorescence intensity as a function of the cumulative 
volume of trypsin added comprised two distinct linear components - a steep 
portion followed by a plateau that was reached when all available MUGB had 
been hydrolysed. The intersection of the extrapolated regression lines for 
these two components was taken as the end point. As shown the coordinates 
for this point were 68 µl of trypsin solution and 28.5 fluorometric units. 
This latter value corresponded to a concentration of 0.254 µM methylumbelli-
ferol as determined from a standard curve constructed by plotting fluorescence 
units as a function of methylumbelliferol concentration. 
From these data the concentration of trypsin active sites in the 
stock solution was estimated to be 0.41 mM. 
using the automatic external standard facility to convert cpm to dpm. 
Appropriate controls included (i) incubation of enzyme with solvent but 
without inhibitor to ensure that enzymatic activity was not lost 
spontaneously during the course of incubation and (ii) incubation of 
radioactive DFP solution without enzyme. With this second control the 
precipitation step was performed with albumin only to provide background 
counts for subtraction. b . df . 1 3 d d Data o taine ram a typica H-DFP stan ar -
isation run are presented in Table 5.1. 
SDS-polyacrylamide gel electrophoresis 
The method for electrophoresis of proteins in polyacrylamide 
gels containing SDS and subsequent autoradiography of gels is described 
in detail in the Appendix A2. 
RESULTS 
Electrophoretic analysis of Mel-PA and urokinase: identification of 
active site subunits 
Mel-PA and urokinase were labelled with radioactive DFP as 
described under Methods. The proteins were then electrophoresed in 
SDS-polyacrylamide slab gels under normal and reducing conditions. 
After electrophoresis the slab gels were processed for autoradiography 
either according to the method of Bonner and Laskey (139)or using 
3 En Hance (Appendix A2.5). 
The results (Fig.5.2) showed that the urokinase preparation 
used contained DFP-binding proteins of MW 56 000 and 32 000. When this 
sample was electrophoresed under reducing conditions one labelled band 
was observed at a position corresponding to MW 32 000. 
Mel-PA showed a radioactive band with a MW 73 000. When 
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Table 5 .1 
Table 5.1 
Radioactive DFP (6 Ci/mmol; 5 mCi/ml) was diluted with non-
radioactive DFP (10 rnM) in isopropanol to give an approximate specific 
radioactivity of 0.3 Ci/mmol. Fifty four microlitres of this mixture 
was then added to 1 ml solutions containing either buffer, trypsin at 
the concentration shown, urokinase or Mel-PA. Mel-PA was dissolved 
in RPMI containing 0.1% Triton and urokinase was dissolved in O.lM Tris 
HCl pH 8.1 containing 0.1% Triton. 
The mixtures were incubated for 16 hr at room temperature. 
At the end of the incubation protease- and inhibitor-free BSA was added 
to a final concent ration of 0.7 mg/ml and SDS was added to a final 
concentration of 0.2%. The proteins were collected by precipitation 
with 6% TCA and centrifugation at 1700g for 30 min. After the precipitates 
had been washed twice with 6% TCA and twice with acetone, they were 
dissolved in O.lM NaOH. The solutions were quantitatively transferred 
in 1 ml volumes to scintillation vials containing 10 ml of Instage l and 
the samples were counted . 
Analysis of data obtained from two typical titrations are 
shown in the table . 
As can be seen, catalytic constants of 0.99 FU/pmol and 
66.8 FU/pmol were calculated for Mel-PA and urokinase respectively. 
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Table 5.1 Active site titration of Mel-PA and urokinase with 3H-DFP 
Expt. Sample Amt.of dpm d:em-bgd pmol FU/pmol 
enzyme pmol calculated 
pmol FU 
1 Buffer 2 485 
Trypsin 41. 8 40 655 913.16 
83.5 76 505 886. 47 
250.6 308 540 1221. 29 
1006.97 
Mel-PA 44.43 50 170 47.36 0.938 
46.83 60 408 57.52 0.814 
274.30 249 655 254.46 1.078 
54.86 51 716 .48. 89 1.122 -
0.988 
2 Buffer 3 251 
Trypsin 41.8 52 988 1189. 89 
83.5 126 494 1475.96 
125.3 180 869 1417.54 
1361.13 
Urokinase 11 619 230 111 172.86 67.22 
11 619 246 951 
1 162 27 246 17.48 66.47 
1 162 26 846 
66.84 
Fi gure 5. 2 Elec t rophoretic analysis of Mel-PA and urokinase labelled 
3 . 
with H-DFP. 
Fifteen microlitres of 3H-DFP (6.5 Ci/mmol; 5 mCi / ml) were added 
to 500 µl T- T(0.02) containing either Mel-PA(~ 250 pmol) or urokinase 
(~ 30 pmol) and the mixtures were incubated at 37°c for 30 mins. A further 
3 15 µl of H-DFP was then added and incubation continued for 16 hours at 
room temperature. After incubation, protein was precipitated by the addition 
of 5 µl of 25% SDS and sufficient TCA to give a final concentration of 6%. 
The precipitates were collected by centrifugation (1700g; 30 min), washed 
in acetone and redissolved in 40 µl of 0.06M Tris-HCl pH 6.8 containing 1% SDS 
and 10% glycerol. Samples (20 µl) of the labelled Mel-PA and urokinase 
preparations were treated with 1 µl of 2-mercaptoethanol. All of the preparations 
were boiled for 1 min and 10 µl samples were electrophoresed in a 5-16% gradient 
polyacrylamide gel slab containing 0.1% SDS. After electrophoresis the slab 
was fixed and stained in Coomassie brilliant blue in 30% methanol:10% acetic 
acid, destained, impregnated with EN 3HANCE and dried. An autoradiograph was 
was by exposure of Osray RP X-ray film to the dried slab for 48 hr at -8o0 c. 
The autoradiograph is presented in the figure. The wells contained 
(1) Mel-PA; (2) urokinase; (3) Mel-PA reduced and (4) urokinase reduced. 
Note: Radioactive bands obtained with unreduced Mel-PA and urokinase electro-
phoresed with mobilities corresponding to molecular weights of 73 000 daltons 
and 56 000 daltons respectively. The urokinase sample contained a 32 000 
dalton component. Reduction separated the active-site subunits of Mel-PA and 
urokinase into components with molecular weights of 35 000 daltons and 32 000 
daltons respectively. 
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electrophoresed under reducing conditions, a single band of MW 35 000 was 
obtained. Staining of the gel with Coomassie brilliant blue showed that 
the band was converted by reduction into two subunits of approximate 
molecular weights of 35 000 and 38 000. The smaller of these subunits 
contained the active site. 
Amidolytic activity of Mel-PA and urokinase · 
The amidolytic activity of the two enzymes was estimated fluoro-
metrically using the substrate Cbz-Gly-Gly-Arg-AMC. Both Mel-PA and 
urokinase hydrolysed the arginine-AMC bond to liberate the AMC which could 
be measured fluorometrically. This assay was linear with enzyme 
concentration and with time for both enzymes (Fig. 5.3 and Fig. 5.4). 
Kinetic parameters for the reaction were calculated using the method of 
Cornish-Bowden and Eisenthal (167), These parameters were used to fit 
straight lines to double reciprocal plots of 1/V vs 1/S (Fig. 5.5). 
This method is preferred to Lineweaver-Burk plots (168) in which least 
squares regression analysis is applied directly. 
Cbz-Gly-Gly-Arg-AMC was found to be a better substrate for 
urokinase (Km= 0.42 mM) than for Mel-PA (Km= 0.81 mM). 
To define catalytic constants relating activity in Fluorometric 
Units to active site concentration, enzyme solutions of defined activity 
3 were reacted with H-DFP of known specific radioactivity and protein-bound 
radioactivity was measured. From the results obtained it cou.ld be 
calculated that 1 prnol of urokinase active sites was equivalent. to 66.8 FU 
and 1 pmol of Mel-PA active sites was equivalent to 0.99 FU (Table 5.1). 
Results obtained when the amidolytic activities of the two enzymes 
were measured using Boc-Val-Gly-Arg-AMC are presented in Figure 5.5. This 
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Hydrolysis of Cbz-Gly-Gly-Arg-AMC by Mel-PA and 
urokinase: kinetics of the reaction. 
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Reactions were carried out at 25°C in glass cuvettes containing 
final concentrations of 0.5 mM substrate and 4% DMSO in O.lM Tris HCl pH 8.1. 
Reactions were initiated by the addition of 50 µl of enzyme 
solution to give a final total volume of 0.5 ml. 
The graphs in the figure show that fluorescence increase ( t F) 
was linear with time for both urokinase (0--0) and Mel-PA(~). 
For this experiment the instrument was standardized with a solution 
of AMC so that one division on the chart represented 2.3 pmol of AMC. The 
reaction cuvettes therefore contained 1.12 FU of Mel-PA and 2.3 FU of 
urokinase. 
One fluorometric unit has been arbitrarily defined as that 
amount of enzyme hydrolysing 10 pmol of substrate in 1 min. 
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Hydrolysis of Cbz-Gly-Gly-Arg-AMC as a function of 
enzyme concentration. 
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The rate of hydrolysis of the substrate by different volumes 
of stock solutions of urokinase and Mel-PA was determined using the 
same experimental conditions as described in the legend to Fig. 5.3. 
Fluorometric units (FU) are as defined in the legend to Fig. 5.3. 
The assay was linear with enzyme concentration for both Mel-PA (..c:~~) 




Figure 5.5 Lineweaver-Burk plots of the amidolytic activities of 
Mel-PA and urokinase. 
Reciprocals of initial reaction velocities with Mel-PA (b---6.) 
or urokinase (D~D) were plotted as functions of the reciprocals of 
Cbz-Gly-Gly-Arg-AMC or BOC-Val-Gly-Arg-AMC concentrations. 
Straight lines were fitted to the observed points using 
kinetic parameters calculated according to the method of Cornish-
Bowden and Eisenthal (167). 
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than was Cbz-Gly-Gly-Arg-AMC and an inferior substrate for urokinase 
(Km 1.47 mM), Catalytic constants for Mel-PA and urokinase with this 
substrate were 1.12 FU/pmol and 17.88 FU/pmol respectively. 
Amidolytic activity was determined as a function of pH for 
Mel-PA and urokinase using Cbz-Gly-Gly-Arg-AMC. The results (Fig. 5,6) 
indicated that both enzymes were neutral proteases with optima at pH 8.5. 
Effect of inhibitors 
Mel-PA and urokinase were tested for their susceptibility to 
inhibition by various proteinase inhibitors. The results obtained are 
summarised in Table 5.2, where the concentration of inhibitor necessary 
to achieve 50% reduction in enzyme activity (I50) is presented. 
From the results presented in the table it can be seen that 
neither Mel-PA nor urokinase were inhibited by Trasylol, soybean trypsin 
inhibitor, pancreatic trypsin inhibitor components (Kunitz) or ovomucoid. 
Iodoacetamide inhibited the enzymes slightly at relatively high concen-
trations. 
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Dithiothreitol, benzamidine, zinc chloride, DFP and NPGB inhibited 
urokinase more effectively than they inhibited Mel-PA. None of the 
inhibitors used, with the exception of the Erythrina inhibitor, (Chapter IV), 
were more effective against Mel-PA than they were against urokinase. 
Effects of fibrinogen, fibrin and other proteins on the catalytic activity 
of urokinase and Mel-PA 
Many authors have reported that "tissue activator" and urokinase 
differ in their binding to fibrin and in the extent to which their plas-
minogen activating activity is enhanced by fibrin (53,57,58,159,161). 
60 
""'· 50 ....... 
E 





> 20 ..... 
..µ 
0 10 < 
Figure 5.6 
3 4 5 6 7 8 9 10 
pH 
Determination of the optimum pH for hydrolysis of 
Cbz-Gly-Gly-Arg-AMC by Mel-PA and urokinase. 
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The amidolytic activity of Mel-PA or urokinase on Cbz-Gly-Gly-




, 50 mM Tris, 
50 mM glycine adjusted to the desired pH's with HCl or NaOH. Conditions 
of the assay were otherwise the same as described in Fig. 5.3. The 
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pH values used for plotting the data were determined by measuring the pH's 
of the final reaction mixtures. 
The pH optima for Mel-PA (1:r--~) and urokinase (~) were 
both approximately pH 8.5. 
Table 5. 2 The effect of inhibitors on the amidolytic activity 
of Mel-PA and urokinase. 
Inhibitor 
_Soybean trypsin inhibitor 
Pancreatic trypsin inhibitor 
compound (Worthington) 











E-aminocaproic acid (EACA) 
ISO (M) 
Mel-PA 
> 5 X 10-s 
> 1 X 10-4 
> 1000 KIU/ml 
> 5 X 10-5 
7 X 10-3 
4.3 X 10-3 
> 1.0 X 10-l 
6.5 X 10-3 
3 X 10-5 
3 X 10-4 
> 2 X 10-l 
Urokinase 
> 5 X 10-s 
> 1 X 10-4 
> 1000 KIU/ml 
> 5 X 10-5 
2,8 X 10-3 
1.2 X 10-3 
0.9 X 10-l 
4.4 X 10-4 
5 X 10-9 
3.5 X 10-5 
2 X 10-l 
Mel-PA ( ~ 20 FU/ml;~ 2 x l0-8M) or urokinase ( ~ 20 FU/ml; 
-10 
~ 3 x 10 M) in T-T (0.02) were mixed with various concentrations of 
inhibitors listed in the table in a total volume of 100 µl. After 
incubation for 60 min at 20~C, 50 µl were withdrawn from the mixture 
and assayed for amidolytic activity. 
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Although it has been reported (57) that neither fibrin nor 
fibrinogen affect the amidolytic actions -of urokinase or "tissue activator" 
on synthetic substrates, I wished to satisfy myself that the same was 
true for Mel-PA. A number of experiments were therefore performed to 
examine this question and the results are presented in Figs 5.7 to 5.13. 
It is important to note that the fibrinogen used in these experiments 
was derived from different sources and purified by the method of 
Mosesson (162) to remove contaminating plasmin or plasminogen. 
For the first experiment Mel-PA was purified by DE-3 affinity 
chromatography of Bowes II cell harvest fluid and samples were incubated 
either with solutions containing fibrinogen, a fibrin clot, casein, 
gelatin or buffer alone. Samples of urokinase were treated identically. 
After incubation at 20°c for 30 min samples were assayed for amidolytic 
activity with Cbz-Gly-Gly-Arg-AMC. The results (Fig. 5.7) were somewhat 
surprising in that they showed that fibrin and fibrinogen had increased 
the ~__midolytic activity of Mel-PA by approximately two-fold. Casein and 
gelatin had no effect on Mel-PA and none of the proteins tested enhanced 
the activity of urokinase. 
A more detailed kinetic analysis of this phenomenon (Fig. 5.8a 
and b) showed that fibrinogen affected the Vmax of Mel-PA for the synthetic 
substrate but had no effect on the Km. Neither the Vmax nor the Km of 
urokinase for the synthetic substrate were altered significantly by 
fibrinogen. 
During the course of these experiments it was noticed that the 
magnitude of the effect of fibrinogen on Mel-PA varied both with the Mel-PA 
and the fibrinogen preparations (Fig. 5.9 and Fig. 5.10). The activity 
of Mel-PA obtained from Bowes II cells cultured under serum-free conditions 
could be enhanced by as much as 10-fold by fibrinogen, whereas the same 














The effect of variouA proteins on the amidolytic activity 
of Mel-PA and urokinase. 
Mel-PA (18 FU/ml) or urokinase (30 FU/ml) were incubated in a 
total volume of 100 µl of T-T (0.02) containing 0.1 mg fibrinogen, 
0.1 mg gelatin, 0.1 mg casein or a washed fibrin clot. Fibrin clots 
were prepared by incubating 0.1 mg of fibrinogen with 0.1 units of 
thrombin in 100 µl PBS for 30 min at 37°c and then washed 3 times 
in T-T (0.1). 
After incubation of the enzymes in the presence or absence of 
proteins for 30 min at room temperature, 50 µl samples were removed for 
determination of amidolytic activity using Cbz-Gly-Gly-Arg-AMC. 
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The bar graph in the figure shows that the ·amidolytic activity 
of Mel-PA was enhanced by fibrinogen and a fibrin clot, but not by gelatin 
or casein. None of the proteins had an effect on urokinase. 
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Figure 5. 8 · 
Figure 5.8 The effect of fibrinogen on the kinetic parameters of 
the amidolytic activities of Mel-PA and ur'okinase. 
Mel-PA or urokinase were incubated at 20°C for 30 min in 
the absence or presence of 0.1 mg fibrinogen in a total volume of 
1 ml of T-T(0.02). Amidolytic activities of the enzymes were t hen 
determined as a function of Cbz-Gly-Gly-Arg-AMC concentration by 
assay of 50 µ1 of the mixture under standard conditions. 
The graphs show Lineweaver-Burk plots relating the amidolytic 
activity to substrate concentration . . The kinetic parameters 
calculated according to the method of Cornish-Bowden and Eisenthal 
(167) were used to fit straight lines to the observed points. 
The calculated results were as follows:-
Parameters 
Enzyme Fibrinogen Km Vmax --
(mM) (pmol/min) 
Mel-PA Absent A-A 0.81 71.9 
Present v-v 0.94 129.7 
Urokinase Absent o-o 0.42 41.8 
Pres.ent 0-~ 0.35 43.5 
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Figure 5.9 The effect of fibrinogen on different preparations of Mel-PA. 
Five different Mel-PA preparations were diluted in T-T (0.02) 
to contain approximately 4-6 FU/ml. 
Fifty microlitre samples of each of these solutions were mixed 
with ei_ther 50 µl of PBS (shaded bars) or 50 µl of PBS containing 0. 2 mg 
of fibrinogen (open bars). After incubation for 10 min at 20°c, amidolytic 
activity of these mixtures was measured. 
preparations as follows: 
The captions identify the Mel-PA 
(i) HF-BI : harvest fluid from Bowes I cells 
(ii) HF-BII : harvest fluid from Bowes II cells 
(iii) Benz : partially purified Mel-PA from Bowes I cells after 
benzamidine-agarose chromatography; 
(iv) Zn: partially purified Mel-PA from Bowes I cells after 
Zn-chelate-agarose chromatography; 
(v) DE-3 : purified Mel-PA from Bowes I cells after 
DE-3-agarose affinity chromatography. 
Note that the amidolytic activities of different Mel-PA 
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Figure 5.10 The effect of different preparations of fibrinogen on Mel-PA. 
Two different preparations of human fibrinogen (F-1 and F-2) 
and two of bovine fibrinogen (F-3 and F-4) were dissolved in T-T (0.02) 
buffer to give solutions containing 4 mg of protein /ml. 
Samples of each of these solutions were diluted with equal 
volumes either of RPMI medium (shaded bars) or of Bowes II harvest fluid 
(open bars), and the amidolytic activity of each mixture was measured. 
Control samples were identical save for the absence of fibrinogen. 
Mel-PA activity was enhanced to different extents by the 
different fibrinogen preparations. 
All fibrinogen preparations had amidolytic activity with 
F-3 having the highest. 
most effectively. 
This preparation also enhanced Mel-PA activity 
(notably those obtained from harvest fluids from Bowes I cells) only 
two-fold or not at all. This difference could not be ascribed to the 
presence of an inhibitor in the Bowes II cell harvest fluid, that was 
dissociated by fibrinogen, since Bowes II harvest fluid, that had been 
depleted of Mel-PA by passage over a DE-3 agarose affinity adsorbent 
(Chapter IV), had no effect on purified Mel-PA in the presence or absence 
of fibrinogen (Fig. 5.11). 
When the different preparations of fibrinogen were tested for 
their effect on the same Mel-PA preparation (Fig. 5.10) they varied in 
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the extent to which they were capable of enhancing the activity of Mel-PA. 
Furthermore it was noted that these fibrinogen preparations had amidolytic 
act~vity in the absence of Mel-PA; and that this activity correlated with 
the enhancement of Mel-PA activity. 
The enhancement of Mel-PA activity by human fibrinogen occurred 
over a short period of time and reached a plateau after about 15 min of 
incubation (Fig. 5.12). The effect was also related to the fibrinogen 
concentration (Fig. 5.13). Enhancement of Mel-PA activity reached a 
plateau at a fibrinogen concentration of approximately 0.5 mg/ml (1.5 µM) 
or a fibrinogen:Mel-PA molar ratio of approximately 30:1. This rather 
large ratio and the fact that a plateau was reached indicated that the 
interaction between Mel-PA and fibrinogen was catalytic rather than 
stoichiometric in nature. This, taken together with the observations 
that fibrinogen affected the Vmax of the reaction but not the Km, and that 
the activities of different Mel-PA preparations were enhanced to different 
extents by the presence of fibrinogen, suggested that the fibrinogen con-
tained an impurity that was capable of converting Mel-PA to a more catalyti-
cally active form without influencing the binding of the substrate to the 
enzyme. The observation that different fibrinogen preparations were 
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Figure S.11 Effect of harvest fluid depleted of Mel-PA on the amidolytic 
activity of Mel-PA in presence and absence of fibrinogen. 
Harvest fluid from Bowes II cells was depleted of Mel-PA by 
passage over a DE-3 agarose affinity adsorbent as described in Chapter IV. 
A purified Mel-PA preparation obtained by affinity chromatography on DE-3 
agarose was diluted two hundred times either in medium containing 0.1% 
Triton X-100 or in harvest fluid depleted of Mel-PA. 
Fifty microlitres of this dilution was mixed with SO µl of 
PBS or SO µl of PBS containing 4 mg/ml fibrinogen 3 (see Fig. S.10). 
After incubation for 30 min at 20°c, the amidolytic activity in the samples 
was determined as described under Methods. Bar (a) represents the 
activity of Mel-PA diluted in medium and bar (c) represents the same in 
the presence of fibrinogen. Bar (b) and (d) represent the activity of 
Mel-PA diluted in harvest fluid depleted of Mel-PA in absence (b) and 
presence (d) of fibrinogen. 
Harvest fluid depleted of Mel-PA had no effect on Mel-PA activity 
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Figure 5.12 Time study of the effect of fibrinogen on Mel-PA. 
Equal volumes of harvest fluid from Bowes II and fibrinogen 1 
(F-1; Fig. 5.10) at 4 mg/ml were mixed and incubated at 20°C. At 
the times indicated, SO µl samples were removed and assayed for amido-
lytic activity. 
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The results are expressed as the percentage of activity relative 
to a control sample containing no fibrinogen. 
It can be seen that maximum enhancement was obtained after an 
incubation period of 15 min. 
180 
60 
"' r-,f 50 
E 





~ a a &I .µ 
0 20 
< 
0 .2 . 4 . 6 . 8 1 
Final Fibrinogen Cone. Cmg/ml) 
Figure 5.13 The effect of fibrinogen on Mel-PA and urokinase. 
Ten microlitre volumes of solutions of fibrinogen 1 (F-1; 
Fig. 5.10) ranging in concentration from Oto 10 mg/ml were added to 
a series of tubes containing 90 µl of a solution of either urokinase 
or Mel-PA in T-T (0.02). The Mel-PA was a purified preparation 
obtained by DE-3 agarose affinity chromatography (Chapter IV). 
The tubes were incubated at 20°c for 60 min after which 
50 µl samples were withdrawn for measurement of amidolytic activity. 
The fibrinogen had no effect on urokinase (0--0) but 
enhanced the activity of Mel-PA (b~) by approximately two-fold. 
capable of hydrolysing the synthetic substrate in the absence of Mel-PA 
(Fig. 5.11) suggested that this impurity might be a protease. 
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The amidolytic activity of fibrinogen could be inhibited by NPGB, 
benzamidine, Trasylol and soybean trypsin inhibitor (Table _5.3). Attempts 
to inhibit the enhancing effect of fibrinogen on Mel-PA by the addition of 
trasylol or soybean trypsin inhibitor however failed, possibly because 
these compounds inhibited the fibrinogen-protease only weakly. Attempts 
to inhibit the protease irreversibly by treatment of the fibrinogen with 
DFP failed, because addition of isopropanol in which the DFP was dissolved 
resulted in precipitation of the protein. After treatment of the 
fibrinogen with 1 mM NPGB and dialysis, the amidolytic activity of fibrino-
gen was reduced by 33%, and the enhancing effect on Mel-PA was reduced 
by approximately 10% (Table 5.4). 
The presence of DFP-binding proteins could be demonstrated in two 
fibrinogen preparations. This was achieved by the addition of 2 µ1 of 
O.lM NPGB or 2 µl of DMSO to 50 µ1 of solutions conta:ning 4 mg/ml of 
fibrinogen preparations 1, 3 (c{ Fig. 5.10). The mixtures were then 
incubated for 1 hour at 37°C after which 2 µ1 3H-DFP (10 µCi; 6 Ci/mmol) 
was added and incubation was continued for 20 hours at room temperature. 
The proteins were mixed with an equal volume of 0.06M Tris-HCl pH 6.8 
containing 2% SDS, 10% 2-mercaptoethanol and 20% glycerol, boiled and 
electrophoresed in a 5-15% polyacrylamide gradient slab gel, containing 
0.1% SDS. Autoradiographs were made of the slab gel by exposure of an 
X-ray film for 5 weeks at -8o 0 c. Faint bands of DFP binding proteins 
that were not present when the fibrinogen had been pretreated with NPGB 
were visible in the autoradiographs and corresponded to approximate 
molecular weights of 69 000, 67 000 and 65 000. A prominent band of 
MW 43 000 was visible in fibrinogen 3. Since the autoradiographic bands 
were too faint for photographic reproduction, I have included a diagram 
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Table 5.3 The effect of inhibitors on the amidolytic activity of fibrinogen 
Inhibitor 
cone. 
(mM) % residual activity 
NPGB 0.16 21.63 
Benzamidine 167 18.39 
EACA 167 100.00 
BPTI 1667 KIU/ml 37.79 
SBTI 0.16 37.79 
DE-3 0.16 54.18 
iodoacetamide 16.7 90.30 
EDTA 16.7 91.63 
EGTA 16.7 91.63 
Thirty microlitres (120 µg) of fibrinogen 4 (F-4; Fig. 5.10) 
was added to 20 µl of T-T (0.1) and 10 µl of inhibitor solution. Control 
tubes were identical save for the fact that they received 10 µl of the 
relevant solvent without inhibitor. 
0 
The mixtures were incubated for 30 min at 20 C and 50 fL l was 
withdrawn for assay of amidolytic activity. Residual activity obtained 
after incubation with inhibitor is expressed as the percentage of activity 
remaining relative to the inhibitor-free control. 
Total activities were as follows: 
fibrinogen + water 
fibrinogen + 10% DMSO 





·2. 99 FU/ml 
Benzamidine and NPGB inhibited the amidolytic activity most 
effectively. 
Table 5.4 Effect of NPGB on the amidolytic and Mel-PA activating 
activities of fibrinogen. 
Sample 
1. Fibrinogen 
2. Fibrinogen (NPGB-treated) 
3. Mel-PA 
4. Mel-PA+ Fibrinogen 















Twenty microlitres of O.lM NPGB Qr DMSO alone were added to 
2 ml of fibrinogen 1 (F-1; Fig. 5.10) containing 4 mg/ml protein, and 
incubated for 30 min at 37°C. 
20 hr at 20°c against PBS. 
The solutions were then dialysed for 
Thirty microlitres of harvest fluid from Bowes II cells were 
then incubated with 30 µl of NPGB-treated fibrinogen (5); 30 µl fibrinogen 
trPated with DMSO (4); or 30 µl of PBS for 30 min at 20°c (3). 
Thirty microlitres of NPGB-treated fibrinogen (2); or 
fibrinogen treated with DMSO (1) were incubated with 30 µl PBS. After 
incubation, the amidolytic activities of the samples were determined as 
described under Methods. 
The results in the table show the amidolytic activity in each 
sample. It can be seen that NPGB reduced the amidolytic activity of 
fibrinogen by 33%. 
reduced by 10%. 
The activating effect of fibrinogen on Mel-PA was 
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to illustrate their electrophoretic mobilities relative to those of the 
marker proteins (Fig. 5.14}. 
The presence of caseinolytic proteases in the different fibrino-
gen preparations was also demonstrated by the zymographic method of 
Granelli-Piperno and Reich (62). Non-reduced samples of fibrinogen 1 
or 3 were electrophoresed in 3-15% polyacrylamide gradient slab gels 
containing 0.1% SDS. After electrophoresis, the gels were washed in 
2.5% Triton _X~lOO and overlaid on agar .slabs containing casein or casein 
and plasminogen. After incubating at 37°c for 48 hr faint bands of 
plasminogen-dependent caseinolysis could be detected in all samples; 
fibrinogen preparation 3 showed several bands. The most prominent 
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band in all samples had an approximate molecular weight of 63 000 (Fig. 5.15). 
The association of proteolytic enzymes in the fibrinogen 
preparations with enhancement of Mel-PA activity suggested that susceptible 
Mel-PA preparations contained an i nactive precursor enzyme that could be 
converted to active enzyme by limited proteolysis. This view was strongly 
supported by the experiments summarized in Fig. 5.16 to Fig. 5.18 and 
Table 5.5. 
When amidolytic activities of different preparations of Mel-PA 
were measured before and after treatment with plasmin (8 µg/ml) for 60 min 
at 20°C varying degrees of enhancement were observed (Fig. 5.16). The 
time course and extent of this enhancement of Mel-PA activity with plasmin 
was similar to that observed when the same Mel-PA preparation was treated 
with fibrinogen (Fig. 5.17). 
The presence of pro-plasminogen activator (Pro-Mel-PA) in some 
Mel-PA preparations could best be demonstrated by electrophoretic and 
enzymatic analysis of purified material obtained by DE-3 agarose affinity 
chromatography of harvest fluid from Bowes II cells (Chapter IV). The 
Figure 5.14 SDS-polyacrylamide gel electrophoresis of fibrinogen 
labelled with 3H-DFP. 
Two microlitres of O.lM NPGB in DMSO or 2 µl of DMSO only 
were added to SO µl of solutions containing 4 mg/ml of fibrinogen 1 or 
3 (F-1 or F-3 ; Fig .' 5.10). The mixtures were incubated for 1 hr 
at 37°c after which 2 µl of 3H-DFP (6 Ci / mmol; 10 µCi ) was added 
0 to each mixture and incubation was continued for 20 hr at 20 C. The 
protein solutions were then mixed with equal volumes of 0.06M Tris HCl 
pH 6 . 8 containing 2% SDS, 10% 2-mercaptoethanol and 20% glycerol. 
After boiling for 1 min the samples were electrophoresed in a 5-15% 
polyacrylamide gradient slab gel containing 0.1% SDS. Autoradiographs 
were made of the dried slab gel by exposure to an X-ray film for 
5 weeks at - 8o 0 c (Appendix 2). 
The figure shows a diagrammatic representation of the auto-
radi ograph. Wells 1 and 3 contained samples of iibrinogen 1 and 3 
that had been pretreated with NPGB. Wells 2 and 4 contained the same 
fibrinogens pretreated with DMSO only. 
Faint bands of DFP binding proteins were visible and corresponded 
to mole cular weights of 69 000, 67 000, 65 000 and 43 000 daltons. 
incubation with NPGB abolished DFP binding. 
Pre-
F-1 F-3 F-1 F-3 
A B 
Figure 5. 15 Ana~ysis of f ibrinogen preparations by electrophoresis 
and zymography. 
Solutions of fibrinogen 1 and 3 (cf. Fig 5.10) containing 
2 mg / ml were made 1% with respect to SDS and 10% with respect to 
glycerol and 15 µl sampl~s were electrophoresed in a 3-15% poly-
acrylamide gradient slab gel containing 0.1% SDS. 
After electrophoresis the slab gel was washed in 2.5% 
Triton X-100 in water for 1 hour and then in water. 
The slab was then overlaid on agar slabs containing 
1.25% agar and 20 mg/ ml casein, with (Gel B) or without (Gel A) 
5 µg/ml plasminogen. 
48 hr. 
The assemblies were incubated at 37°c for 
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Figure 5.16 The effect of plasmin on various Mel-PA preparations 
Various Mel-PA preparations were diluted to contain approximately 
4 FU/ml in T-T (0.1), and 295 µl samples of these solutions were added to 
5 µl of plasmin solution (0.5 mg/ml) or 5 µl PBS and incubated for 60 min 
at 20°C. 
Fifty microlitres were then removed and added to 10 µl of a 
solution of BPTI (1000 KIU/ml). Fifty microlitres was then withdrawn 
from this mixture and the amidolytic activity was measured. The shaded 
bars represent amidolytic activity in the absence of plasmin and the open 






d) and e) 
harvest fluid from Bowes II cells; 
harvest fluid from Bowes I cells; 
Mel-PA from Bowes II cells purified on DE-3-agarose 
Mel-PA from Bowes II cells on DE-3-agarose adsorbent 
in the presence of 0.1 KIU/ml BPTI. 
adsorbent 
Plasmin enhanced the activity of the various preparations to 
varying extents. By subtracting the amidolytic activity observed in absence 
of plasmin from that observed in presence of plasmin the amount of pro-Mel-PA 
1..n the samples could be calculated. It .can be seen that harvest fluid from 
Bowes II cells grown 1.n absence of serum contained the highest amount of pro-Mel-PA. 
Purification of Mel-PA from this harvest fluid caused a certain degree of 
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Figure 5.17 Time study of Mel-PA activation by plasmin. 
Harvest fluid from Bowes II cells was adjusted to contain 8 µg/ml 
of plasmin and incubated at 20°c. At the times shown, 50 µl samples 
were removed and added to 10 µl of a solution of BPTI (1000 KIU/ml). 
This solution (50 µl) was then assayed for amidolytic activity(~). 
The results are expressed as a percentage activity observed relative 
to a control incubated in the absence of plasmin. Plasmin enhanced 
the activity of the Mel-PA to a maximum of 6-fold in approximately 30 min. 
In the presence of fibrinogen (.tr--~; cf Fig. 5 .12) the 
same Mel-PA preparation was also enhanced 6-fold. 
results of a typical experiment are shown in Fig. 5.18. The preparation 
used in this experiment contained 80% of Mel-PA as pro-activator as 
judged by amidolytic assay before and after plasmin treatment. This 
sample contained only one protein band with a molecular weight of 
approximately 70 000 daltons after electrophoresis in SDS-polyacrylamide 
gels under non-reducing conditions. Under reducing conditions most of 
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the protein also migrated in the 70 000 dalton region. Plasmin treatment 
converted the 70 000 dalton, single chain enzyme to the S-S-linked, two 
subunit form. Under reducing conditions this migrated as two bands with 
apparent molecular weights of 35 000 daltons and 38 000 daltons. 
These experiments were still open to the interpretation that the 
one chain form of Mel-PA was not a true "pro-" enzyme in the sense that 
it possessed enzyme activity albeit with a low specific activity. To 
exclude this interpretation ~a preparation containing a mixture of active 
enzyme and putative pro~Mel-PA was incubated with 5 mM DFP to inhibit 
all detectable traces of amidolytic activity. 
residual pro enzyme was treated with plasmin. 
The DFP was removed, the 
After neutralization of 
the plasmin with BPTI, amidolytic activity was measured to give the results 
summarised in Table 5.5. These show that Mel-PA was indeed present in 
a form that was enzymatically inactive, impervious to the action of DFP, 
and activatable by plasmin to active Mel-PA. 
Neither trypsin nor thrombin converted Pro-Mel-PA to Mel-PA 
-16 -6 when added at low concentrations (1 x 10 M trypsin; 1.6 x 10 units/ml 
thrombin) and trypsin at high concentration (1 x l0-9M) caused a decrease 
of Mel-PA activity. 
These experiments also showed that Mel-PA released by Bowes II 
melanoma cells cultured in the complete absence of serum was present mainly 
a b C d e 
., 
Figure 5.18 Limited proteolytic cleavage of pro-Mel-PA to Mel-PA 
by plasmin. 
Mel-PA was purified by affinity chromatography on DE-3 agarose 
(Chapter IV) to give a solution containing 100 µg of protein/ml , and 
dialysed into T-T(O.l). 
Samples of this solution were mixed with equal volumes of PBS or 
PBS containing 5 µg/ml of plasmin. 0 After incubation for 16 hr at 20 C, 
SDS was added to a final concentration of 0.1% and the proteins were 
precipitated with 6% TCA. The precipitates from 200 µl samples of original 
enzyme solution were washed in acetone and redissolved in 20 µl of 0.06M 
Tris HCl pH 6.8 containing 1% SDS and 10% glycerol. Where necessary, these 
samples were reduced at this stage by the addition of 2 µl of 1 M DTT and 
incubation at 37°c for 30 min. 
All samples were then boiled for 1 min, and 20 µl of each was 
electrophoresed in a 5-15% polyacrylamide gel slab containing 0.1% SDS . 
After electrophoresis the gel was stained with Coomassie brilliant blue 
and destained as described in the Appendix (AZ). 
(a) molecular weight markers; 
(b) untreated Mel-PA, reduced; 
(c) plasmin-treated Mel-PA, reduced; 
(d) plasmin alone 
(e) untreated Mel-PA, nonreduced 
The tracks contain 
As can be seen from the photograph, plasmin treatment converted 
the one-chain form of Me l-PA into a two-chain form. 
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Table 5.5 Activation of DFP-treated, pro-Mel-PA with plasmin. 
Treatment Activiti (FU/ml) 
DFP Plasmin 
a) + o.oo 
b) + + 8.23 
c) 6.25 
d) + 17. 48 
Samples (500 µl) of a Mel-PA preparation containing approximately 
20 FU/ml of total activator in T-T(O.l) were incubated in the presence 
(a and b) or the absence (c and d) of 5 mM DFP for 60 min at 20°c. Free 
DFP was removed according to the method of Penefsky (228) by centrifugation 
of 100 µl samples of the reaction mixtures through 1 ml columns containing 
Sephadex G25 fine equilibrated with T-T(O.l). 
Volumes of 3 µl of 0.5 mg/ml plasmin (band d) or 3 µl of PBS 
(a and c) were added to these samples and they were incubated for 30 min 
at 20°c. Fifty microlitres of each sample was then removed from the 
solution and added to 10 µl BPTI (lOOOKIV/ml) to inhibit plasmin activity. 
The amidolytic activity in each sample was then determined using the 
fluorometric assay. 
Note that the sample had a total Mel-PA content of 17.48 FU/ml (d) 
of which 6.25 FU/ml was present in active enzyme form (c). The active 
enzyme was inhibited to undetectable levels by treatment with DFP (a). 
After treatment with DFP active enzyme could be generated by incubation 
with plasmin, showing that the precursor of Mel-PA was resistant to DFP 
treatment and lacked measurable enzyme activity. 
to assume that pro-Mel-PA is a true pro-enzyme. 
It is therefore reasonable 
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in the pro-activator form. On the other hand, Mel-PA obtained from 
Bowes I cells that required the intermittent presence of serum, was mainly 
present as the active enzyme. Treatment of Mel-PA in harvest fluid from 
Bowes II cells with low concentrations of foetal calf serum (0.01% to 2%) 
resulted in conversion of Pro-Mel-PA to Mel-PA (Table 5.6). 
It was concluded from these results that Mel-PA is secreted 
by melanoma cells mainly as the inactive precursor enzyme. This becomes 
converted to the active enzyme by proteases present in foetal calf serum 
added to the medium. Purification of Mel-PA from harvest fluid of 
Bowes II cells usually yielded a mixture of Pro-Mel-PA and Mel-PA in 
roughly equal proportions. If basic pancreatic trypsin inhibitor (BPTI) 
(0.1 KIU/ml) was included during the purification procedure using DE-3 
agarose, approximately 90% of the Mel-PA was obtained in Pro-Mel-PA form 
(Fig. 5 .16). 


















Ninety microlitres of harvest fluid from Bowes II cells were 
mixed with 10 µl of foetal calf serum diluted in RPMI and incubated 
for 3 hr at 20°c. Amidolytic activity was determined in 50 µl samples 
withdrawn from the mixtures. 
The values for activity given in the table represent activities 
obtained after subtraction of activities observed when foetal calf serum 
was incubated in medium only. 
for all dilutions tested. 




Immunochemical and electrophoretic studies reported in previous 
chapters have indicated that differences exist between urokinase and Mel-PA. 
It was therefore of importance to establish whether differences in these 
enzymes existed with respect to their enzymatic and functional properties. 
In this chapter I report the results of a series of experiments that were 
designed to analyse the catalytic properties of these enzymes on well 
defined synthetic substrates. In addition, the effects of various protease 
inhibitors and macromolecules, such as fibrinogen, on the catalytic activity 
of the two activators were examined. 
In the first part of this chapter it was established that both 
urokinase and Mel-PA bind radioactive DFP, and that the DFP binding proteins 
had an approximate molecular weight of 73 000 daltons, in the case of Mel-PA, 
and 56 000 daltons and 32 000 daltons in the case of urokinase . . Both 
activators were composed of two polypeptide chains joined by disulphide 
bridges. The subunit containing the active serine site of Mel-PA had a 
molecular weight of approximately 35 000 daltons and was larger than that 
of urokinase which had a molecular weight of approximately 32 000 daltons. 
The active site of Mel-PA was located on the smaller subunit of the two 
chain molecule. These results, that most plasminogen activators are 
composed of two polypeptide chains (68,130,134,170), correlate roughly 
with those reported in the literature. My results agree with those of 
Rijken et al (130) who found that the active site of Mel-PA was located 
on the smaller subunit of the two chain molecule. 
The major part of this chapter was concerned with the differen-
tiation of the two plasminogen activators with respect to their catalytic 
properties towards simple synthetic substrates. Well-defined synthetic 
substrates have been widely used in the past to differentiate between 
enzymatic specificity of different enzymes. , A number of synthetic 
substrates that are specifically useful for the analysis of plasminogen 
activators have already been synthesised. These include chromogenic 
substrates (158,171,172) and the more sensitive fluorogenic substrates 
(133,155,156,173,174). In both cases it has been shown that plasminogen 
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activators from various sources are able to catalyse the hydrolysis of 
tripeptide substrates with arginine or lysine (only in the case of urokinase) 
at the C-terminal end adjacent to the leaving groups (155,156,157). 
"Tissue plasminogen activator" could be clearly differentiated froni uro-
kinase by its requirement for blocked N-ter,;ninal groups in these substrates 
(155,156). 
Ln the experiments described in this chapter I have compared 
Mel-PA and urokinase for their ability to hydrolyse two fluorogenic 
substrates, namely Cbz-Gly-Gly-Arg-AMC and Boc-Val-Gly-Arg-AMC. The 
first of these substrates proved to be a better substrate for urokinase 
(Km= 0.42 mM) than for Me.1-PA (Km= 0.81 mM) whereas the second substrate 
was worse for urokinase (Km= 1.47 mM) and better for Mel-PA (Km= 0.48 mM). 
The catalytic constant of urokinase for the first substrate was approxi-
mately 70 times larger than the corresponding value for Mel-PA, whereas 
in the second ·substrate it was only 16 times larger. Urokinase, therefore, 
seemed to be the more catalytically active enzyme as far as these two 
synthetic substrates were concerned. 
Using Cbz-Gly-Gly-Arg-AMC for the measurement of amidolytic 
activity I have arbitrarily defined 1 fluorometric unit (1 FU) as that 
amount of enzyme that could hydrolyse 10 pmol of substrate in one minute 
at 25°c in O.lM Tris HCl pH 8.1 containing 5 x l0-4M substrate and 4% 
(v/v) DMSO. 
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The assay of plasminogen activators using the synthetic substrate 
Cbz-Gly-Gly-Arg-AMC proved to be a useful standard assay for enzyme 
quantitation and formed the basis for comparison of the two activators 
in more complex assays involving plasminogen-dependent fibrinolysis. 
experiments will be described in the next chapter. 
3 Active site titration of the activator with H-DFP of known 
These 
specific activity enabled me to show that one fluorometric unit of Mel-PA 
represented 1.012 pmol of active enzyme and one fluorometric unit of 
urokinase represented 0.0149 pmol of enzyme. Having these catalytic 
constants has meant that enzyme samples could be standardised by fluorometric 
assays and their concentrations expressed in terms of pmol of active sites/ml. 
Other commonly used methods for active site titration of trypsin-like 
enzymes (164, 175, 181) could not be used for the titration of Mel-PA. 
Apart from its usefulness for the direct quantitation of plas-
minogen activators, the fluorogenic substrate also proved useful for the 
analysis of the effects of inhibitors on Mel-PA and urokinase. The 
secondary inhibitory effects on plasmin that are encountered in the 
commonly used two-stage assays for plasminogen activators could thus be 
excluded. 
Urokinase and Mel-PA appeared to differ in their susceptibility 
to a variety of inhibitors. The most pronounced difference was seen in 
the case of NPGB. Differences in the susceptibility to other inhibitors 
such as DFP and benzamidine could be merely a reflection of the different 
amounts of enzyme present in the assay. In these assays usually about 
100 times more Mel-PA in terms of pmol of active enzyme than urokinase was 
presep.t. From these studies it can be concluded that Mel-PA is a serine 
protease with trypsin-like specificity and is in this respect similar to 
plasminogen activators studied so far (68,74,80,109,116,118,130,176). It 
is also similar to other activators in that it was not inhibited by any 
of the macromolecular trypsin inhibitors tested (133,142). So far, none 
of the commonly used inhibitors would be useful to clearly differentiate 
between urokinase and Mel-PA. The only useful inhibitor in this respect 
is the DE-3 inhibitor described in Chapter IV. 
It has been reported in the literature by various investigators 
that urokinase and the "tissue activator" or the "vascular activator" 
differ in their interaction with fibrin. "Tissue activators" and 
197 
"vascular activators" have been found to bind to fibrin (58,57,130,161,169) 
whereas urokinase does not (58,161,169), unless it is in a pro-activator 
form (177). In addition, plasminogen activation by tis 'sue and vascular 
activators is greatly enhanced by the presence of fibrin (53,57,159,160), 
while urokinase is not affected (53,57). In this chapter I have reported 
unexpected results showing that Mel-PA activity was enhanced in the presence 
of fibrinogen and fibrin. At first this seemed to conflict with the results 
of other investigators. Usually "tissue activator" activity i.s not enhanced 
by fibrinogen (57), and neither fibrin nor fibrinogen are believed to have 
an effect on "tissue activator" activity if this is measured in amidolytic 
assays (57). I was able to show, however, that fibrinogen did have an effect 
upon Mel-PA that correlated with the presence of a contaminating protease. 
This protease, the precise nature of which I was not able to define, caused 
the conversion of a pro-enzyme form of Mel-PA (Pro-Mel-PA) to the active 
enzyme, Mel-PA, and thus increased the effective enzyme concentration in the 
assays. This was reflected by an increase in the Vmax of Mel-PA for the 
synthetic substrate, while the Km was not significantly affected. From these 
results I was able to explain the great variations in Mel-PA activities I 
observed when different Mel-PA preparations were measured in the presence of 
different fibrinogen preparations. 
The pr7sence of Pro-Mel-PA in various proportions in different 
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preparation of the enzyme could be demonstrated by the fact that plasmin 
treatment of these samples resulted in an increase in amidolytic activity. 
Furthermore, this increase was similar to that observed if the sample was 
treated with fibrinogen. Using a purified Mel-PA preparation it could be 
shown that plasmin caused the conversion of an inactive, DFP-resistant, one 
chain form of Mel-PA to an active two chain form with an active site serine 
residue available for covalent binding to DFP. 
The existence of a one chain form of Mel-PA has also been 
demonstrated by Rijken et al (130,179) who showed that the yield of the 
one chain form could be greatly increased by inclusion of trasylol during 
cell culture and purification. Similar findings were reported by others 
working with urokinase (134,178). It can therefore be assumed that 
plasminogen activators are released in a pro-activator form from cells 
and tissues, and become converted to the active enzyme by proteases in the 
surrounding medium. The source of this protease in the case of melanoma 
cells cultured in vitro is presumably the foetal calf serum usually used 
to maintain growth of such cells. I was able to support this suggestion 
by the observations that a melanoma cell line that could be cultured in 
complete absence of serum (Bowes II cells; Chapter I) released Mel-PA 
mainly in the pro-activator form. Mel-PA present in harvest fluid from 
serum-dependent cells was mainly ·in the active two-chain form. Low 
concentration of foetal calf serum could be shown to increase Mel-PA 
activity in harvest fluid from Bowes .II cells; • 
During the course of my studies I noticed at a fairly early stage 
that urokinase and Mel-PA differed markedly in their behaviour within and 
between various different assays where plasminogen alone, or plasminogen 
and a plasmin substrate, such as fibrin, were present. Such differences 
in behaviour of various plasminogen activators in different assay systems 
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was noticed by others (53,57,180) and has been ascribed mainly to the effect 
fibrin has on the "tissue" or "vascular" type activators. Since these 
functional differences between the activators have important implications 
for their possible physiological roles in vivo and for their quantitation 
in vitro, I have undertaken a study of these two enzymes with regard 
to their plasminogen activating potential in the presence and absence 
of other macromolecules. These experiments will be described in the 
following chapter and the results will be discussed in the light of 
conclusions reached from the experiments described in the present chapter. 
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CHAPTER VI 
ACTIVATION OF PLASMINOGEN BY MEL-PA AND UROKINASE: COMPARISON OF ACTIVATION 
KINETICS AND EFFECT OF FIBRINOGEN, FIBRIN AND OTHER MOLECULES ON THE 
REACTION. 
In the previous chapter I considered and compared urokinase and 
Mel-PA for their ability to function as plasminogen-independent amidolytic 
enzymes. In this chapter, I examine their contribution to the more complex 
phenomenon of plasminogen activation. 
One might have predicted that the limited proteolytic action of-
Mel-PA and urokinase on their putative natural substrate, plasminogen, 
would have been essentially similar to their action as amidolytic enzymes 
when acting upon low-molecular-weight, synthetic substrates. While this 
prediction proved to be reasonably valid in the case of urokinase, it was 
far from accurate where Mel-PA was concerned. 
In the case of Mel-PA I found that the ability of this protease 
to activate plasminogen was limited by factors other than the conventional 
limitations of substrate availability or of enzyme concentration. Furthermore, 
the catalytic behaviour of Mel-PA was unusual inasmuch as it was strongly 
influenced by the presence of fibrin or fibrinogen. Finally, Mel-PA showed 
a pronounced tendency to bind to fibrin that was less prominent with uro-
kinase. The implications of these observations for the in vivo functions 
of these two enzymes and for their in vitro assay are considered. 
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MATERIALS AND METHODS 
The melanoma plasminogen activator was obtained and isolated from 
Bowes I melanoma cells cultured in vitro as described in Chapter I and 
Chapter IV. 
Partially purified human urokinase was obtained commercially from 
Leo Pharmaceutical Products, Ballerup, Denmark, as a white lyophilized powder 
which, in SDS-gel electrophoresis, was found to contain many impurities 
(Appendix Al. 5). The contents of one vial (5000 Ploug units) were dis-
solved in a suitable volume (usually 2.5 ml) of O.lM Tris HCl pH 8.1 
containing 8 mg/ml bovine serum albumin or 0.1% Triton X-100. The 
solution was dispensed into 50 µl volumes and stored in liquid nitrogen. 
Human fibrinogen (A.B. Kabi, Stockholm, Sweden) or bovine fibrino-
gen (Sigma Chemical Company, St. Louis, Mo., U.S.A. Fraction I, F-4000) was 
further purified by salt precipitation according to the method of Laki (182) 
and freed from plasminogen by the method of Mosesson (162). The latter 
method exploits the differential solubility of fibrinogen and plasminogen 
in the presence of lysine. The methods are described in detail in the 
Appendix Al.l. Electrophoretic analysis of the different purified pre-
parations showed that they had been degraded to varying degrees (Appendix 
Al. l). They also varied widely in the extent to which they were contaminated 
with amidolytic activity (Chapter V). 
Generally speaking, human fibrinogen preparations obtained from 
A.B. Kabi were superior to those obtained from other sources in that they 
showed a higher relative content of intact a chains and a lower amidolytic 
. . Th . d f h . f 125 f 0 b . activity. ese preparations were use or t e preparation o I- i rino-
b d . h 125 f.b . .b . . gen to e use int e I- i rin assay. Fi rinogen was labelled with 
Na
125r according to the method of Helmkamp et al as described in detail in 
the Appendix Al.2. 
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Human plasminogen was purified from outdated or fresh frozen 
human plasma by affinity chromatography on lysine-sepharose by a modification 
of the method of Deutsch and Mertz (45)(Appendix Al.3). Usually, both 
Lys- and Glu-plasminogen were obtained by this procedure and no attempt 
was made to separate these two species. Plasminogen was labelled with 
N 
125 d' h ' d' hl 'd h d f H lmk 1 (183) a I accor ing tote io ine monoc ori e met o o e amp et a 
(Appendix Al. 4) • 
Other reagents and their connnercial sources are listed in the 
Appendix (AS). 
Brief outlines of the methods used for the various enzyme assays 
are given under the relevant "Results" section. Detailed descriptions are 
given in the Appendix (A3). 
RESULTS 
In the absence of fibrin, urokinase was a more efficient activator of 
plasminogen than was Mel-PA. 
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Two methods were used for the direct measurement of the rate of 
conversion of plasminogen to plasmin. The first method was that described 
by Danp and Reich (142) in which 
125
I-plasmin6gen was incubated with 
plasminogen activators in the presence of bovine pancreatic trypsin 
inhibitor (BPTI). Plasmin heavy and light chains and unreacted plasminogen 
were then separated by electrophoresis in SDS-polyacrylamide gel slabs under 
reducing conditions. The relative amounts of each species were determined 
by counting slices of the gel. The results are expressed as the percentage 
of the plasminogen converted in a given period of time. Despite every care 
to isolate plasminogen free of plasmin, I was unable to obtain plasminogen 
that did not contain approximately 10% of the total radioactivity that 
migrated electrophoretically in the position of plasmin. This "background',,. 
or "spontaneous conversion" of plasminogen to plasmin remained . a constant 
fraction of the total, even when incubated for prolonged times. In 
presenting my results, I have subtracted this background to give values for 
enzyme catalyzed conversion as "specific conversion". 
The second assay used was that described by Mangel et al (181). 
Purified plasminogen and plasminogen activators were incubated together 
without BPTI. Timed aliquots were removed from the mixture for measurement 
of plasmin by active-site titration using the fluorescent compound di(p-
guanidinobenzoyl)-fluorescyl-6-thioureido(p-benzoic acid)(FDE). The 
results are expressed as pmol of plasmin generated in a given period of time. 
When plasminogen conversion was studied as a function of time, the 
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Figure 6.1 · 125 1 · · . b k" d M 1 PA I-p asminogen activation y uro inase an e -
measured as a function of time. 
Mel-PA (10 FU/ml; 10.12 pmol/ml) (Lr-.6.) or urokinase (6.67 FU/ml; 
0.099 pmol/ml) (o--a) were incubated at 37°c in a total volume of 300 µl 
of T-T(.02) containing 29 µg/ml 125I-plasminogen (4.6 x 107 cpm/ml) and 
100 KIU/ml of BPTI. Control wells contained no plasminogen activator. 
At the indicated times 25 µl samples were removed from the solutions and 
added to tubes containing 5 µl 10% SDS~ 5 µl glycerol and 2.5 µl 2-mercapto-
ethanol. The samples were boiled and 5 µl aliquots of the mixtures were 
electrophoresed in 11% polyacrylamide-SDS gel slabs to separate plasmin 
and plasminogen. After autoradiographic identification, plasminogen 
and plasmin were recovered from the gels by excision. These were counted 
and% conversion was calculated as described in Appendix A3.3. Each point 
represents duplicate estimates of the% conversion after the percentage of 
spontaneous conversion (8.15%) had been subtracted. 
Linearity of plasminogen conversion with time was observed until 
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Plasminogen activation by urokinase and Mel-PA measured by 
~ctive site titration of plasmin formed from plasminogen 
with time. 
Mel-PA (40 FU/ml; 40.5 pmol/ml)(6~) or urokinase (40 FU/ml; 
0.6 pmol/ml) (O--a) were incubated at room temperature in a total volume 
of 500 µl of T-T(0.02) containing .756 mg/ml of plasminogen. At the 
indicated times SO µl aliquots were removed and added to 950 µl PBS 
containing 0.79 µg/ml of FOE. After exactly 2 min incubation at room 
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temperature, 20 µl of 0.1 mg/ml NPGB was added and the fluorescence was 
measured with excitation and emission wavelengths set at 491 nm and 514 nm 
respectively. The amount of plasmin generated was calculated from the 
fluorescence readings by reference to the fluorescence of a standard 
solution of completely hydrolysed FOE of known concentration. Blank 
values (i.e. fluorescence readings observed when samples of plasminogen 
without activators were assayed) were subtracted. 
The rate of plasminogen activation by both urokinase and 
Mel-PA was linear with time for at least 20 min. 
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urokinase was more efficient as an activator of plasminogen than was Mel-PA. 
In the experiment shown in Fig. 6.1 the initial . rate of conversion of 
urokinase and Mel-PA were roughly equivalent, yet the molar concentration 
of Mel-PA was 100-fold higher. In the experiment in which plasmin gener-
ated was measured by active site titration (fig. 6.2) the rate of plasminogen 
conversion by Mel-PA was approximately one-half that by urokinase yet the 
molar concentration of Mel-PA was 67-fold higher than that of urokinase. 
It can also be seen that, in both assays, and with both urokinase and Mel-PA 
plasminogen conversion was linear with time for approximately 20 min, after 
which the time course of the reaction departed from linearity. 
When plasminogen conversion was plotted as a function of the amount 
of plasminogen activator used in the assay it was once again evident that 
Mel-PA was very much less efficient than was urokinase. For the convenience 
of graphic presentation, the plasminogen activator concentration in these 
experiments (Fig. 6.3 and Fig. 6.4) is expressed in fluorometric units/ml 
(FU/ml). This enabled me to plot curves for ~he two enzymes with the 
same abscissal scale. It should be recalled (Chapter V) that 1 FU of Mel-PA 
represents 67 times more enzyme on a molar basis than does 1 FU of urokinase. 
It is apparent from the data presented in Fig. 6.3 that the rate of conversion 
of plasminogen was reasonably linear with plasminogen activator concen-
tration until approximately 5% of the substrate had been converted after 
which the rate fell. 
The ability of Mel-PA to catalyse plasminogen conversion was enhanced by 
the presence of fibrinogen or fibrin. 
Numerous reports in the literature have indicated that fibrin 
serves as a "co-factor" for the conversion of plasminogen to plasmin by 
"tissue activator". The experiments performed to examine this phenomenon 
15 
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1251-plasminogen activation by urokinase and Mel-PA as 
a function ot · activator concentration. 
Mel-PA (4-20 FU/ml; 4.05-20.24 pmol/ml)(.6---b) or urokinase 
(4-27 FU/ml; 0.06-0.40 pmol/ml)(D---{]) were incubated together with 
7 0 plasminogen (29 µg/ml; 4.6 x 10 cpm/ml) and BPTI (100 KIU/ml) at 37 C. 
After 20 min, plasminogen conversion to plasmin in each mixture was 
determined by electrophoresis and autoradiography as described in ~he 
legend to Fig. 6.1 and the Appendix (A3.3). 
Each point represents the mean of duplicate estimates of the 
percentage conversion after subtraction of the percentage spontaneous 
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conversion (9.50%). Linearity of plasminogen conversion by both plasminogen 
activators was observed until approximately 5% of the substrate had been 
converted. 
Measured in terms of plasminogen activator conversion/mole of 
plasminogen activator, urokinase converted the plasminogen approximately 
167 times more efficiently than did Mel-PA. 
'"" ~
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Plasminogen activation as a function of Mel-PA and 
urokinase concentration. 
Mel-PA (10-133 FU/ml; 10.12 - 134.6 pmol/ml)(~) or 
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urokinase (5 - 50 FU/ml; 0.07-0.75 pmol/ml)(n--o) were incubated 
at room temperature with 0.756 mg/ml plasminogen in a total volume 
of 200 µl. After 10 min plasmin generated was determined in 50 µl 
aliquots by active site titration using FDE as described in the 
Appendix A3.4). 
In this assay urokinase was approximately 169 times more 




Figure 6.5 The effect of fibrinogen or a fibrin clot on the conversion 
f 
1251 1 . 1251 1 . b 1 A k " o -p asminogen to -p asmin y Me -P or uro inase. 
Sixteen reaction tubes were prepared so that each received the 
7 125 . 
same amount (8.7 µg; 1.4 x 10 cpm) of 1-plasminogen and 30 KlU of 
BPTl in a total final reaction volume of 300 µ1 of T-T(.02). 
Six of the tubes contained 6 FU (6.06 pmol) of Mel-PA and 
six contained 6 FU (0.09 pmol) of urokinase. Duplicate tubes from 
each activator serie~ contained either buffer alone, 20µg of fibrinogen, 
or a washed fibrin clot formed by the addition of 0.02 units of thrombin 
to 20 µg of fibrinogen. 
Duplicate control tubes for the measurement of spontaneous 
plasminogen conversion contained buffer or fibrinogen but no plasminogen 
activator . 
The tubes were incubated at 37°c for 20 min after which 50 µ1 
aliquots were analysed for plasminogen conversion to plasmin by electro-
phoresis, autoradiographic identification and radioassay as described 
in the Appendix (A3.3). 
Each bar represents the average of duplicate estimates of the 
percentage plasminogen converted after the percentage of spontaneous 
conversion (7.12% and 7.18%) had been subtracted. 
Mel-PA activity was enhanced by the presence of fibrinogen and 
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Figure 6.6 
Figure 6.6 125 1 · . b M 1 PA d k. . I-p asminogen conversion y e - an uro 1nase 1n 
presence and absence. of insolubilized fibrinogen . 
Each well of a Linbro multiwell tissue culture plate received 
200 µl of 5 mM NaCl or of 5 mM NaCl containing 30 µg of fibrinogen. 
The well contents were dried on to the plastic surface by 
incubating the plate at 45°c for 48 hr. 
The wells . were then washed with PBS and to each was added 
300 µl of T-T(O.l) buffer containing 30 KIU of BPTI; 8.7 µg 125r-
plasminogen (1.4 x 107 cpm) and either 3 FU (3.04 pmol) Mel-PA or 2 FU 
(0.03 pmol) of urokinase. 
The plates were incubated at 37°c and samples of the well 
contents were taken at the time points indicated for assay of plasminogen 
to plasmin conversion by electrophoresis, autoradiography and radioassay 
of the excised bands (Appendix A3. 3) • Each point repre_sents the mean 
of duplicate analyses after subtraction of plasminogen that converted 
spontaneously (8.15%). 
Key to symbols as follows:-
Mel-PA + fibrinogen 'v---V 
Mel-PA without fibrinogen b:--/:l. 
Urokinase + fibrinogen¢---<> 
Urokinase without fibrinogen Cr--0 
Mel-PA and urokinase showed roughly comparable ·activities "in 
the absence of fibrinogen in this experiment. It should, however, 
be noted that each well contained approximately lOOx more Mel-PA than 
urokinase on a molar basis. 
The activity of Mel-PA was enhanced by fibrinogen to a far 




Mel-PA :r,--------v Q) 01 
0 " 40 C ~ .,.. "" 
E 
co C 30 0 0 
r-t .,.. 
a_ co 
L 20 0 Q) 
·r-t > 
4- C 
· r-t 0 
0 u 10 
Q) 
Cl.. 
~ U) 0 






0 " 40 C ~ 
·r-t "" 
E 
co C 30 0 0 
r-t .,.. 
a_ co 









0 20 40 60 80 100 
Time (min) 
213 
for its relevance to plasminogen conversion by Mel-PA are presented in 
Fig. 6.5 to Fig. 6.9. The results may be sunnnarised as follows: 
(i) Soluble fibrinogen and a suspended fibrin clot enhanced Mel-PA 
activity but had no effect on the activity of urokinase. 
When 
125
1-plasminogen conversion by Mel-PA or urokinase were 
examined in the presence of soluble fibrinogen or a suspended fibrin clot, 
it was observed that Mel-PA activity was enhanced approximately three-fold 
by fibrinogen and 1.7 fold by fibrin whereas urokinase activity was 
unaffected (Fig. 6.5). The "spontaneous conversion" of plasminogen to 
plasmin (approximately 7%) was unaffected by fibrinogen alone. 
(ii) Fibrinogen and fibrin adsorbed to plastic surfaces enhanced the 
activity of Mel-PA to a far greater extent than it enhanced the 
activity of urokinase. 
Thirty micrograms of purified fibrinogen in solution were added 
to each well of several Linbro tissue culture plates. The plates were then 
incubated at 45°C for 48 hr to dry the solutions and to secure adsorption 
of the fibrinogen onto the surfaces of the wells. Each well was then 
d . h mb f . h f 1251 1 · use as a reaction ca er or measuring t e conversion o -p asminogen 
to plasmin by Mel-PA or urokinase. Control wells contained either no 
adsorbed fibrinogen or no plasminogen activator. The results of these 
experiments are shown in Fig. 6.6 where plasminogen conversion by Mel-PA 
or urokinase were measured as functions of time. 
Mel-PA was more susceptible to the enhancing effect of the 
adsorbed fibrinogen than was urokinase. After 90 min in the absence of 
fibrinogen both Mel-PA . and urokinase catalyzed the specific conversion of 
approximately 8% of the plasminogen to plasm.in. In the case of urokinase 
the presence of fibrinogen increased this conversion by approximately 2-fold. 
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With Mel-PA plasminogen conversion was increased by approximately 6-fold. 
To investigate the effect of fibrin rather than fibrinogen, a 
similar experiment was performed with wells to which 1 ml of 0.1 NIH units/ 
ml of thrombin in PBS had been added. The results of this experiment are 
shown in Fig. 6.7 and are essentially similar to those obtained with 
fibrinogen. The activity of Mel-PA was enhanced whereas that of urokinase 
was not. As indicated in the Appendix (A3.l) I was unable to -satisfy 
myself that thrombin treatment of surface-adsorbed fibrinogen effectively 
converted it to fibrin. I am therefore uncertain whether the effects I 
observed on enhancement of Mel-PA activity were attributable to fibrin or 
fibrinogen in this experiment. 
In order to establish whether or not other proteins have a similar 
stimulatory effect on plasminogen activation an experiment was performed 
in which casein and gelatin were attached to the plastic surfaces of Linbro 
wells and compared with fibrinogen and fibrin in the 125I-plasminogen con-
version assay. The results are presented in Fig. 6.7 from which it can be 
seen that the activity of Mel-PA was enhanced by fibrinogen, casein and 
fibrin but not by gelatin, Casein caused a two-fold increase of activity 
of urokinase while other proteins had lesser stimulatory effects on the 
action of this enzyme. In the case of Mel-PA, fibrinogen was most active, 
casein and fibrin stimulated plasminogen activation to a lesser extent and 
gelatin was without effect. 
Fig. 6.8 depicts the results of an experiment in which plasminogen 
conversion was studied as a function of Mel-PA or urokinase concentration in 
the presence of absence of fibrinogen. It is evident from the data obtained 
that fibrinogen enhanced the activity of Mel-PA at all concentrations of this 
enzyme to an extent that was greater than was observed with urokinase. 
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Figure 6.7 
Figure 6.7 Effect of fibrinogen, casein, gelatin and fibrin on 
plasminogen activation by urokinase and Mel-PA. 
Each well of a Linbro multiwell tissue culture plate received 
200 µ1 of 5 mM NaCl or 200 µ1 of 5 mM NaCl containing 30 µg of the protein 
indicated. The plates were then incubated at 45°c for 48 hr to dry 
the well contents and to secure protein attachment to the bottom surfaces 
of the wells. The wells were then washed in PBS and to each was added 
300 µ1 of T-T(O.l) buffer containing 8.7 µg of 
125
1-plasminogen (1.4 x 107cpm), 
30 KIU of BPTI and either 2 FU (0.03 pmol) of urokinase or 3 FU (3.03 pmoles) 
of Mel-PA. This Mel-PA sample contained negligible amounts of pro-Mel-PA. 
Control wells did not receive plasminogen activator. 
The plates were incubated at 37°c for 20 min, after which 
plasminogen conversion to plasmin in each well was determined by electro-
phoresis, autoradiography and radioassay as described in Appendix A3 . 3. 
Each bar represents the average of duplicate· estimates of the 
ratio of plasminogen conversion in the presence of protein to that observed 
in the absence of protein. Spontaneous conversion of plasminogen to 
plasmin in the absence of plasminogen activator was approximately 12%. 
This value was subtracted from the experimental values before calculating 
the results. 
Maxim~m specific conversion by urokinase in the presence of 
casein was 10%; conversion by Mel-PA in the presence of fibrinogen or 
casein was 19.57. or 13.17. respectively. 
Note that Mel-PA activity was strikingly enhanced by fibrinogen, 
casein and fibrin. 
casein. 
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Figure 6.8 
Figure 6.8 The effects of insolubilized fibrinogen and of plasminogen 
. . h . f 1251 1 . activator concentration on t e conversion o -p asnunogen 
to plasmin by Mel-PA and urokinase. 
Wells of Linbro multiwell tissue culture plates were prepared 
with or without adsorbed fibrinogen (30 µg/well) and used to study 
1251-plasminogen conversion in 20 min by Mel-PA or urokinase at the 
concentrations shown. 
125 1 . . d 1 h . I-p asnunogen conversion was measure bye ectrop oresis, 
autoradiographic identification and radioassay as described in Appendix A3.3. 
Mel-PA activity was greatly enhanced by fibrinogen (~ vs 
l::r--6.) whereas urokinase activity was not (o---0 vs D--0). 




C Mel-PA (D 
O') 30 
0 " C ~ ..... """ 25 E 
co C 




0 (D ..... > 
4. C 10 ..... 0 
0 u 
(D 5 a.. 
U) 
0 
0 4 8 12 16 20 
Mel-PA Concentration CFU/ml) 
35 
C Urokinaae (D 
O') 30 
0 " C ~ ..... """ 25 E 
co C 




0 (D ..... > 
4. C 10 ..... 0 
0 u 
(D 5 a_ 
U) 
0 
0 20 40 60 80 100 
UK Concentration CFU/ml) 
(iii) The enhancement of MeZ-PA activity inc:reased with fibrinogen 
concentration. 
When plasminogen conversion by Mel-PA (2.02 pmol) or urokinase 
(0.04 pmol) was measured in wells coated with increasing amounts of 
fibrinogen the results illustrated in Fig. 6.9 were obtained. In the 
case of urokinase a slight increase of activity was observed when small 
amounts of fibrinogen were present in the wells. The enhancement was 
unaffected by increasing amounts of fibrinogen. Mel-PA activity on the 
other hand showed a marked and progressive increase with fibrinogen 
addition until approximately 0.2 mg (0.606 nmoles)/well was reached. 
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Since each well only contained 2.02 pmol of plasminogen activator it is 
clear that the enhancement of plasminogen activation by fibrinogen was not 
stoichiometric with activator. 
Fig. 6.9 also depicts data showing that Mel-PA bound to fibrinogen 
whereas urokinase did not. These data are considered in the next section. 
Mel-PA binds to fibrin 
A number of studies have shown that "tissue activator", "vascular 
activator" or Mel-PA can be adsorbed to fibrin,either during clot formation 
(58,130,169), or when the fibrin is bound to celite or to sepharose (90,57). 
To examine this phenomenon in more detail, I performed the following 
experiments. 
In the first experiment Mel-PA or urokinase were incubated in 
Linbro wells that had been coated with fibrinogen . . Nonadsorbed activators 
were then removed by washing in O.lM Tris HCl pH 8.1 containing 0.02% Triton 
X-100. Radioactive plasminogen was added and, after 20 minutes of incubation, 
the contents of the wells were analysed by electrophoresis and autoradiography 




1251 1 ' ' b 1 A d k. -p asminogen conversion y Me -P an uro inase 
as a functi.on of fibrinogen concentration and binding 
of the activators to the insolubilized substrate. 
Individual wells of a Linbro plate were coated with the amounts 
of fibrinogen shown. These wells were then used to measure the conversion 
of 
125
1-plasminogen to plasmin by 2 FU (2.02 pmol) of Mel-PA or by 3 FU 
(0.045 pmols) of urokinase in 20 min . at 37°c (solid lines). 
Mel-PA activity (~) increased with increasing amounts of 
fibrinogen until a plateau was reached at 200 µg/well of fibrinogen. 
Urokinase activity (D--[]) was unaffected. 
To examine the binding of plasminogen activators to insolubilized 
fibrinogen, Mel-PA (2 FU; 2.02 pmol) or urokinase (3 FU; 0.045 pmol) 
were incubated in the wells for 30 min at room temperature. Unbound 
plasminogen activators were then removed by washing the wells 3x with 
T-T(0.1). 1251-plasminogen and BPTI were then added and conversi"on 
by bound activators was measured (interrupted lines). 
the graph represents the mean of dupl'icate estimates. 
Each point on 
Mel-PA (Lr---A) was strongly adsorbed to the insoluble 
fibrinogen, whereas urokinase was not (O---cl). 
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amount of urokinase capable of activating plasminogen was adsorbed to the 
wells. This was unrelated to the amount of fibrinogen in the wells and 
was presumably non-specific. 
In the case of Mel-PA, increasing amounts of the activator were 
adsorbed with increasing amounts of fibrinogen. The adsorption phenomenon 
reached a plateau at an approximate fibrinogen concentration of 0.2 mg 
(0.606 nmoles) per well. The same amount of fibrinogen gave maximum 
enhancement of Mel-PA activity (cf the previous section). 
A similar experiment was carried out in which radioactive fibrino-
gen rather than radioactive plasminogen was used. Plasminogen activation 
was then determined by measuring plasminogen-dependent solubilization of 
the 125I~fibrinogen substrate coated on to Linbro wells under conditions 
where the amount of activator present would have been rate-limiting. 
U k . M 1 PA dd d 125 I f 0 b . d . b 11 ro inase or e - were a e to - i rinogen-coate Lin ro we sand 
incubated at room temperature for 30 mins. Free activators were then 
removed by washing three times with Tris buffer containing either 0.3 mg/ml 
BSA or 0.02% Triton X-100. Plasminogen was then added and' solubilization 
of the radioactive substrate was measured after incubating for 60 min at 
37°C. Conditions were chosen so that, at this time, linear kinetics for 
release of radioactive fibrin degradation product were still obtained. 
The results (Fig. 6.10) demonstrated that up to 50% of the available Mel-PA 
was adsorbed to the matrix whereas only 20% of the available urokinase was 
bound. 
It was once again apparent that only a small fraction of the 
adsorbed fibrinogen was involved in the binding of Mel-PA since in this 
experiment fibrinogen and Mel-PA were present in a molar ratio ~f approxi-
mately 2000 to 1, yet only approximately one half of the available Mel-PA 
activity was bound. 
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Figure 6.10 
Figure 6.10 The binding of Mel-PA and urokinase to insolubilized fibrinogen 
d . h 125I f.b ' as measure int e - i rin assay. 
L. b 11 d . h 125I f.b ' (3 in ro we s were coate wit - i rinogen O µg; 5 1 x 10 cpm/ 
well), treated with 10% plasminogen-free FCS in RPMI, and washed with PBS 
as described· in the Appendix (A3.l). 
To some of the wells Mel-PA was added; other wells received 
urokinase and others buffer alone. All additions were in 300 µl of O.lM 
Tris-HCl pH 8.1 containing 270 µg/ml of BSA. 
The plates were incubated for 30 min at room temperature after 
which the wells were washed with O.lM Tris HCl pH 8.1 containing 0.3 mg/ml 
BSA (T-BSA) or with O.lM Tris HCl pH 8.1 containing 0.02% Triton X-100 
(T-T (0.02)). 
Wells previously exposed to urokinase or Mel-PA received, in a 
final volume of 300 µl, 2 µg of plasminogen and 80 µg of BSA in O.lM Tris 
·HCl pH 8.1. 
Wells previously exposed to buffer alone received, in addition 
to BSA and plasminogen, either Mel-PA. or urokinase in amounts equal to 
those added initially to the washed wells with which they were to be . 
compared. 
Total 125I-fibrin solubilized was measured as a percentage of 
the total adsorbed radioactivity after 60 min at 37°c. 
Open bars represent the means of triplicate measurements of total 
activity of plasminogen activator. Shaded bars represent corresponding 
values for the activators that had remained bound to the matrix after 
washing. It can be seen that up to 50% of the total Mel-PA added remained 
bound to the matrix, while only 20% of the urokinase added was bound. 
Plasminogen activator activity was greater when Triton X-100 was 
present in the fluid used to wash the fibrin layers. The reason for this 
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Mel-PA employed for this experiment was mainly ' in the active 
enzyme form. In another experiment (Table 6.1) I found that a larger 
percentage of total enzyme was bound when the Mel-PA preparation was in the 
proactivator form indicating that binding of plasminogen activators to 
fibrin was probably not only a function of the fibrinogen preparation used 
but it may also be related to the form of the enzyme. 
Mel-PA is not degraded by plasmin 
It has been suggested in the literature (142,181) that deviations 
from linearity in the kinetics of plasminogen-dependent fibrinolysis may be 
ascribed to degradation of plasminogen activator by plasmin generated during 
the course of the reaction. In order to test this suggestion, I performed 
an experiment in which urokinase (approximately 0.2 pmol) or Mel-PA 
(approximately 24 pmol) were incubated in the absence or presence of 0.25 mg/ml 
of plasmin at room temperature for up to 5! hours. At different times 
during the course of incubation 50 µl samples were removed and the plasmin 
that they contained was immediately neutralized by the addition of 10 µl 
of BPTI (10 KIU). Fifty microlitres of this mixture was then measured for 
Mel-PA or urokinase activity in the fluorometric assay. As can be seen 
from Table 6.2, the activity of urokinase and Mel-PA remained constant · in 
the presence of plasmin and showed no decrease relative to the activity in 
untreated samples. From this it could be concluded that plasmin did not 
degrade either Mel-PA or urokinase. 
The kinetics of plasminogen-dependent fibrinolysis by Mel-PA and urokinase 
One of the assays frequently used for the quantitation of plasminogen 
activators is that which measures the plasminogen-dependent degradation of 
insoluble 
125
I-labelled fibrin. As commonly employed by ourselves (106) 
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Table 6.1 The binding of Mel-PA to insolubilized fibrin. 
% Pro-Mel-PA(b) Fibrinolytic activity Mel-PA Sample (a) 
(% 1251-fibrin solubilized 

















Activity % bound 
after wash 
29.48 98.8 




Five Mel-PA samples were obtained as described below and their 
contents of active Mel-PA and Pro-Mel-PA was determined from the results of 
fluorometric assays before and after plasmin treatment as described in 
Chapter V. These samples were then diluted in T-T(O.l) so that 0.2 ml 
would, in the presence of 2 µg of plasminogen, release approximately 
30 to 50% of the 1251-fibrin coated on the bottom of Linbro wells in 1 hr. 
Aliquots (0.2 ml) of the samples were then added in quadruplicate 
to Linbro wells coated with 1251-fibrin (30 µg; 100 000 cpm). After 
0 incubation for 1 hr at O C two wells of each quadruplicate set were washed 
three times with T-T(O.l) to remove unbound Mel-PA. Bound activity was 
measured as the amount of 1251-fibrin solubilized in 1 hr after the addition 
of 0.3 ml of Tris HCl pH 8.1 containing 2 µg of plasminogen and 80 µg of BSA. 
Total Mel-PA activity added to the wells was measured as the amount of 
125
1-fibrin solubilized in 1 hr after the addition of 2 µg of plasminogen 
and 80 g of BSA (0.3 ml of the same buffer) to wells that had not been 
washed. 
227 
Table 6. 2 The effect of plasmin on Mel-PA and urokinase 
Time of Amidolytic activity (FU/ml) 
incubation (min) 
Mel-PA Mel-PA Urokinase Urokinase 
+ Plasmin + PBS + Plasmin + PBS 
2 42.24 33.37 22.81 21.21 
30 42.03 34.86 22.79 23.21 
120 44.08 36.60 22.14 20.27 
300 42.33 36.11 21. 88 20.02 
330 44.20 37.95 21. 72 20. 62 
Urokinase (approximately 0.20 pmol; 13.5 FU) or Mel-PA 
(approximately 24.3 pmol; 24 FU) were incubated with or without 0.125 mg 
plasmin in a final volume of 0.5 ml PBS at room temperature. 
At the times give, 50,u- l aliquots were removed and added· 
to tubes containing 10 µ1 (10 KIU) of BPTI. The amidolytic activity 
1.n 50 µ1 of this mixture was then determined in the fluorometric assay 
(Appendix 3.2) to give the values shown in the table. Plasmin controls, 
containing no plasminogen activator, showed no activity. 
The activity of both Mel-PA and urokinase stayed constant over 
the 5.5 hr incubation period indicating that they were not degraded by 
plasmin. 
and by others (118,120) this assay uses plasminogen concentrations that 
are rate-limiting. Since quantitative differences in plasminogen-
dependence between Mel-PA and urokinase have important implications for 
the quantitation of these enzymes, I performed the experiment sunnnarized 
in Fig. 6.11. 
In this experiment, two concentrations of Mel-PA (0.47 and 0.24 
pmol/ml) and of urokinase (0.4 and 0.2 pmol/ml) were tested for their 
ability to catalyse the degradation of solid-phase 125I-fibrin in the 
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presence of plasminogen concentration ranging from Oto 106 µg/ml. It can 
be seen from the data shown that the rate of fibrinolysis (measured as the 
percentage of total 125I-fibrin hydrolyzed/60 min) increased monotonically 
with plasminogen concentration. 
Data for values less than 80% of total fibrinolysis (i.e. when 
. 1 b. 1 · f 125I f 'b . 1 · . . ) 1 d b h avai a i ity o - i rin was not rate- imiting were ana yse y t e 
method of Cornish-Bowden and Eisenthal (167).These analyses gave apparent 
Km's for plasminogen for the two concentrations of Mel-PA of 16.2 µg/ml 
(0.18 µM) and 17.9 µg/ml (0.2 µM). The corresponding values for urokinase 
were 33.2 µg/ml (0.37 µM) and 37.3 µg/ml (0.42 µM). 
The data illustrate that the apparent Km for plasminogen for Mel-PA 
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Effect of plasminogen concentration on fibrinolytic 
activity of Mel-PA and urokinase measured in the 
1251 f.b . - i rin assay. 
The fibrinolytic activities of Mel-PA (approximately 0.47 pmol/ 
ml)(Lr----b) and of urokinase (approximately 0.4 pmol/ml) (D--0) were 
d · h 1251 f 0 b . . h 1 . . measure int e - i rin assay using t e p asminogen concentrations 
h (0 1 2 M) 125 f 0 b . 1 b · 1 · . d f 60 . sown - . µ . 1- i rin sou i ization was measure a ter min 
· · 37° d. · f 125 f.b · incubation at C. The con itions o the 1- i rin assay are 
described in detail in the Appendix (A3.1). 
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The rate of fibrinolysis increased with plasminogen concentration . 
for both Mel-PA and urokinase. These data could be transformed into 
Lineweaver-Burk plots using Km and Vmax parameters calculated according 
to Cornish-Bowden and Eisenthal (167). 
Fig. 6.12. 
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Lineweaver-Burk plots of the rate of fibrinolysis of 
Mel-PA and urokinase as a function of plasminogen 
concentration. 
The data of Fig. 6.11 were used to construct Lineweaver-Burk 
plots of the reciprocals of the fibrinolytic activities of Mel-PA(~) 
or urokinase (D---tJ) as functions of the reciprocals of the plasminogen 
concentrations. Analysis of the data by the method of Cornish-Bowden 
and Eisenthal (167) yielded Km values of 0.2 µM for Mel-PA and 0.38 µM 
for urokinase, and Vmax values of 78.4%T/60 min for Mel-PA and 
95.9%T/60 min for urokinase. 
lines to the observed points. 
These parameters were used to fit straight 
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DISCUSSION 
The sites in plasminogen at which local proteolytic cleavage 
takes place to give rise to plasmin are well defined (17,19,36) and in 
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this molecular sense the basis for the conversion of plasminogen to plasmin 
by urokinase or Mel-PA is well understood. When, however, one studies 
the kinetics of this conversion, th~ complexities become apparent, since 
little plasmin is generated if pure solutions of plasminogen activator and 
plasminogen are mixed. This is particularly true for Mel-PA. 
The rate of plasminogen activation is profoundly influenced by 
the presence of certain amino acids (e.g. lysine, 6-aminohexanoic acid, 
trans-(ariri.no-methyl) cyclohexane-carboxylic acid)(29,32,34,184), by the 
presence of fibrin (53,57,160) or certain denatured proteins (159), or by 
whether or not the plasminogen has lost N-terminal residues (34). 
Any comprehensive accou?t of plasminogen activation should, 
therefore, accommodate the following considerations. 
1) The rate of conversion of plasminogen to plasmin by plasminogen 
activators is accelerated by the presence of fibrin. 
There is general consensus about this fact. It has been 
documented on many occasions with various assays for the quantitation of 
plasminogen activation (53,57,159,160) and I have had no difficulty con-
firming it myself. This observation gives rise to a number of subsidiary 
questions which may be stated as follows: 
a) Is the effect that is docwnented for fibrin also observed 
with fibrinogen? 
A number of workers have addressed this question and their results 
are generally in agreement and allow the conclusion that fibrin but not 
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fibrinogen catalyses the activation of plasminogen (57,159,160). 
My own observations in this regard are two-fold. :Firstly, 
when studying the conversion of pro-Mel-PA to Mel-PA (Chapter V) I was able 
to obtain unequivocal evidence to show that both fibrinogen and fibrin 
may be contaminated by a protease which is able to perform this function. 
If, therefore, a plasminogen dependent fibrinolytic system contained large 
amounts of pro-Mel-PA, enhancement of overall fibrinolysis by fibrinogen 
could be ascribed in part by conversion of pro-Mel-PA to the active enzyme. 
Since, however, pro-Mel-PA is rapidly converted to Mel-PA by plasmin it 
is unlikely that much enhancement could be attributed to this mechanism. 
Secondly, I have been able to document an accelerating effect of 
fibrinogen on the conversion of plasminogen to plasmin by Mel-PA but not by 
urokinase (Fig. 6.5). In fact, in the experiment referred to where 
plasminogen activation was measured directly the effect of fibrinogen was 
more marked than that of fibrin. I am at a loss to explain an effect of 
fibrinogen in this context when others (57,159,160) have not been able to 
document such an effect. It may be that the fibrinogen preparation that 
I used, although apparently free of denatured or polymerized material, did 
contain traces of fibrin, aggregates or other impurities that were responsible 
for this effect. 
b) Is the effect of fibrin on the enzymatic activation of 
plasminogen equally evident with urokinase and with Mel-PA? 
The evidence that is · available in the literature (53,57,160) and 
the experiments that I have presented in this chapter (Fig. 6.5 to 6.9) 
would indicate that the catalytic action of Mel-PA is very much more 
susceptible to enhancement by fibrin than is the action of urokinase. It 
should be noted however, that plasminogen may exist in the Lys- or the Glu-
forms. A failure to show an effect of fibrin on the activity of urokinase 
may have been due, in the particular experiments that addressed this problem, 
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to the fact that all of the plasminogen was in the wrong form for this 
effect to be demonstrable. This leads to the following question. 
c) Is the enhancement of pZasminogen activation by fibrin in 
any way influenced by prior removal of the ''preactivation 
peptide" from the N-terminaZ end of pZasminogen? 
The literature does not give a satisfactory answer to this 
question. The appropriate experiment would require a· factorial design 
and would examine for evidence of interactions between forms of plasminogen, 
type of plasniinogen activators and the presence or absence of fibrin. It 
would seem that such experiments have not been done. 
It is well known that urokinase activates Lys-plasminogen more 
efficiently than it does Glu-plasminogen (32,33,34,184), and it would seem 
that fibrin has no effe.ct upon the action of urokinase. No one appears 
to have looked specifically for an interaction between the effects of fibrin 
and the effects of plasminogen modification. The same criticism may be 
levied at experiments that have examined the effects of fibrin on the 
action of Mel-PA. In this case, however, it is not enhancement by fibrin 
that is in question, since that has been very adequately demonstrated. 
Here one would ask whether or not synergism between the effects of fibrin 
and of plasminogen modification could be demonstrated. 
2) Plasminogen binds to fibrin 
In seeking an explanation for the enhancing effect of fibrin on 
plasminogen activation a number of workers have found direct evidence for 
a physical interaction between plasminogen and fibrin that could be detected 
by binding assays. Typical experimental approaches have been those of 
Rak.oczi et al (185) and Cederholm-Williams (186,187) who measured incor-
poration of radioactive plasminogen into fibrin clots or Thorsen (39) who 
measured the partition of plasminogen between clot and supernatant solution 
when a clot was formed in the presence of plasminogen. The experiments 
that relate to this phenomenon and that have been performed by others are 
generally convincing and the situation may be summarized as follows: 
(a) Plasminogen that has been modified by limited proteolysis 
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and so converted from glutamic acid-terminal to lysine- or methionine-
or valine-terminals binds more efficiently to fibrin than does native 
plasminogen (39). The dissociation constant for the reversible 
binding of Lys-plasminogen to fibrin has been estimated to be 
approximately 6.3 nM (186). Values for the Kd of other forms 
of plasminogen do not appear to have been published yet. 
(b) The binding of plasminogen to fibrin is mediated by lysine 
binding sites (40,42,188) that can be uncovered by the action of 
6-aminohexanoic acid prior to removal of the preactivation peptide 
from Glu-plasminogen (189). Plasminogen contains one binding 
site with high affinity (Kd 9-16 µM) for 6-aminohexanoic acid 
(41,42) and four with low affinity (Kd ~ 5 mM) (41). One of 
the binding sites is located on the first kringle structure 
(Kd = 16 µM) and another one on the fourth kringle structure 
(Kd = 35 µM)(42). 
(c) The ease with which fibrin-bound plasminogen can be released by 
lysine or EACA (40) or the readiness with which these compounds 
inhibit binding of plasminogen to fibrin (39,187) testifies to the 
reversibility of the binding and to the role of the lysine binding 
site in its mediation. 
(d) Although it is said that both fibrinogen and fibrin bind 
plasminogen, most of the studies of this phenomenon have been 
performed with fibrin in experiments in which plasminogen incorporation 
3) 
into the fibrin meshwork during the clotting process has been 
measured (39,185,186). The data for the binding to fibrin are 
therefore sound. This is less so in the case of fibrinogen. 
It is, however, connnon laboratory experience that the best 
"plasminogen-free" preparations of fibrinogen are obtained by a 
method in which the protein is precipitated in presence of high 
concentrations of lysine (162) or by treatment of the fibrinogen 
preparation with lysine-sepharose (190). 
Wiman and Wallen (40) have reported experiments showing 
that plasminogen was bound by fibrinogen coupled covalently to 
sepharose. It is of interest to note in this regard that Ball 
et al (191) using density gradient centrifugation were unable to 
show association between plasminogen and fibrinogen. Influenced, 
presumably, by the general belief that such binding should have 
been demonstrable, they attributed their failure to demonstrate 
it .to the fac~ that the fibrinogen was contaminated with non-
radioactive plasminogen to the extent that no further free 
plasminogen binding sites were available. 
Plasminogen activators bind to fibrin 
The results that I obtained (Fig. 6.9 and 6.10) showed quite 
clearly that Mel-PA bound to the fibrinogen or fibrin that was adsorbed 
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to the bottom of a tissue culture well, and that it could not be displaced 
by subsequent washing. Urokinase, on the other hand, bound very little if 
at a11. A number of other reports are available in the literature that 
confirm the fact that plasminogen activators bind to fibrin. 
Husain et al (90) were able to isolate plasminogen activator 
from normal plasm~ with a celite-fibrin affinity column using arginine 
to elute bound enzyme. It is of interest to note that the fibrin-celite 
column showed selectivity in that it adsorbed only certain of the plas-
minogen activators present in plasma and allowed others to run through. 
The authors did not identify which of the enzymes did not bind. It 
should be noted in this regard that plasma contains a complex mixture of 
plasminogen activators that include Mel-PA or "vascular activator" (64,66) 
a latent urokinase (63) and such compounds as kallikrein and Factor XII 
(192,193). 
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Several groups (58,130,169) have shown that plasminogen activators 
were incorporated into fibrin clots if the enzymes were added before the 
clotting process was initiated with thrombin. Adsorbed activator could 
subsequently be eluted from the clot demonstrating the reversibility of the 
process. Urokinase-type activators were not taken up into the clot whereas 
"tissue plasminogen activator", "vascular plasminogen activator" and "Mel-PA" 
were (58,130,169). In a recent report Allen and Pepper (169) have shown 
that vas.cular activator is incorporated into a fibrin clot more efficiently 
than Mel-PA suggesting a means for distinguishing these two plasminogen 
activators it', indeed, they are different. In a recent abstract Husain 
et al (1977) claim to have used fibrin-celite to purify the urokinase pro-
activator from urine but the final publication of these results is not as 
yet available _ to me. 
Relatively few attempts have been made to identify the molecular 
basis of the plasmin~gen activator-fibrin interaction. Allen and Pepper 
(169) have subjected plasmin-derived soluble fibrin polymers and plasminogen 
activators to co-chromatography on molecular exclusion gels and have shown 
co-acervate formation, suggesting that plasminogen activator binding sites 
in fibrin survive plasmin treatment. Unfortunately, however, the 
appropriate controls were not done to establish the specificity of these 
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interactions. It is by no means uncommon during biochemical studies of 
fibrinolysis to find diverse intermolecular interactions that are clearly 
trivial in nature and have little relevance to the coordinated function 
of this system. 
To the best of my knowledge no systematic studies have been done 
to quantitate the interaction between plasminogen activator and fibrin, so 
that dissociation constants and molar stoichiometric ratios are not available. 
The data I have presented in Fig. 6.9 would indicate that the ability 
of adsorbed fibrinogen or fibrin to bind added plasminogen activator 
was saturated at a very low Mel-PA: fibrin ratio (approx. 1 : 300). This 
would suggest that it is neither fibrin nor fibrinogen that is binding but 
rather some contaminating component. 
support or refute this supposition. 
Unfortunately I have no data to 
No reports are available to indicate whether binding of plasminogen 
activators to fibrinogen is in any way different from binding to fibrin. 
When I analysed tae binding layer at the bottom of a Linbro well I found 
that much of the radioactivity had an electrophoretic mobility in SDS-gels 
that corresponded to unaltered fibrinogen (Appendix A3.1). I cannot, 
however, use that evidence to deduce the nature of the activator-binding 
molecule since the electrophoretic technique may well have failed to detect 
fibrin. Moreover, fibrinogen may have been denatured in the process of 
preparing the coated Linbro wells. 
An abstract has appeared to indicate that soluble fibrinogen does 
not bind "tissue activator" whereas fibrinogen covalently coupled to solid 
surface does (194). This work promises to make an informative contri-
bution when the final data are available in published form. 
4) The enzymatic activation of plasminogen is an inherently 
limited phenomenon. 
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A number of studies of plasminogen activation have shown that the 
rate of conversion of plasminogen to plasm.in follows an unusual kinetic 
course in which there is an initial rapid rate which progressively slows 
until a plateau is reached where no further plasminogen conversion is 
observed despite the abundant presence of residual plasminogen in non-rate 
limiting concentrations (159,181). Although reports on this intriguing 
phenomenon are somewhat conflicting it is worth presenting the following 
summary of those observations that appear to be valid. 
(i) Radcliffe and Heinze (159) noted that the "plateau phenomenon" 
occurred after no more than a few percent of the available plasminogen 
had been converted. They were able to re-ini.tiate plasminogen conversion 
by the addition of urokinase to the mixture. From these observations 
they reasonably concluded that a reduction in plasminogen concentration was 
not rate-limiting. By diluting "plateaued" reaction mixtures or by the 
addition of fresh components these authors were able to show that the 
phenomenon was not due to irreversible loss of plasminogen activator activity 
nor was it due to degradation of the "stimulator" molecule (e.g. fibrin 
or denatured protein) that was required as a co-factor. They attributed 
the phenomenon to "feedback" inhibition and indicated that they were 
engaged in its further study. They also made the important observation 
that the plateau was seen with Mel-PA but not with urokinase. 
(ii) Dan~ and Reich (142), in a detailed kinetic study of plasminogen 
activation as a function of plasminogen activator concentration and time, 
found that the rate of the reaction levelled off after approximately five 
minutes in the absence of bovine pancreatic trypsin inhibitor whereas 
activation was linear for at least twenty minutes in the presence of 
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inhibitor. They ascribed this effect to the protection of the plasminogen 
activator against plasmin formed in the course of the reaction. Moreover, 
Mangel et al (181), in describing their assay for plasminogen activator, 
noted that the rate of the reaction slowed after a certain critical plasmin 
concentration had been reached. They indicated that the phenomenon was 
currently under investigation in the laboratory and suggested that it was 
the result of digestion by plasmin of itself, of plasminogen activator and 
of plasminogen. The experiment that I performed (Table 6.3) showed that 
neither urokinase nor Mel-PA were susceptible to digestion by plasmin. 
Mel-PA appeared to have a lower Km for plasminogen in the presence 
of fibrin than did urokinase (Fig. 6.12). This would imply that Mel-PA 
is more efficient than urokinase as a plasminogen-mediated fibrinolysin 
despite the inferior action of Mel-PA as an amidolytic reagent (Chapter V) 
and the inferior conversion of plasminogen to plasmin in the presence of 
fibrinogen or fibrin in the direct assay (Fig. 6.8). ·Since the 1251-fibrin 
assay involves sequential substrates, one of which is in an insoluble form, 
the kinetics are complex and are not linear with time. Furthermore, in the 
experiment I performed to study the effect of plasminogen concentration 
on the rate of fibrinolysis the initial reaction rates were not measured. 
The Km's given, therefore, have descriptive and comparative value only and 
should not be considered in the conventional rigorous sense. Values 
obtained by other workers are surmnarized in Table 6.3 and range from 
0.2 µM to 40 µM depending, understandably, on the source of the activator 
and the nature of the experimental system. 
Although I have no doubt that fibrin binds Mel-PA and plasminogen, 
and that it accelerates plasminogen activation by Mel-PA, 
of the mechanisms by which these phenomena are mediated. 
I am uncertain 
In Chapter VI showed that fibrinogen and fibrin are contaminated 
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Table 6.3 Published Km values of plasminogen activators for plasminogen 
P.A. type Plasminogen Assay Km Reference 
Murine PA human 125 . I-p lasnu.nogen 0.18µM 142 
conversion 
PA from rat cells dog active site 7.56µM 181 
(RT4-71-D2) titration of 
plasmin with FDE 
Urokinase human hydrolysis of 40µM 196 
(lys-plasminogen) Bz-Arg-OEt 
by plasmin 
Urokinase human hydrolysis of 32µM 197 
(glu-plasminogen) Bz-Arg-OEt 
by plasmin 
by a protease that converts pro-plasminogen activator to plasminogen 
activator. These observations and stoichiometric considerations give 
reason to suspect that the other effects of fibrinogen and fibrin may 
similarly be mediated by impurities. Unfortunately I have no sound data 
that bear upon this suspicion, nor can I draw upon experimental results 
of my own or others that GOntribute to the intriguing suggestion by 
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Radcliffe and Heinze (159) that fibrin is representative of other "denatured" 
proteins that may enhance plasminogen activation by a complex mechanism in 
which"negative feedback'' is involved. 
The unanswered questions and the uncertainties that exist reflect 
the complexity of this system and the great difficulty that one has in 
obtaining pure reagents. Plasminogen, plasminogen activators and fibrinogen 
are relatively unstable molecules that are notoriously liable to form 
coacervates with contaminating protein; they may exist in any one or more 
of several molecular forms reflecting degradation or complex formation, 
and they are all difficult to purify and to isolate. It is scarcely 
surprising, therefore, that results have been conflicting, that stoichiometric 
relationships between interacting components have been difficult to define 
and that there is as yet no entirely satisfactory account of the complex 
processes that are involved in plasminogen activation by Mel-PA. 
As a speculative suggestion which might serve as a basis for 
further experimental study, I propose the following model for in vitro 
plasminogen activation by Mel-PA. The scheme is depicted diagrannnatically 
in Fig. 6.13 and incorporates - the following elements: 
Firstly, it is assumed that plasminogen activation by Mel-PA 
requires a "third factor" that is provided by fibrin or, possibly, by other 
denatured proteins. This factor may provide a "catalytic surface" in 
much the same way that glass provides a surface for the activation of 
Hageman factor or antigen-antibody complexes supply the molecular substratum 
required for the assembly and activation of the first components of complement. 
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Plasminogen activator (reaction (1)) and plasminogen (reaction (2)) 
bind to the fibrin 11 surface11 • 
as reversible and sequential. 
ln fig. 6.13 1 have shown these reactions 
There is good reason to believe that both 
of them are reversible; there is less reason to believe that they are 
sequential although there might well be advantages to plasminogen activator 
binding to fibrin having an effect upon the fibrin-plasminogen dissociation 
constant. 
Bound plasminogen activator converts bound plasminogen to plasmin 
(this is depicted as reaction (3) in Fig. 6.13 and is shown as being 
irreversible). It is assumed that, for practical purposes, the binding 
of plasminogen activator and plasminogen to fibrin is essential for 
activation to take place. 
The plasminogen activator-plasmin-fibrin complex may suffer either 
of two fates. Firstly (reaction (4)) the plasmin may dissociate to generate 
fresh binding sites for additional plasminogen to bind. This reaction 
has not to the best of my knowledge been documented. Secondly, the plasmin 
may digest the fibrin to which it is bound generating fibrin degradation 
of products to which plasminogen activator is attached (reaction (5)). It 
is known that the binding of plasminogen activator to fibrin survives plasmin 
treatment (169). 
Plasminogen activator bound to fibrin degradation products may 
dissociate (reaction (6)) to release plasminogen activator to participate 
afresh in reaction (1) by binding to fibrin. 
This schematic representation of plasminogen activation and the 
way it is influenced by fibrin has the advantage that it explains all of 
the well documented observations relating to this complex process and, in 
addition, provides an explanation for the "plateau effect11 described by 
Radcliffe and Heinze (159). lt is clear that the overall rate of fibrino-
lysis could be limited by the off-rate for plasmin from the plasminogen 
+ 
Figure 6.13 
3 -PA P'GEN PLASMIN FIBRIN FIBRIN 
Schematic representation of plasminogen activation 
by Mel-PA in the presence of fibrin. 
(For discussion see text) 
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activator-fibrin-plasmin complex (reaction (4)) and by the rate of dis-
sociation of plasminogen activator from the fibrin degradation products 
(reaction (6)). An accumulation of plasmin or of FDP's 
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would, by mass action effects, provide the "negative feedback" that Radcliffe 
and Heinze suggested. 
All of the proposed reactions in this schematic representation 
are amenable to study and verification. 
This model incorporates most of the suggestions set forward by 
Lijnen and Collen (195). It does not consider interactions with inhibitors 
that might be expected to influence reaction rates in vivo and which are 
fully dealt with in the informative and imaginative review that Lijnen and 
Collen have recently published. 
IMPLICATIONS FOR THE ASSAY OF PLASMINOGEN ACTIVATORS 
Whatever the steps involved in plasminogen activation may be, the 
role of fibrin and the distinct differences that exist between urokinase and 
Mel-PA have implications for the measurement of plasminogen activators. 
I therefore compared the relative sensitivities of several differ-
ent assays for plasminogen activators and recorded the extent to which they 
gave different results for Mel-PA and urokinase. 
In documenting these comparisons, I have used, as standards of 
reference, solutions whose enzyme content was defined in terms of moles of 
active sites per litre. This was achieved by the 
amidolytic activity and active-site labelling with 
fluorometric assay of 
3H-DFP of known specific 
activity (Chapter V). The relative sensitivities of the different assays 
for urokinase and Mel-PA were then assessed using these standard solutions. 
The results are presented in Table 6.4. 
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All of the methods used are described in detail in the Appendix 
(A3) and I shall only draw attention to the salient features of each 
procedure. 
To each assay I have assigned a value for "sensitivity" to provide 
some indication of the minimal amount of enzyme that would be reliably 
measured with that procedure. The estimate for sensitivity that I give, 
in each case, is unfortunately somewhat arbitrary since I have not gone to 
great lengths to establish this value in a rigorous way. This would have 
involved "blind" assays on coded samples and extensive statistical analyses 
that, at the time, I did not think were warranted. My estimates of 
"sensitivity" therefore are based upon the subjective judgements of myself 
and my associates in the laboratory. These judgements incorporate, not 
only the assessment of what constituted reliable reading above background, 
but also an evaluation of a reasonable time for the assay to proceed. 
1) The fluorometrio assay 
The amidolytic activities of Mel-PA and urokinase were measured 
according to the method of Zinnnerman et al (133) (Appendix A3.2). 
Two fluorogenic substrates were used. These were Cbz-Gly-Gly-
Arg-AMC and Boc-Val-Gly-Arg-AMC. Since straightforward, linear kinetics 
were observed in these assays (Chapter V) they were used in conjunction with 
3H-DFP labelling of active sites as a basis for the standardization of 
plasminogen activators. Using Cbz-Gly-Gly-Arg-AMC, it could be calculated 
that one fluorometric unit of urokinase corresponded to 0.015 pmol of 
urokinase and one fluorometric unit of Mel-PA corresponded to 1.01 pmol of 
Mel-PA. 
One pmol of urokinase hydrolyzed 668 pmol of Cbz-Gly-Gly-Arg-AMC 
or 179 pmol of Boc·Val-Gly-Arg-AMC per min under the standard conditions 
used. One pmol of Mel-PA hydrolyzed 9.88 pmol of Cbz-Gly-Gly-Arg-AMC and 
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11.2 pmol of Boc-Val-Gly-Arg-AMC per min. These assays could measure 
-15 , -13 1.5 x 10 mol of urokinase and 1 x 10 mol of Mel-PA in 5 min. 
2. C . f 125I ' . ' . onvers~on o -pvasm~nogen to pvas~n 
In this assay, described by Danp and Reich (142), purified 
plasminogen is labelled with radioactive iodine and incubated with plasminogen 
activator in the presence of the plasmin-inhibitor, BPTI. Following 
incubation, the plasmin and unreacted plasminogen are separated by SDS 
polyacry!amide gel electrophoresis under reducing conditions and relative 
amounts of each species are determined by radioassay of gel bands. Since 
the specific radioactivity of the plasminogen was known activity estimates 
in terms of pmol of plasminogen converted per min for urokinase or Mel-PA 
could be obtained. Under the standard conditions employed (Appendi_x 3. 3) 
one pmol of urokinase catalysed the conversion of 8.L pmol of plasminogen 
per min and one pmol of ~el-PA catalysed the conversion of 0.05 pmol · of 
plasminogen per min. In this assay therefore, urokinase was approximately 
160 times more efficient than Mel-PA. In the presence of fibrin or 
fibrinogen insolubilized on a plastic surface one pmol of Mel-PA catalyzed 
the conversion of O.~l pmol of plasminogen per min. 
substrate had no significant effect on urokinase. 
The same insolubilized 
3. Active site titration of the plasmin formed from plasminogen· 
This procedure was developed and described by Mangel et al (181) 
as a sensitive direct assay for plasminogen activators released by cells in 
culture. In this method, plasminogen activators and plasminogen are incu-
bated together and the plasmin formed is measured fluorometrically using 
the plasmin active site titrant, FDE. Since the amount of fluorescent 
product of hydrolysis can be easily quantitated by reference to chemically 
pure material, the amount of plasmin formed can be accurately determined. 
The assay is rigorous and yields results in terms of molar concentrations 
of plasmin active sites in the test solution. 
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Under the standard conditions of the assay described in Appendix 
3.4, one pmol of urokinase catalyzed the conversion of 38.7 pmol of plasmino-
gen per min and one pmol of Mel-PA catalysed the conversion of 0.25 pmol 
plasminogen per min. Urokinase was therefore once again, approximately 
160 times more efficient than Mel-PA in the activation of plasminogen. 
4. h 125 t·b . T e I- 1, ri.n assay 
In this procedure, a solid-phase substrate is provided by radio-
active fibrinogen/fibrin deposited as a very thin layer on the surface of a 
plastic tissue culture well. Firm attachment is assured by drying for 
0 48 hr at 45 C. Samples· to be assayed are added to the wells as solutions 
and plasminogen activator activity is measured as the plasminogen-dependent 
solubilization of radioactivity as a function of time. 
This technique was originally developed in Reich's laboratory (118). 
It was refined by Strickland and Beers (120) and subsequently by Wilson and 
Dowdle (106). Details of the assay are given in the Appendix (A3.l). 
In this assay, one pmol of urokinase, might solubilize the radio-
active fibrin with an initial reaction velocity of approximately 50% of the 
total radioactivity per min. The corresponding value for Mel-PA might be 
35%. These values would depend very much upon the "age" of the fibrin plate 
used and on the quality and concentration of the plasminogen. In the table 
I give data obtained from three different assays. It can be seen that 
urokinase is approximately 1.5 times more efficient than Mel-PA in this 
assay. This fact should be borne in mind if urokinase standards are run 
in the assay simultaneously to serve for both enzymes. 
it should also be ·remembered: 
With this assay, 
(a) - that the kinetics are not linear with time particularly at low 
enzyme concentration. This is illustrated in Fig. 3.1.1 in the 
Appendix (A3,l), 
(b) - that, as usually used, plasminogen concentrations are rate 
limiting. If urokinase standards are used to measure Mel-PA, 
it is important that the concentration of plasminogen should 
be rate limiting, since, as discussed earlier in this Chapter 
(Fig. 6.12), urokinase and Mel-PA have different apparent Km 
248 
_ values for plasminogen in this assay. Therefore, at a plasmino-
gen concentration of 6 µg/ml the fibrinolytic activity of one pmol 
or urokinase would be approximately 1.5 times that · of ·l pmol of 
Mel-PA. At 25 µg .plasminogen/ml however, one pmol of urokinase 
would have a fibrinolytic activity that was app~oximately 2.5 times 
that of an equivalent amount of Mel-PA. 
(c) - that the absolute fibrinolytic rate observed for a given amount 
of urokinase and Mel-PA is influenced by a number of other techni-
. 
cal variables such as the salt concentration and the absence or 
presence of particular amino acids. Since most of these effects 
act upon plasmin in the second phase of the reaction they affect 
the fibrinolytic activity of Mel-PA and urokinase to the same 
extent and may be compensated for by the use of urokinase standards. 
(d) h h 125 f'b . b h 1 PA d 1 PA - tat t e I- i rin assay measures ot pro-Me - an Me -
activator. The justification for this statement is provided in 
the data in Table 6.5. 
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Table 6. 4 
Table 6.4 
The data in this table represent a compilation in summary form 
of the results obtained in this chapter and Chapter V. 
in reading the table c!Ccount should be given to the following 
considerations:-
(i) specific activity for Mel-PA and urokinase in the different assays 
were calculated from the results obtained when enzyme solutions that 
had been standardized with 
3H-DFP of known specific activity were assayed 
using the procedures listed in the first column. 
(ii) The assay units are those that I have arbitrarily defined as 
indicated. 
(i i i) The ratios for specific activities of urokinase to speci fic 
activities of Mel~PA given in column 5 indicate the relative efficiency 
with wh ich the two enzymes were measured with the different procedures listed. 
(iv) The values given for "sensitivity" in columns 6 and 7 are intended 
to provide an approximate idea of the minimum amount of enzyme that could 
confidently be measured with each procedure. These values are somewhat 
arbitrary in that I have not attempted an extensive analysis of all the 
variables or criteria that would normally be considered in assigning a 
value of this sort. I have however taken into account the need to complete 
the assay in the reasonable period of time that I have given in. parenthesis. 
The "reasonableness" of this period was judged in terms of convenience, 
linearity of the reaction, stability of the reagents, and tolerable "signal 
to noise" ratios. 
( ) II S ' ' ' • II f h 
1251 f • b ' k • h f v ens1t1v1t1es or t e - 1 rin assays ta e into account t e act 
that the reaction only became linear when approximately 20% of the radio-
active fibrin had been solubilized. Owing to instability of t he reagents 
under conditions cf. the assay and increasing background levels this assay 
could rtot be used to obtain reliable quantitative results after approxi-
mately 8 hr. It could however be prolonged for 24 to 48 hr if all that 
was required was an indication that enzyme was present. 
(vi) The fibrin-plasmin-agarose assay has not been included in the above 
comparison since it was not possible to define a unit of activity and since 
the slopes of the lines relating the log of the enzyme concentration to the 
area of the lytic zone were not the same for Mel-PA and urokinase. The 
relative sensitivity of this assay for urokinase and Mel-PA and the amounts 
of these enzymes required to produce an 8 mm zone of fibrinolysis in 90 min 














































































































































































































































































































































































































































































































Table 6.5 1251 f"b . The - i rin assay of different Mel-PA preparations 
Mel-PA (a) Amidolytic Activity(b) Fibrinolrtic Activitr 
Amidolytic Activity prepar-
Fibrinol}~{c ation Active Total Pro-Mel-PA 
Enzyme Enzyme (% of total) activity Active Total 
(FU/ml) (FU/ml) (UK u/ml) 
I 
1 20.39 23.31 12.5 55.2 2. 72 2.4 
2 23.93 25.98 7.9 69.1 2.9 2.7 
3 27.21 32.43 16.1 74.5 2.7 2.3 
4 1. 61 13.03 . 87.6 31.4 19.5 2.4 
5 1.56 12.55 87.6 30.4 19.5 2.4 
6 1. 33 12.20 89.0 24.4 18.3 2.0 
(a) Mel-PA preparations consisted of serum-free harvest fluids collected 
from Bowes I cells '(1,2 and 3) or serum-free harvest fluids collected from 
Bowes II cells (4,5 and 6) as described in Chapter I. 
(b) Amidolytic activity of the samples was measured in the fluorometric 
assay as described in the Appendix A3.2. Active enzyme was determined 
without plasmin treatment of the Mel-PA preparation. Total enzyme was 
measured after incubation of the samples with plasmin. 
taken as the difference between these two values. 
Pro-Mel-PA was 
(c) 125 The fibrinolytic activity of the samples was measured in the I-
fibrin assay as described in the Appendix A3.l. 
Note that the ratio of fibrinolytic activity to total amidolytic ac£ivity 
was constant at approximately 2.4 for all Mel-PA preparations whereas the 
ratio of fibrinolytic activity to active enzyme in the amidolytic assay was 
affected by the Pro-Mel-PA content. These results indicate that the 1251-
fibrin assay measures total Mel-PA. This is not surprising since plasmin 
generation during the course of this assay clearly converts all of the 
Pro-Mel-PA to active enzyme. 
The fibrin-/casein-agarose assay 
One of the assays most commonly used by leading European and 
Scandinavian workers (217) involves the formation of a plasminogen-rich 
fibrin clot that is prepared as a thin film. Plasminogen activator 
samples are applied as drops of uniform size to the clot. These are 
allowed to diffuse and to digest the fibrin over a 17 hr period at 37°c. 
The diameter of the lysis zones given by a standard set of urokinase 
dilutions is used to determine the amount of plasminogen activator present 
in an unknown sample by interpolation. The relationship that is obtained 
between the diameter of the fibrinolytic zone and the amount of enzyme 
applied is not linear and it has not been rigorously established that 
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"tissue activator" and urokinase behave similarly in this assay. Never the-
less, this is one of the original assays for plasminogen activators and 
credit for its introduction is due largely to Astrup and his co-workers 
(218). 
Although this procedure is theoretically straightforward and, for 
the most part, technically an easy assay to perform, I found it difficult 
to cast the clot, apply the sample and incubate the assembly in such a way 
that symmetrical, radial diffusion took place to give zones of fibrinolysis 
that were circular, concentric with the point of application of the sample 
and easy to read. 
Furthermore, I wished to compare casein and fibrin as possible 
plasmin substrates in assays of this kind and I also wished to define 
conditions for the optimal zymographic detection of plasminogen activators 
using the fibrin-/casein-agarose underlay procedures developed by Granelli-
Piperno and Reich (62). 
I therefore developed a technique in which the radial diffusion 
principle of the fibrin plate assay was maintained but in which a more stable 
medium for diffusion was provided by incorporating the substrate in an 
agarose matrix. This also had the convenient advantage of allowing me 
to substitute casein for fibrin as a, final substrate. 
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In these assays, slabs of agarose containing purified plasminogen 
and fibrin or casein are cast in suitable moulds and allowed to set. Wells 
are then punched in the substrate layers into which samples of plasminogen 
activator solution are introduced. After diffusion and incubation under 
suitable conditions the visible zones of fibrinolysis or caseinolysis are 
measured and related to plasminogen activator activity. These assays are 
described in detail in the Appendix (A3.5). 
It soon became apparent that the assay depended upon two distinct 
processes. In the first, plasminogen activator diffused radially from the 
point of application in the well to a distance that was a direct function 
of the concentration of the enzyme in the well. The second process 
involved the activation of plasminogen and the digestion of the second 
substrate, casein or fibrin, to produce the zone of clearing whose dimensions 
were to be related to enzyme concentration. It was clearly possible that 
during this second phase, plasmin generated might also diffuse with ·the 
result that the radius of the zone of ultimate lysis would be a function of 
the distance moved by plasminogen activator and plasmin and might be influenced 
by any interactions between plasminogen, plasminogen activator, substrate 
and matrix that might result from plasminogen activation. 
To separate these processes I resorted to the strategy of allowing 
the first phase of plasminogen activator diffusion to take place at 4°c for 
16 hr. At this temperature activation of plasminogen did not occur. 
second phase of the assay, which led to the development of the zone of 
fibrinolysis or caseinolysis, was accomplished by incubating the gels at 
0 
37 C for 1~5 hr. The results of assays of this kind are presented in 
The 
Fig. 6.14 and 6.15, from which it can be seen that sharp circular zones of 
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Figure 6.14 
Figure 6.14 The fibrin-/casein-agarose assay. 
The photographs show typical appearances of (A) a fibrin-agarose 
plate and (B) a casein-agarose plate. 
Fibrin~ or casein-agarose plates were prepared as described in 
the Appendix (A3.5) by pipetting a 45°c solution of 1.25% agarose in 
O.lM Tris HCl pH 8.1 containing 50 µg/ml of plasminogen and either 2% 
casein or .25% fibrin, into a mould fashioned from two glass plates 
separated by 1 mm diameter strands of wire. When the agarose had set, 
the top siliconized plate was removed and· 2. 5 mm diameter holes were 
punched into the agarose layers. 
Samples (3 µ1) of Mel-PA or urokinase were then inoculated into 
the wells. The plates were incubated at 4°c for 16 hr and then at 37°c 
for 90 min, after which time the diameters of the clear rings of lysis were 
measured. 
From left to right ihe wells contained serial two-fold dilutions 
starting with a concentration of 250 FU/ml (253 pmol/ml) of Mel-PA 
(rows a & b) and 250 FU/ml (3.7 pmol/ml) of urokinase (rows c & d). 
Note: (i) that the rings of lysis were much sharper in the 
casein-agarose plates • . 
(ii) the rings of lysis produced by urokinase were 
larger than those produced ~y equivalent amounts of Mel-PA. 
(iii) equivalent amounts of Mel-PA gave larger rings in 
the casein plates than in the fibrin plates. 
urokinase. 
The reverse was true for 
A 
B 





Figure 6.15 The fibrin-/casein-agarose assays. 
The figure shows the linear relationship between the areas 
of zones of proteolysis, as observed in ·Fig. 6.14, and the logarithm 
of the concentrations of plasminogen activators. Two-fold dilutions 
of Mel-PA (l:r---A) and urokinase (0--0) starting with a concentration 
of 250 FU/ml were analysed. 
Note: (i) that in both assays urokinase gave larger areas of lysis 
than equivalent amounts of Mel-PA. 
(ii) that the slopes of the regression lines for Mel-PA and 
urokinase differed. 
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substrate clearing were visible, that could easily be measured. The casein 
proved to be a more satisfactory substrate in terms of the clarity of the 
edge of the lytic zone and the ease with which the edge could be measured. 
It was noted that a linear relationship could be defined between 
the area of the zone of proteolysis and the logarithm of the concentration 
of the enzyme in the sample introduced into the well. This is shown in 
Fig. 6.15a where fibrin was used as a substrate and in Fig. 6.15b where 
casein was digested. In these figures the concentration of the enzyme in 
the samples introduced into the wells is given in terms of fluorometric 
units/ml. 
The results illustrate two striking facts. Firstly, this assay 
is very much less sensitive for Mel-PA than it is for urokinase. This is 
shown by the fact that the slope of the line relating the log of Mel-PA 
concentration to the area of the zone of lysis was considerably less for 
Mel-PA than it was for urokinase. As a result, a given amount of Mel-PA 
in fluorometric units produced a very much smaller zone of lysis than did 
an equivalent amount of urokinase measured in fluorometric units. If one 
. 
takes into account the fact that one fluorometric unit of Mel-PA represents, 
in molar terms, approximately 6 7 times the amount of urokinase giving o.ne 
fluorometric unit of activity, it is apparent that this assay is indeed 
very much less sensitive for Mel-PA than it is for urokinase. 
In the second place, it can be seen that the discrepancy between 
urokinase and Mel-PA was less marked with casein than it was with fibrin. 
The results are summarized in Table 6.6 where the relevant calculations are 
given to show that, with fibrin as the substrate approximately 5000 times 
less urokinase than Mel-PA was needed to give a lysis. zone of 8 mm diameter. 
With casein as the substrate approximately 260 times less urokinase than 
Mel-PA was required. 
I presume, without complete justification for doing so, that the 
Table 6.6 Fibrin/casein agarose assay. 
Fibrin Casein 
Urokinase Mel-PA Urokinase Mel-PA 
Sensitivity (m) 76.9 16.6 45.0 26.6 
Relative 
sensitivities 4.6 1. 7 
pmol for 8mm diam. 
zone of proteolysis 0.4 2070 1.1 283 
This table was compiled from the parameters obtained when the 
data presented in Fig.6.14 and 6.15were fitted by linear least squares 
regression analysis to the equation: 
y = m log x + c 
where y = square of the diameter (in mm2) of the zone of proteolysis 
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and x = the concentration, in FU/ml, of enzyme introduced into the wells. 
In each case the slope of the line (or the parameter m) indicates the 
increase in area one would expect for a 10-fold increase in enzyme 
concentration. This is taken to be a measure of the sensitivity of the 
. assay. Relative sensitivities for the assays are calculated as ratios 
of the relevant slopes. 
To provide a more intuitive idea of the relative efficiency 
with which urokinase and Mel-PA were detected in the different assays 
I have also given the amounts of each enzyme that would have been required 
to give zones of lysi~ 8 mm in diameter. This diameter was chosen as 
one that could be conveniently measure.d with reasonable accuracy.. 
poor performance of Mel-PA in this assay can be attributed firstly to its 
tendency to bind to fibrin so that its diffusion through the -matrix was 
impaired and secondly to the fact that agarose, with or without casein, 
failed to provide an entirely satisfactory environment for Mel-PA to 
diffuse and to function as an activator of plasminogen. 
Conclusions 
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The experiments that I have done to compare various assay systems 
for plasminogen activators have been limited both in their variety and in 
their design and I am thus able to draw only limited conclusions regarding 
the best assays to use or the factors that influence them. 
feel justified in making the following statements: 
I nevertheless 
(i) Provided sufficiently pure enzyme is available the fluorometric 
assay using synthetic substrates gives most satisfactory results in 
the sense that activity can be defined in terms of pmoles of active 
sites per unit volume. 
(ii) Despite the shortcomings associated with lack of linearity at 
low enzyme concentrations and the need for simultaneous assay of 
f d d h 125 f. b . . d . . d re erence stan ar s, t e I- i rin assay provi es a sensitive an 
convenient procedure for the assay of plasminogen activators. 
Provided the correct concentration of plasminogen is chosen 
and provided measurements are confined to that part of the time 
curve before which the radioactive substrate becomes rate limiting, 
the assay gives approximately equivalent rates of fibrinolysis for 
equimolar amounts of urokinase and Mel-PA. An additional advantage 
of this assay is that it measures both Mel-PA and pro-Mel-PA. 
(iii) The assays based on the radial diffusion of PA through agarose 
containing plasminogen and plasmin substrates are best used to measure 
urokinase with casein as the second substrate. They have the 
advantage of ease of performance but they lack sensitivity. It is 
of intereat to note in this regard that Camiolo et al (53) found 
that the zone of lysis on a fibrin plate given by Mel-PA was 
considerably larger than that given by equivalent amounts of 
urokinase as measured in the caseinolytic assay. 
The assay is not quantitative in the sense that enzyme activity 
cannot be expressed in useful units. For this reason dilutions of 
a standard plasminogen activator solution whose activity is known 
would have to be included as described for the 
125
r-fibrin-assay. 
Since the assay measures urokinase and Mel-PA with different 
sensitivities urokinase standard solutions cannot be used for the 
quantitation of Mel-PA and vice versa. The activity of each type 
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of plasminogen activator would have to be measured against ·a standard 
of the same type of enzyme. 
(iv) The assay of plasminogen activator based on the direct measurement 
of conversion of radioactive plasminogen to plasmin is laborious and 
has little practical value with regard to the routine measurement of 
plasminogen activator. It has, however, proved very useful in the 
analysis of mechanisms underlying plasminogen activation and the 
effects of various macromolecules on this process. 
(v) The measurement of plasminogen conversion based upon active site 
titration of generated plasmin has more practical value than the one 
involving radioactive plasminogen because it is comparatively easy to 
perform and because it gives a more quantitative measure of plasmin 
generation. In addition, as described by Mangel et al (181) the 
technique is sufficiently sensitive to allow measurement of plasminogen 
activator activity secreted by cells cultured in vitro. Drawbacks of 
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this assay would be its relative insufficiency for detecting Mel-PA 
type plasminogen activators and the large amounts of purified plasmino-







Bovine fibrinogen (Fraction I, F-4000, Sigma Chemical Company) or 
human fibrinogen (A.B. Kabi) were obtained commercially and further 
purified by precipitation as described by Laki (182). They were then 
freed of plasminogen by the method of Mosesson (162) which exploits the 
differential solubility of fibrinogen and plasminogen in the presence 
of lysine. The details are as follows:-
A solution of 2g of fibrinogen in 100 ml of O.lM potassium phos-
phate buffer, pH 6.4, was adjusted to 200 ml with distilled water. After 
standing overnight at 4°C the solution was centrifuged at 1000g for 15 min 
and the pellet was discarded. 
The fibrinogen was precipitated by the addition of ammonium 
sulphate to a final concentration of 25%, collected by centrifugation and 
redissolved in 50 ml of 0.6M NaCl. 
After adjusting the pH to 7.4 with dilute NH40H, the fibrinog
en 
solution was dialysed against three changes of 0.6M NaCl and adjusted 
with 0.6M NaCl to contain 10 mg/ml of fibrinogen. Lysine HCl (0.12M in 
0.005M sodium phosphate buffer, pH 7.0) was then added to a final lysine 
concentration of 0.02M. 
The solution was brought to o0 c in a salt/ice bath ·and any precipi-
tate that formed was discarded. The fibrinogen was then precipitated by 
addition of ice-cold ethanol to a final concentration of 7%. The 
precipitate was collected by centrifugation, redissolved ·in 0.6M NaCl 
and adjusted to a protein concentration of 10 mg/ml. Ethanol precipitation 
in the presence of lysine was repeated once. The final precipitate was 
dissolved in 0.6M NaCl and dialysed against PBS. The protein concentration 
was adjusted to 10 mg/ml and the final solution was stored frozen in 2 ml 
0 
aliquots at -20 C. 
Electrophoretic analysis of different preparations of human 
or bovine fibrinogen in SDS-polyacrylamide gels under reducing conditions 
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showed that they varied in subunit chain composition. The electrophoretic 
patterns of 2 different preparations of bovine and of human fibrinogen 
are shown in Fig. Al.1.1. All .bovine fibrinogen preparations showed 
degradation. The human fibrinogen preparations were the best in that 
they still contained intact a chains. 
Al.2 . f 125 t·b . . Preparat~on o I-~ ~nogen 
The p~rified fibrinogen was labelled with 
1251 using the iodine 
monochloride method of Helmkamp et al (183); 
125 
Carrier free Na I (10 mCi; 17.5 mCi/µg) was diluted to 1 ml 
with 0.4M borate buffer, pH 7.65 containing 0.32M NaCl. To this was 
added 0.3 ml of 0.6% Na2so3 in water to destroy any peroxides pr
esent. 
After standing at room temperature for 15 min, the pyrex tube containing 
the solution was placed in a boiling water bath and aerated for 15 min. 
After cooling to room temperature 0.8 ml 2M NaCl containing 242 nmoles of 
ICl was rapidly added and the mixture was squirted into a tube containing 
4 ml of 20 mg fibrinogen in borate buffer. The reaction mixture was . then 
passed through a 2 ml column of Dowex AG-1X8 that had previously been 
treated with nonradioactive fibrinogen to block nonspecific binding sites. 
The 
1251-fibrinogen was collected as the non-adsorbed radioactive fraction 
and was dialysed against three changes of PBS containing antibiotics. It 
was then passed through a 0.45µ Millipore filter and stored at 4°c. 
4 
Specific activities of 6-9 x 10 cpm/µg protein were regularly 
achieved. 
Figure Al.1.1 Electrophoretic analysis of different fibrinogen preparations 
Solutions of either human or bovine fibrinogen (2mg/ml) were 
mixed with an equal volume of O.lM Tris HCl pH 6.8 containing 2% SDS, 
20% glycerol, 10% S-mercaptoethanol and 0.004% phenol red. They were 
boiled for 1 min and 5 µl samples were then electrophoresed in a 6-15% 
gradient of polyacrylamide contain ing 0.1% SDS. After electrophoresis 
the slab gel was stained with 0.1% Coomassie brilliant blue in 30% methanol 
and 10% acetic acid and then destained. 
The photograph shows the electrophoretic patterns of 2 human 
fibrinogen preparations (tracks 1 and 2) and 2 bovine fibrinogen 
preparations (tracks 3 and 4). 
Note that the bovine fibrinogen preparation in track 3 was 
heavily degraded. The other bovine fibrinogen preparation was considered 
good enough for use in fibrin agar indicator gels (see Appendix 3.5). 
Human fibrinogen preparations, which generally showed the least 
degradation were used for iodination and for the preparation of fibrin 
coated plastic wells to be used for the 1251-fibrin assay. 
• 
Al.3 Purification of pl-asminogen and pxiepax-ation of pl-asmin. 
Plasminogen was isolated from human plasma according to a 
modification of the method of Deutsch and Mertz (45) using affinity 
chromatography on lysine-sepharose. 
Fresh or expired blood bank human plasma collected ~n acid 
citrate dextrose was centrifuged at 1700g for 30 min and the pH was 
adjusted to pH 7.4. A 200 to 300 ml sample was then passed, at room 
temperature, through a lysine-sepharose 4b column (2.5 x 20 cm) that 
had been equilibrated with PBS containing 0.5 mg/ml of streptomycin and 
0.5 mg/ml of penicillin. 
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The column was then washed with 0.18M potassium phosphate buffer 
pH 7.4 containing 0.6M NaCl and 40% ethylene glycol. This step eluted 
a large opalescent peak of lipo-proteinaceous material that contained no 
plasminogen. Adsorbed plasminogen was eluted with O.lM potassium 
phosphate, pH 7.4, containing 0.2M EACA. 
EACA was removed from the eluate by dialysis against PBS at 4°c 
after which traces of contaminating plasmin were inactivated by treatment 
with 10 mM DFP for 2 hr at 40°C. Unreacted DFP was removed by dialysis 
against PBS. The final solution was dispensed in 1-2 ml volumes and 
stored at -20°c. 
When analysed by SDS-PAGE, the plasmino·gen preparations showed 
two protein bands in roughly equal proportions with approximate molecular 
weights of 90 000 and 86 000 daltons. These presumably corresponded to 
partially degraded lysine-plasminogen and native glutamic-acid plasminogen. 
Human plasmin was obtained by activation of plasminogen with 
urokinase-coupled sepharose. Corrnnercial urokinase (Leo; 5 000 Ploug 
units) was dissolved in 1 ml of O.lM NaHC03 pH 8.9 and coupled to 1 ml 
of CNBr-acti vated. sepharose 4b. One ml of plasminogen at 5 mg/ml in 
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O.lM Tris HCl pH 8.1 containing O.lM lysine was mixed with 1 ml of 
urokinase-sepharose and incubated at room temperature for 3 hr. The 
urokinase-sepharose was recovered by filtration and the filtrate·· was 
0 
stored at -20 C. 
Al.4 Radio-iodination of plasminogen 
Human plasminogen was iodinated by the iodine-monochloride 
method of Helmkamp et al (183) using a five-fold molar excess of ICl over 
plasminogen and 5 mCi of Na
125r (15.7 mCi/µg; Amersham). 
c·arrier-free Na12
5r (S mCi) was diluted to 2 ml with 0.2M borate 
buffer pH 7.65 containing 0.16M NaCl and 100 µl of 5 x l0-
4M ICl was 
added. Two millilitres of plasminogen (0.9 mg) in PBS was then added 
and the mixture was incubated at room temperature for 10 min. Free iodine 
was removed by passage of the mixture over a 2 ml colunm of Biorad AG1-X8 
ion exchange resin that had been equilibrated in saline. Nonspecific 
binding sites on the colunm and tubes used in the procedure were blocked 
by pre-exposure to non-radioactive plasminogen . 
. . The radioactive plasminogen was passed through a 45 ].!.Millipore 
filter, dispensed in volumes of 200 µland stored at 4°c. 
The specific radioactivity of the preparation was 90.6 Ci/mmol of 
plasminogen (0.04 ·atoms 
1251/mol). This preparation was used as a substrate 
. h 125 1 . . ( . 3 3) int e I-p asminogen conversion assay Appendix , , 
Al.5 Urokinase 
Partially purified urokinase was obtained from Leo Laboratories 
Ltd., Hayes, Middlesex. The contents of 1 vial (5000 Ploug units) were 
dissolved in a suitable volume (usually 2.5 ml) of O.lM Tris HCl pH 8.1 
containing 8 mg/ml bovine serum albumin or 0.1% Triton X-100. 
was dispensed into so µl volumes and stored in liquid nitrogen. 
The solution 
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Electrophoretic analysis of 15 µl of a typical urokinase 
preparation in an 11% polyacrylamide gel containing SDS showed that it 
contained many impurities (Fig. Al.5.1). 
Al.6 Bovine serwn aZbwnin 
Protease and inhibitor-free bovine serum albumin was prepared 
according to Wilson et al (106). 
Bovine serum albumin (BDH) was dissolved in water to a concen-
tration of approximately 10 mg/ml and acid-labile protease inhibitors were 
removed by adjusting the pH of the solution to pH 3.0 with O.lM HCl and 
incubating at room temperature for 2 hr. The solution was then 
neutralized with O.lM NaOH and protease activity was removed by incubation 
with 10 mM DFP at 40°C for 2 hr. After extensive dialysis against O.lM 
Tris HCl pH 8.1, the solution was adjusted to 8 mg/ml and was stored at 
-20°c. 
Fluorescein-labelled bovine serum albumin was prepared by mixing 
a 10 mg/ml solution of the protein with 15 µg fluorescein (FITC)/mg of 
protein in 0.05M sodium carbonate buffer pH 9.0. 
for 2 hr at 4°c and then dialysed against PBS. 
The solution was stirred 
This preparation was used for the electrophoretic analysis of 
urine samples as described in Chapter III. 
Al.? Benzarrridine sepharose 
Meta-aminobenzamidine was prepared from m-nitro benzamidine by 
catalytic hydrogenation according to the method of Hixson and Nishikawa 
(135). 
Meta-nitrobenzamidine HCl (25 g) together with 150 ml methanol 
was introduced into a 500 ml Parr glass hydrogenation vessel. 









Figure Al.5.1 Electrophoretic analysis of commercial urokinase. 
Fifteen microliters of a commercial urokinase solution 
(2500 Ploug units/ml) in 0 . 05M Tris HCl pH 8.1 containing 1% SDS 
and 10% glycerol were electrophoresed in a gradient of 6-15% 
polyacrylamide containing 0.1% SDS. After electrophoresis the 
gel was fixed and stained with Coomassie brilliant blue . 
The urokinase preparation contained many i mpurities . 
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(10% on charcoal; 300 mg) was introduced rapidly and the vessel was 
re-stoppered. The vessel was then placed into a screen cage and connected 
to a Parr pressure r£action apparatus equipped with a mechanical shaker. 
The vessel was purged with hydrogen, and hydrogenation proceeded at an 
initial pressure of 50 psi for 2 hours. 
At the end of the reaction the catalyst was removed from the 
solution by filtration on a bed of diatomaceous earth. Anhydrous diethyl 
ether (100 ml) and concentrated HCl (0.125 moles) were then added and the 
solution was placed at -15°C for 16 hours. The fine white needles of 
meta-aminobenzamidine were collected by filtration, washed with ice-cold 
tetra-hydrofuran and dried. The yield was 22.13 g. 
Sepharose CL-4b was activated with CNBr according to the method 
of Nishikawa and Bailon (136). 
Cyanogen bromide was dissolved 1n N-methyl pyrrollidone to give 
a 12.5% solution. Forty millilitres of the solution were then added 
dropwise with stirring to 100 ml of wet, settled sepharose CL-4b suspended 
in 50 ml of water. The reaction was carried out at 15°c for 10-15 minutes 
while a constant pH of 10.8 was maintained by the automatic addition of 
2M NaOH with a Radiometer Autoburette assembly. 
After thorough washing in water and O.lM NaHC0
3 
pH 8.9, 13.1 g 
of E-amino-caproic acid dissolved in 30 ml of O.lM NaHC0
3
, pH 8.9 was 
added. After reaction at 4°C for 24 hr with tumbling, the matrix was washed 
with 0.2M NaCl. Titration of the carboxyl-groups indicated that 22 µmoles 
of EACA had been linked/ml of gel. 
Aminobenzamidine was linked to the CH-sepharose by carbodiimide 
coupling according to the method of Hixson and Nishikawa (135). 
Meta-aminobenzamidine (8g) was dissolved in 40 ml 0.2M NaCl 
pH 4.75 and 5 g of l-ethyl-3-(3 1-dimethyl amino-propyl) carbodiimide HCl 
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(EDC) was dissolved in 10 ml of water. This solution was added to 100 ml 
of settled CH-sepharose and the pH was maintained at 4.75 with 2M HCl. 
The reaction was continued at 4°C for 24 hr after which the 
matrix was washed exhaustively and sequentially with O.OlM HCl in O.SM NaCl; 
O.OlM NaOH in O.SM NaCl and 0.2M NaCl. 
Al.8 Insolubilized inhibitor (DE-3) or IgG 
Proteins were linked directly to sepharose that had been activated 
with cyanogen bromide (210). 
Sepharose CL-4b (Pharmacia) was activated with CNBr according 
to the method of Nishikawa and Bailon (136) as described in Appendix Al.7. 
Alternatively, commercially available CNBr-activated sepharose 4b (Pharmacia) 
was used. 
For the coupling of proteins to the matrix, 3-10 mg of the protein 
~ 
per ml of settled matrix was used. Coupling was performed in O.lM NaHC03 
pH 8.9 in all cases and the suspensions were mixed by tumbling at 4°C for 
approximately 16 hrs. 
The matrices were then washed with at least 5 volumes of coupling 
buffer and incubated in the presence of lM ethanolamine pH 8.5 for 2 hr at 
room temperature to block residual binding sites. The matrices were then 
washed with O.lM sodium acetate buffer pH 4.5 containing O.SM NaCl followed 
by coupling buffer and then they were equilibrated in the buffer used for 
chromatography. 
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Al.9 Radio-iodination of DE-3 
DE-3 was iodinated with Na125r according to the method of 
Greenwood et al (43) using chloramine T. 
DE-3 (100 µg) in 0.5 ml of 0.05M phosphate buffer, pH 7.5 and 
0.5 ml of a 1 mg/ml solution of chloramine Tin water were rapidly added to 
1 1 f . f . f 125 (1 . 0 µ o a solution o carrier- ree Na I mCi; 100 mCi/ml) obtained 
from Amersham. The mixture was stirred at room temperature for 5 min and 
0.5 ml of 1 mg/ml Na2so5 was added. 
The mixture was then irmnediately removed and loaded on to a 
Sephadex G25 fine column (1 x 20 cm). Free iodine was separated from 
the labelled protein by elution with 0.05M phosphate buffer pH 7.5 containing 
0.02% NaN3 . Fractions containing radioactivity that eluted in the void 
volume were pooled to give 3 to 4 ml of radioactive solution. 
The specific radioactivity of DE-3 obtained was between 0.9 and 
1.25 x 105 cpm/pmol (60 - 80 µCi/nmol). 
POLYACRYLAMIDE GEL ELECTROPHORESIS A.2 
A2.1 Sodiwn-dodecyl sulphate CSDS) polyacxylamide gel electrophoresis 
The discontinuous system of Laemmli (223) as described by 
Maizel (137) for electrophoresis in polyacrylamide slab gels containing 
SDS was used. The upper stacking gel contained 3% polyacrylamide: 
0.08% bisacrylamide in 0.125M Tris HCl pH 6.8 containing 0.1% SDS, 0.1% 
TEMED and 0..02% ammonium persulphate. The lower resolving ~l .contained 
either a uniform concentration or a linear gradient of polyacrylamide 
bisacrylamide (30:0_.8) in 0.38M Tris HCl pH 8.8 containing 0.1% SDS, 
0.1% TEMED and 0.02% ammonium persulphate. Reservoir buffer consisted 
of 0.025M Tris, 0.192M glycine pH 8.5 containing 0.1% SDS. 
Electrophoresis was carried out at 4°c at a constant current 
ranging from 8 mA to 20 mA depending upon gel size and cooling efficiency. 
After electrophoresis the gels were prepared for analysis as required for 
each experiment. 
Samples to be electrophoresed were generally made 2.5% or 1% 
with respect to SDS and 10% with respect to glycerol; 4 µg/ml of phenol 
red was added to serve as a tracking dye. The samples were heated for 
1 min in a boiling water bath before loading. 
For reduction of disulphide bonds the samples were made 5% with 
respect to e-mercaptoethanol in addition to the SDS and glycerol. 
Usually 5-10 µg of total protein was loaded per well on small 
gels (60 x 70 x 1 mm) and 20 - 100 µg were loaded per well on large gels 
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(150 X 120 X 2mm). After electrophoresis the gels were fixed and stained 
with 0.1% Coomassie brilliant blue R250 in 10% acetic acid : 30% methanol. 
For the detection of bands containing very small amounts of 
protein the silver stain method of Merril et al (215) as modified by 
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Dr. D. Belin of the Rockefeller University (personal communication) was 
used. After electrophoresis, the gels were immersed in fixing solution 
consisting of 30% methanol : 10% acetic acid in water for a minimum of 
1 hr. The gels were then expanded in water for 30 min. The water was 
changed every 10 min. A freshly made solution of 10% glutaraldehyde in 
water was then added and the gels were incubated for 30 min. The glut~r-
aldehyde-was then removed by washing the gel in 3 x 1 litre volumes of 
H20 over 30 min. 
A silver stock solution was made by dissolving 20g AgN0
3 
in 
100 ml of water. Immediately before use, 1.6 ml of the 20% solution 
of AgN03 was added slowly to 8.4 ml of 0.09M NaOH and 0.56 ml of 28% NH40H. 
After all the AgN0
3 
had dissolved the volume was made up to 40 ml with 20% 
ethanol in H2o. The gel was incubated in this mixture for 5 min and then 
washed twice (2 min) in water. Bands were developed by immersion of the 
gel in an aqueous mixture containing 0.005% citric acid, 0.0185% formaldehyde 
and 10% ethanol. After the desired intensity of staining had been achieved, 
the gels were washed in 2 x 1 litre volumes of water and dried. 
Proteins at low concentration were also prepared for electro-
phoresis by precipitation with trichloracetic acid (TCA) in the p~esence 
of 0.1% Triton X-100 according to the method of Retz and Steel (165). 
Samples containing 0.1% Triton were made 0.1% with respect to 
SDS and the proteins were precipitated by the addition of TCA to 6% final 
concentration. The proteins were pelleted by centrifugation at 3000 rpm 
for 30 min in round bottomed tubes. The precipitates were washed in 1 ml 
of acetone, recentrifuged and dissolved in a minimum volume of 0.06M Tris 
HCl pH 6.8 containing 2.5% SDS, 5% glycerol and 4 µg/ml phenol red, The 
samples were heated for 1 min in a boiling waterbath before loading on the 
gels. 
A2.2 Alkaline discontinuous po lyac:ry lamide gel electrophoresis 
This was carried out according to the method of Maizel (137). 
Upper stacking slab gels consisted of 3% polyacrylamide : 0.08% bis-
acrylamide in 0.0625M Tris HCl pH 6.7. Lower resolving slab gels 
consisted of 7% polyacrylamide : 0.19% bisacrylamide in 0.38M Tris HCl 
pH 8.9. TEMED at 0.1% and annnonium persulphate at 0.02% were used as 
catalyst and initiator respectively. 
Tris, 0.038M glycine, pH 8.5. 
The reservoir buffer was 0.005M 
Samples for electrophoresis were diluted with O.OlM Tris HCl 
pH 6.7 containing 5% glycerol and 4 µg/ml phenol red. Before electro-
phoresis the samples were boiled for 1 min. 
A2.3 Polyacrylamide gel electrophoresis and zymography on fibrin 
agar gels 
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The procedures followed were as described by Granelli-Piperno and 
Reich (62). Enzymes were separated by SDS-polyacrylamide gel electrophoresis 
and active enzyme bands were localized by layering the polyacrylamide slab 
on an agar gel layer containing plasminogen and fibrin. 
After electrophoresis SDS was removed from the gels by incubation 
with gentle agitation, in 2.5% aqueous Triton X-100 for 1 hr at room 
temperature. The gel was then rinsed in water, drained and layered on the 
fibrin-plasminogen indicator gel. 
The indicator gel was cast in a mould to give a slab that was 
0.8 mm in thickness and that contained 1.25% agar, 5 µg/ml of purified human 
plasminogen, 2 mg/ml of bovine fibrinogen and 0.06 units/ml of thrombin in 
0.05M Tris HCl pH 8.1. "Casein" gel contained 20 mg/ml of skinnned milk 
powder instead of fibrinogen and thrombin. 
The whqle assembly was incubated at 37°c in a humid chamber. 
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Bands of protease activity could be seen as clear lysis zones in the opaque 
fibrin layer under dark background illumination. After the desired size 
of lysis bands had been achieved the fibrin gel could be preserved by 
staining for 10 min in a solution of 0.1% amide black in 70% methanol and 
10% acetic acid and destaining in 70% methanol and 10% acetic acid. 
Fibrin gels without plasminogen were employed for the zymography 
of plasminogen-independent proteases and to provide a control indicator 
system for the definitive identification of plasminogen activators. 
Molecular weight marker proteins could be coelectrophoresed in 
the same gels. After electrophoresis the tracks containing the markers 
were separated and stained in 0.1% Coomassie brilliant blue in 30% methanol 
10% acetic acid. 
A2.4 Zymography in gelatin-SDS polyacrylamide gels 
This technique for the electrophoretic analysis of proteases in 
SDS-polyacrylamide gels containing copolymerized plasminogen and gelatin 
has been described in detail in Chapter II. 
A2.5 Autoradiography of polyacrylamide gel slabs containing 
electrophoresed radioactively labelled compounds. 
For the autoradiography of slab gels containing proteins labelled 
. h 125I h 1 f. . d d f. . % . . 1 . wit t e ge s were irst staine an ixed in 0.1. Coomassie bri liant 
blue in 30% methanol: 10% acetic acid. After destaining in 30% methanol 
10% acetic acid, the gels were shaken for 30 min in 200 ml water to which 
had been added approximately 2 ml of glycerol. The gels were then dried 
between cellophane sheets under vacuum. The dried gels were placed in 
contact with Osray RPl X-ray film (Agfa-Gevaert) for various times before 
development and fixing of the films. 
For the detection of B-emitters, such as 
3
H, the fluorographic 
method of Bonner and Laskey (139, 166) was used. Gel slabs were soaked 
twice for 30 min in 20 times their volume of DMSO. They were then 
'immersed in 4 times their volume of 20% 2,5 diphenyloxazole (PPO) in 
DMSO for 3 hr. The scintillant was then precipitated in the gel by 
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immersion in water for 1 hr, and the gels were then dried between cellophane 
sheets. Osray RPl X-ray film was exposed to the gel at -80°C for varying 
lengths of time. 
Alternatively, Coomassie blue stained gels were impregnated with 
"En3Hance" (Packard Instrument Company, Inc. Ill. U.S.A.) according to the 
manufacturers instructions. 
A2.6 Molecular weight determination in SDS polyacrylamide gels 
The method of Weber and Osborne (224) was used for the deter-
mination of molecular weights using co-electrophoresed marker proteins 
obtained from Pharmacia Fine . Chemicals (phosphorylase b - 94 000 daltons; 
bovine serum albumin 67 000 daltons; ovalbumin - 43 000 daltons; carbonic 
anhydrase 30 000 daltons; trypsin inhibitor - 20 100 daltons; and 
a -lactalbumin - 14 400 daltons). 
Molecular weights of unknown proteins were obtained by inter-
polation from a curve constructed by plotting the logarithm of the molecular 
weights of the marker proteins as a function of their electrophoretic 
mobility relative to phenol red. 
A3 ASSAYS FOR PLASMINOGEN ACTIVATOR 
A3. l h 125 ,..b . Te I-,r1, nn assay 
In this procedure a solid-phase substrate was provided by radio-
active fibrinogen/fibrin deposited as a thin layer on the bottom inside 
surface of plastic tissue culture wells. Samples to be assayed were 
added to the wells as solutions and plasminogen activator activity was 
measured as plasminogen-dependent solubilization of radioactivity as a 
function of time. 
laboratory (118). 
This technique was originally developed in Reich's 
It was refined by Strickland and Beers (120) and 
subsequently by Wilson and Dowdle (106). 
The preparation of 1251-fibrinogen has been described (Al.2). 
Fibrinogen preparations from different sources as well as from different 
batches within the same source varied widely in subunit . integrity and 
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composition (Al.2) and in intrinsic amidolytic activity (Chapter V). Only 
fibrinogen preparations that yielded low background values in the 1251-
fibrin assay were used. 
For the preparation of insolubilized substrate plates 200 µl 
of a 5 mM NaCl solution containing 30 µg (100 000 to 130 000 cpm) of 
125 f.b · dd d h 11 f . b . . I- i rinogen were a e to eac we o Lin ro multiwell tissue culture 
plates. The plates were then incubated at 45°c for 48 hr to dry the 
solutions and to assure firm attachment of the fibrinogen to the surface of 
the wells. Before each assay, 1 ml of PBS was added to each well and the 
plates were incubated at 37°c for 30 min. Unbound radioactivity, usually 
amounting to 20 - 30 000 cpm, was removed by washing each well twice with 
PBS and once with O.lM Tris HCl pH 8.1. 
removed with suction. 
Residual liquid in the wells was 
For the assay 280 µl of O.lM Tris HCl pH 8.1 containing 2 µg 
of human plasminogen and 80 µg of protease and inhibitor-free bovine serum 
0 
albumin (Appendix 1.6) were added to each well at O C. 
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Dilutions of plasminogen activators in suitable buffers (usually 
O.lM Tris HCl pH 8.1 containing 0.1% Triton X-100) were added to the wells 
in 20 µl volumes and the plates were incubated at 37°C. At various time 
points the plates were set on chipped ice and 50 µl aliquots were removed 
from each well for radioassay in a Packard Gamma counter. Control wells 
contained plasminogen without plasminogen activator for the determination 
of fibrinolysis by the plasminogen on its own. 
Samples were also assayed in the absence of plasminogen to measure 
plasminogen-independent proteolytic activity. 
The total radioactivity that could be solubilized from a well was 
determined by incubation of the substrate in 300 µl medium containing 
2.5 mg/ml trypsin. 
The cumulative radioactivity released into each well was calculated 
and, after subtraction of the cumulative radioactivity released by plasmino-
gen alone, the percentage of radioactivity released relative to the total 
radioactivity released by trypsin could be calculated. The results were 
then expressed as the percentage of total radioactivity solubilized in a 
given time (e.g. %T/30 min). 
Since the release of radioactive fibrin degradation products 
measures effects upon two sequential substrates and since the second of these 
substrates is present in an insoluble form, the kinetics are understandably 
complex. Thus one usually finds that the release of radioactivity is not 
linear with time but follows rather a sigmoid curve characterized by an 
initial "lag period" followed by a fairly linear period of cumulative release 
with a plateau when available radioactive fibrin becomes rate-limiting. 
These kinetic features are illustrated in Fig. A3.l.l which illustrates two 
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Figure 3. 1.1 Kinetics of plasminogen activator activity 1n the 
125I f"b . - 1 r1n assay. 
Twenty microlitres of Mel-PA or urokinase were added to 280 µl of 
O.lM Tris HCl pH 8.1 containing 2 µg of plasminogen and 80 µg bovine 
lb . . 1 . 11 d . h 1251 f"b . h serum a umin 1n a p ast1c we coate wit - 1 r1nogen. Te 
plate was incubated at 37°c and 25 µl aliquots were removed at different 
times. The radioactivity was counted in each sample and the percentage 
of ramioactivity relative to the total radioactivity released by 
300 pl of 2.5 mg/ml trypsin was calculated • . The fi~ure depicts 
the increase in the percentage of total radioactivity released with 
time by two different dilutions each of Mel-PA (----) or urokinase 
(----- ). 
It can be seen that relatively linear k1netics were obtained 
for both urokinase and Mel-PA at the higher concentrations. At the 
lower concentrations both enzymes showed a lag phase. 
pronounced with Mel-PA than it was with urokinase. 
This was more 
from the figure the deviation from linearity of the cumulative time curve 
was most pronounced when low concentration of enzyme were being assayed 
i.e. amounts of plasminogen activator that released 20% or less of the 
trypsinizable radioactivity in the first hour. 
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Secondly, it can be seen that Mel-PA and urokinase behaved in 
this assay with essentially similar kinetics with the only difference being 
that at low enzyme concentrations the initial lag with Mel-PA was more 
evident than it was with urokinase. 
I presume that this initial lag with low enzyme concentrations 
reflects the fact that both plasminogen activator and plasminogen were 
rate limiting and that a steady rate of fibrinolysis only comes about when 
an adequate concentration of plasmin has been attained. 
When any comparative estimates of fibrinolytic activity of 
plasminogen activator preparations were required (e.g. in chromatography 
fractions), different dilutions of the preparations were assayed and only 
those samples capable of releasing at least 20% of the total radioactivity 
in 1 hr were used for the calculation of enzyme activity. Such activity 
estimates varied widely between assays and depended largely on the "age" 
of the insolubilized substrate and the plasminogen preparation used in the 
assay. 
This inconsistency between assays could be accommodated by 
including, with each run, serial doubling dilutions of a standard urokinase 
preparation, usually starting at a concentration of 0.2 Ploug units per 
well. As can be seen in Fig. A3.l.2, a useful linear relationship between 
amount of enzyme and percentage of total trypsinisable radioactivity released 
over a limited range of concentration at any given time could be observed 
for both Mel-PA and urokinase. Fibrinolytic activity of unknown samples 
could thus be estimated in terms of urokinase units/ml (UK u/ml) by 
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Figure A3.l.2 Relationship of enzyme concentratioa and cumulative 
release of radioactive fibrinogen degradation products 
h 1251 f.b . int e - i rin assay. 
The cumulative release of radioactive fibrinogen degradation 
products by six doubling dilutions of urokinase (b---~) or Mel-PA(~---~) 
d · h 
125 f.b . f 45 . d 6 . h was measure int e I- i rin assay a ter min an O min. Te 
highest concentration of urokinase in the experiment was 0.2 Ploug 
units/well. 
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A double logarithmic plot of the data gave a useful linear 
relationship of enzyme concentration and cumulate release of radioactivity 
at the times tested. 
As originally described (120) the 
125
I-fibrin assay required 
conversion of fibrinogen to fibrin by thrombin that was believed to be 
present in serum. The authors gave as evidence for the fact that con-
version to fibrin had taken place data to indicate that approximately 13% 
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of the radioactivity was solubil.ized with thrombin treatment. 
amount one would have expected as the result of thrombin action. 
This is the 
Since I was uncertain both of the need to convert adsorbed 
fibrinogen to fibrin by exposure to thrombin present in serum and of 
the efficacy of this procedure; and since I felt that inhibitors present 
in serum might interfere with the assay, I performed an experiment in which 
I "activated" Linbro plates with 10% plasminogen-free foetal calf serum 
in RPMI as is usually done by others or with 0.1 NIH units/ml thrombin in 
PBS contai~ing 1 mM CaC12. Test plates were treated with PBS alone. 
After washing, the 
125
I-fibrinogen/fibrin layers were examined 
for their ability to serve as substrates for the assay of Mel-PA and uro-
kinase . . As can be seen from the data summarised in Fig. A3.l.3 it made 
no difference either to the total counts remaining adsorbed to the dish or 
to the amount of radioactivity released by equivalent amounts of Mel-PA or 
equivalent amounts of urokinase whether the layers were treated with PBS 
alone, PBS and thrombin or dilute foetal calf serum. 
-After treatment of the radioactive substrate with 100 µl of 
0.065M Tris HCl pH 6.5 containing 1.0% SDS, 10% glycerol and 5% 2-mercapto-
ethanol at 60°C for 10 min, approximately 25% of the total radioactivity 
could be released. Analysis of this material obtained from wells treated 
with FCS, thrombin or PBS by SDS-polyacrylamide gel electrophoresis, showed 
that the material released from the wells was the same in all cases and was 
similar to the material originally put on the wells. I was not able to 
conclusively establish whether conversion of fibrinogen to fibrin took 
0 
·place f n incubation of the substrate with either thrombin on foetal calf serum. 
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Figure 3 .1. 3 f 125 f.b . d Effect of pretreatment o I- i rinogen coate 
Linbro plate wells. 
. . . 1 b. 1 · d 125 f. b . (30 To wells containing inso u i ize I- i rinogen µg; 
100-120 000 cpm) were added 1 ml of either RPMI containing 10% plasminogen-
free foetal calf serum (a); 0.1 NIH units/ml thrombin in PBS containing 
1 mM CaC12(b); or PBS (c). The plate was incubated at 37°c for 2 hr 
and each well was then washed twice with PBS and once with O.lM Tris HC°l 
pH 8. 1. 
The release of radioactivity from the wells by trypsin, Mel-PA, 
urokinase or buffer alone was then measured, and the results are shown 
in the bargraph. 
As can be seen from the figure, pretreatment of the insolubilized 
1251 f.b · · h h · d.d k d.ff - i rinogen wit t e various reagents i not ma e any i erence to 
the radioactivity released by trypsin, Mel-PA, urokinase and buffer alone. 
A 30 min preincubation with PBS to remove loosely bound counts 
is, therefore, all that is needed to prepare plates for the assay. It 
is not necessary to prepare plasminogen-free serum or dilute thrombin. 
A3. 2 Fluorome tric ass_ay 
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The fluorescent substrates, N-Cbz-glycyl-glycyl-arginyl-7-amino-4 
methyl coumarin (Cbz-Gly-Gly-Arg-AMC) and Boc-Val-Gly-Arg-AMC were used 
to assay amidolytic activity of pro,teases according to the method of 
Zimmerman et al (133) and Morita et al (173). 
Assays were carried out either in glass cuvettes or in quartz 
cuvettes at 25°c. A volume of 0.05 ml of enzyme at appropriate dilution 
was added to 0.45 ml of O.lM Tris HCl pH 8.1 containing 4% DMSO, and 
5 x l0-4M of substrate. The initial rate of AMC release and concomitant 
increase in fluorescence was monitored using a Perkin Elmer fluorescence 
spectrophotometer, model MFP-43A, equipped with a recorder. The excitation 
and emission wavelengths were set at 383 nm and 455 nm respectively. The 
instrument was standardized every day . such that a 4 x 10-7 solution Qf AMC 
in the assay mixture gave full scale recorder pen deflection(= 100 relative 
fluorescence units). 
Activities of enzymes are expressed as fluorometric units/ml 
(FU/ml), where 1 FU represents that amount of enzyme capable of hydrolysing 
10 pmol of substrate in one minute under the assay conditions. 
A.3.3 A +': t f th . f 125 .., . ssay Jor measuremen o e convers~on o I-p~as~nogen 
to plasmin by plasminogen activators 
In this assay the conversion of the single chain of plasminogen 
to the two chains of plasmin by plasminogen activators was measured. The 
method of Dan~ and Reich (142) was employed. 
Purified human plasminogen was radiolabelled with 
125
Iodine 
according to the method of Helmkamp et al (183) (Appendix Al), The 
specific radioactivity of the plasminogen was 90.6 Ci/nnnol. 
286 
In the assay 60 µ1 of radioactive plasminogen (2.3 x 108 cpm/ml; 
0.147 mg/ml), 30 µ1 of basic pancreatic trypsin inhibitor (BPTI) (1000 KIU/ml) 
and 20 µ1 urokinase or Mel-PA at suitable concentrations were incubated 
at 37°c in a total volume of 300 µl of O.lM Tris HCl pH 8.1 containing 
0.02% Triton. 
After 20 min incubation, 50 µ1 aliquots were removed from the 
mixture and added to 10 µ1 of 10% SDS containing 0.004% phenol red, 10 µl 
glycerol and 5 µl 2-mercapto-ethanol. The samples were heated for 1 min 
in. a boiling water bath and 5 or 10 µ1 were loaded on 6-15% gradient 
polyacrylamide gels (120 x 65 x 1 nnn). All samples and gels were prepared 
in duplicate. After electrophoresis, the gels were fixed in 10% acetic 
acid 30% methanol and dried. Autoradiographs were made by exposure of 
Osray RP-1 Xray films (Agfa-Gevaert) to the dried gel for 24 hr at -20°c. 
The bands corresponding to plasminogen, and the two chains of 
plasmin were excised from the dried gel and the radioactivity determined. 
The percentage of radioactivity recovered after background subtraction in 
the bands of plasmin heavy and light chains relative to the total radio-
activity recovered in each track indicated the extent of conversion. 
Background counts for subtraction were obtained in corresponding areas of 
tracks in which non converted plasminogen had migrated. 
The radioactive plasminogen in the gel consisted of a closely 
spaced doublet, presumably corresponding to the Lys- and Glu-forms of 
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the plasminogen molecule (18). The two forms could also be observed in 
the plasmin heavy chains, but not in the light chains. Furthermore, it 
could be clearly seen that cleavage of plasminogen by both Mel-PA ar.d 
urokinase resulted in the same product plasmin chains, indicating that both 
activato;s activate plasminogen via the same mechanism, i.e. by cleavage 
of a susceptible Arg-Val bond of plasminogen. 
A3.4 PZasminogen conversion assay using active site titrant for 
pZasmin {FDE-assay) 
In this procedure described by Mangel et al (181) plasminogen 
activators are assayed by measuring the rate of generation of plasmin from 
plasminogen. Plasmin is measured by active site titration. 
The fluorescent active site titrant, di-(p-guanidino-benzoyl) 
fluorescyl-6-thioureido-(p-benzoic acid), (abbreviated FDE) used in these 
studies was synthesized in this laboratory according to the method of Mangel 
1 et al (181). 
Plasminogen at a final concentration of 0.756 mg/ml (8.4 µM) was 
incubated at room temperature with various concentrations of Mel-PA and 
urokinase, ranging from 50 - 2000 FU/ml in O.lM Tris HCl buffer pH 8.1 
containing 0.02% Triton. After 10 min incubation 50 µl aliquots were 
removed and added to 950 µl PBS containing FDE to give a final concen-
tration of 0.75 µg/ml in the assay tube. After exactly 2 min incubation 
at room temperature, 20 µl of a 1 mg/ml solution of NPGB was added and 
the fluorescence was measured immediately in a Perkin Elmer fluorQmeter, 
with excitation and emission wavelengths set at 491 nm and 514 nm respectively. 
The amount of plasmin in pmol was determined by reference to the intensity 
of fluorescence given by a standard solution of hydrolysed substrate. 
1 
I am grateful to Dr. M, Bailey for supplies of this material. 
A.3. 5 The fibrin agarose plate assay 
In this assay the plasminogen dependent lysis of fibrin in an 
agar gel by urokinase and Mel-PA was compared. 
For the preparation of the fibrin agarose plates, the same 
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. . . . 1 . d. h 125 f"b . purified human fibrinogen and human p asminogen as use int e I- i rin 
assay were used. The plates were prepared according to the method of 
Granelli-Piperno and Reich (62) where they were used as indicator gels for 
localizing plasminogen activator activity in SDS-polyacrylamide gels. The 
slabs (110 x 90 x 1 mm) were cast between two glass plates held apart by 
thin wires 1 mm in diameter. Mixtures of 1.25% agarose, 2.5 mg/ml 
plasminogen-free human fibrinogen, 0.05 mg/ml purified human plasminogen 
and 0.06 NIH units/ml thrombin in O.lM Tris HCl pH 8.1 were poured between 
the plates at 45°c, and allowed to solidify at room temperature. 
For casein agarose plates the fibrinogen and thrombin were 
replaced by incorporating 20 mg/ml skim milk powder (Protea) into the 
agarose. 
Holes of 2 mm diameter were punched into the slabs after removal 
of one of the glass plates. Samples were inoculated into the holes in 
3 µl volumes. The plates were first incubated at 4°c for 16 hours to 
allow diffusion of the plasminogen activators and then at 37°c for 90 min 
for plasminogen dependent lysis to occur. 
The diameters of the clear lysis zones were then measured and 
related to plasminogen activator activity. 
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A.4 PROTEIN DETERMINATION 
Different methods were used to determine the protein concen-
trations in solutions, depending on the concentration of protein to be 
measured as well as the buffer system in which the proteins were dissolved. 
A4.1 Determination by UV absorption 
This method was adapted from Layne (225) and was used to give 
approximate estimates of proteins at high concentrations. The absorbance 
of a protein solution was measured at wavelengths of 280 nm and 260 nm in 
a Unicam Spectrophotometer, and the protein concentration was calculated 
according to the formula. 
Protein concentration in mg/ml= l.55 _on280 - 0.76 OD 260 
A4.2 D~termination by the Lowry method 
This method of Lowry et al (226) was used for protein solutions 
in the concentration range of 50 - 200 µg/ml and with buffers that did not 
contain substances such as Triton X-100, that interfered in the assay system. 
Solutions of BSA were used to construct a standard curve. Since 
this method does not give a linear relationship between concentration. and 
absorbence, the standard curve of on 750 
vs µg BSA was constructed by 
fitting a second degree polynomial equation to the observed points. The 
concentrations of unknown samples could then be compared by interpolation 
using the parameters of the quadratic equation. 
A4.3 The Coomassie blue dye binding assay 
This assay of Bradford et al (227) which employs the quantitative 
binding of Coomassie brilliant blue to proteins in an acid environment, was 
used to measure proteins in dilute solution in the presence of substances 
that interfered in the other assays. Although BSA gives a higher reading 
than most other proteins, it was still employed to construct a standard 
curve, since it was the major contaminant encountered in samples to be 
measured. Standards ranging from 1 - 15 µg and samples in 100 µl volumes 
were mixed with 1 ml of the Coomassie blue G250/phosphoric acid reagent 
and the absorbance was read at 595 nm. 
as in the other assays. 
Standard curves were constructed 
Since this assay can be performed rapidly it was mainly used 




Special reagents or laboratory ware were obtained from the 
following sources: 
Cell culture media and foetal bovine serum, Grand Island Biological Co., 
Grand Island, N.Y.; Standard disposable plastic tissue culture ware, 
Falcon Plastics, Oxnard, Calif., C.A. Greiner und SBhne GMBH, Nlirtingen, 
W. Germany; CQrning Ltd., Stone, Staffordshire, England; Linbro 
Multiwell plates, Flow Laboratories Ltd., Irvine, Scotland; 
Cbz-glycyl-glycyl-arginyl-AMC and Boc-glycyl-valyl-arginyl-AMC, 
Bachem Feinchemikalien AG, Bubendorf, Switzerland; urokinase, Leo 
Pharmaceutical Products, Ballerup, Denmark; human fibrinogen, 
streptokinase, A.B. Kabi, Stockholm, Sweden; thrombin, Parke-Davis 
Laboratories (Pty) Ltd., Isando, Tvl, South Africa; 3H-leucine, 
3H-DFP (diisopropylfluorophosphate), Na125I, Amersham International 
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plc, Amersham, Buckinghamshire, England; bovine trypsin, soybean trypsin 
inhibitor, pancreatic trypsin inhibitor compound; ovomucoid, Worthington 
Biochemical Corporation, Freehold, N.J.; iminodiacetic acid, nitro-
benzamidine, Aldrich Chemical Company Inc., Milwaukee, Wisc.; ECD, The Ott 
Chemical Company, Muskeg<;m, Mich.; DE-.52 cellulose, Whatman Ltd., 
Springfield M~ll, Maidstone, Kent, England; e-aminocaproic acid, 
cyanogen bromide, tetrahydrofuran, Fluka AG, Buchs SG, Switzerland; 
acrylamide, bis-acrylamide, Eastman Kodak Company, Rochester, N.Y.; 
agar, trypsin for tissue culture, Difeo Laboratories, Detroit, Michigan; 
X-ray RP-1 film, Agfa Gevaert, Belgium; 2,5 diphenyloxazole, Dimilume, 
Instagel, Soluene, Packard Instruments Company Inc., Downer's Grove, 
Ill.; 3 En Hance, New England Nuclear, Boston, Mass.; molecular weight 
marker protein mixture, Sepharose 4b, Sepharose Cl-4b, Cn~r-activated 
sepharose 4b, Sephadex G75, Sephadex G25, Cytodex, Pharmacia Fine Chemicals, 
Uppsala, Sweden; · Coomassie brilliant blue G250, Serva Feinbiochemica, 
Heidelberg, W. Germany; Streptomycin sulphate, penicillin, Glaxo-
Allenburys (SA)(Pty) Ltd., Wadeville, Tvl, South Africa; lysine-HCl, 
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bovine serum albumin, Triton X-100, sodium dodecyl sulphate, N,N,N' ,N'-
tetra methylethylene diamine (TEMED), a-mercaptoethanol, Coomassie brilliant 
blue R250, chloramine T, N-methyl pyrrolidone, BDH Chemicals Ltd., 
Poole, England; diisopropylfluorophosphate (DF~), 1,4 butane diol 
diglycidyl ether, phenol red, thrombin, bovine fibrinogen, 4-methylumbelli-
feryl p-guanidinobenzoate, 4-methylumbelliferone, benzamidine, HEPES, 
Sigma Chemical Company, St. Louis, M.O.; ethylene glycol, sodium 
borohydride, glutaraldehyde, silver nitrate, formaldehyde, trichloracetic 
acid, amido black, dimethyl sulphoxide, g~latin, arginine, potassium 
thiocyanate, E. Merck, Darmstadt, W. Germany. , 
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